

## Protein Sequence Searches - February 2005

All of the sequence databases on ABSS have recently been updated.

- Please note that the curators of the UniProt database have purged some temporary accession numbers from the most recent version of UniProt. These sequences have been assigned new permanent accession numbers. The new UniProt record may not contain the previous temporary accession number.
- If you encounter an accession number from an older search run against UniProt (results file extension .rnp) that can no longer be found in the database, the permanent record with the new accession number can be found by searching the old accession number in the UniProt Protein Archive database (UniPARC) at:

<http://www.pir.uniprot.org/database/archive.shtml>

If you have any questions regarding this information or your results, please contact any STIC searcher.

**When submitting sequence search results for scanning into IFW, please include a copy of this attachment to assist any future Examiners or members of the public who may encounter UniProt temporary accession numbers.**

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:44:31 / Search time 54.0459 Seconds  
(without alignments)  
484.925 Million cell updates/sec

Title: US-09-211-297-39

Sequence: 1 MRBASRDYTKYLRCSEMG.....LLDPDQATYFGAFKRDID 317

Scoring table: BLOSUM62  
Gapop 10.0, Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database: Issued Patents, AA:\*  
1: /cgn2\_6/prodata/1/1aa/5.COMB.pep.\*  
2: /cgn2\_6/prodata/1/1aa/6.COMB.pep.\*  
3: /cgn2\_6/prodata/1/1aa/H.COMB.pep.\*  
4: /cgn2\_6/prodata/1/1aa/CTUS.COMB.pep.\*  
5: /cgn2\_6/prodata/1/1aa/RE.COMB.pep.\*  
6: /cgn2\_6/prodata/1/1aa/backfill1.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1685	100.0	317	2 US-08-996-139-13	Sequence 13, Appl
2	1685	100.0	317	2 US-08-995-659-13	Sequence 13, Appl
3	1685	100.0	317	2 US-09-215-649A-13	Sequence 4, Appl
4	1685	100.0	317	2 US-09-052-521C-4	Sequence 13, Appl
5	1685	100.0	317	2 US-09-577-800-13	Sequence 13, Appl
6	1685	100.0	317	2 US-09-466-96-13	Sequence 13, Appl
7	1685	100.0	317	2 US-09-871-856-13	Sequence 13, Appl
8	1685	100.0	317	2 US-09-871-291-13	Sequence 2, Appl
9	1685	100.0	317	2 US-09-396-937-2	Sequence 13, Appl
10	1685	100.0	317	2 US-09-865-163-13	Sequence 13, Appl
11	1685	100.0	317	2 US-09-688-459-13	Sequence 6, Appl
12	1685	100.0	317	2 US-09-957-944-6	Sequence 8, Appl
13	1685	100.0	316	1 US-08-842-842-7	Sequence 7, Appl
14	1685	100.0	316	1 US-08-989-362-2	Sequence 2, Appl
15	1685	100.0	316	2 US-09-052-521C-2	Sequence 2, Appl
16	1685	100.0	316	2 US-09-671-658A-2	Sequence 2, Appl
17	1685	100.0	316	2 US-09-396-937-4	Sequence 6, Appl
18	1685	100.0	316	2 US-09-396-937-6	Sequence 6, Appl
19	1685	100.0	316	2 US-08-996-139-11	Sequence 11, Appl
20	1685	100.0	316	2 US-08-995-659-11	Sequence 11, Appl
21	1685	100.0	316	2 US-09-577-800-11	Sequence 11, Appl
22	1685	100.0	316	2 US-09-466-96-13	Sequence 13, Appl
23	1685	100.0	316	2 US-09-871-856-13	Sequence 13, Appl
24	1685	100.0	316	2 US-09-871-291-13	Sequence 2, Appl
25	1685	100.0	316	2 US-09-396-937-2	Sequence 13, Appl
26	1685	100.0	316	2 US-09-865-163-13	Sequence 13, Appl
27	1685	100.0	316	2 US-09-688-459-13	Sequence 6, Appl

28	1326.5	78.7	294	2	US-09-871-856-11	Sequence 11, Appl
29	1326.5	78.7	294	2	US-09-871-291-11	Sequence 11, Appl
30	1326.5	78.7	294	2	US-09-877-650-11	Sequence 11, Appl
31	1326.5	78.7	294	2	US-09-865-363-11	Sequence 11, Appl
32	1326.5	78.7	294	2	US-09-688-459-11	Sequence 11, Appl
33	1326.5	78.7	294	2	US-09-396-937-8	Sequence 10, Appl
34	769	45.6	173	2	US-09-396-937-10	Sequence 12, Appl
35	759	45.0	173	2	US-09-396-937-12	Sequence 14, Appl
36	721.5	42.8	188	2	US-09-396-937-14	Sequence 16, Appl
37	711.5	42.2	182	2	US-09-396-937-16	Sequence 18, Appl
38	691	41.0	173	2	US-09-396-937-18	Sequence 20, Appl
39	670	39.8	173	2	US-09-396-937-20	Sequence 8, Appl
40	538	31.9	109	2	US-09-911-777-8	Sequence 11, Appl
41	418	24.8	77	2	US-09-632-287A-11	Sequence 11, Appl
42	418	24.8	77	2	US-10-286-636-11	Sequence 11, Appl
43	363	21.5	77	2	US-09-632-287A-10	Sequence 10, Appl
44	363	21.5	77	2	US-10-286-636-10	Sequence 10, Appl
45	251.5	14.9	279	2	US-09-072-993C-3	Sequence 3, Appl

## ALIGNMENTS

RESULT 1  
US-08-996-139-13  
Sequence 13, Application US/08996139  
Patent No. 6017729  
GENERAL INFORMATION:  
APPLICANT: Anderson, Dirk M.  
APPLICANT: Galibert, Laurent  
APPLICANT: Marakovskiy, Eugene  
TITLE OF INVENTION: Receptor Activator of NF-kappaB  
NUMBER OF SEQUENCES: 19  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: Immunex Corporation, Law Department  
STREET: 51 University Street  
CITY: Seattle  
STATE: WA  
COUNTRY: USA  
ZIP: 98101  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: Apple Power Macintosh  
OPERATING SYSTEM: Apple Operating System 7.5.5  
SOFTWARE: Microsoft Word for Power Macintosh 6.0.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/996,139  
FILING DATE: 22 DECEMBER 1997  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/60/064,671  
FILING DATE: 14 OCTOBER 1997  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/813,509  
FILING DATE: 07 MARCH 1997  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/772,330  
FILING DATE: 23 DECEMBER 1996  
ATTORNEY/AGENT INFORMATION:  
NAME: Perkins, Patricia Anne  
REGISTRATION NUMBER: 34,693  
REFERENCE/DOCKET NUMBER: 2851-A  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (206)587-0430  
TELEFAX: (206)233-0644  
INFORMATION FOR SEQ ID NO: 13:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 317 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-996-139-13

Query Match 100.0%; Score 1685; DB 2; Length 317;  
Best Local Similarity 100.0%; Pred. No. 2e-163;  
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPIAHAPPAPPHQPPAASRSMFVALLGLGLGQV 60  
DB 1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPIAHAPPAPPHQPPAASRSMFVALLGLGLGQV 60

QY 61 VCSVALFFYPRAQMDPNRISDGTGHCYRILRLHENDAFODTTLESODTKLIPDSCRIR 120  
DB 61 VCSVALFFYPRAQMDPNRISDGTGHCYRILRLHENDAFODTTLESODTKLIPDSCRIR 120

QY 121 QAFQGAOVKELQHVGSQHIRAEKAMVDGSMWDLAKRSKLEAOPFAHLTTINATDIPSGSH 180  
DB 121 QAFQGAOVKELQHVGSQHIRAEKAMVDGSMWDLAKRSKLEAOPFAHLTTINATDIPSGSH 180

QY 181 KVSLSWYHDSGMAKISNMTFSGNKLIVNODGFYLLYANICFRHETSGDLATEYLQLMV 240  
DB 181 KVSLSWYHDSGMAKISNMTFSGNKLIVNODGFYLLYANICFRHETSGDLATEYLQLMV 240

QY 241 YVTKTSIKIPSSHTLMKGSSTKYWSGNSSEPHFYSINVGGFFKLRSGEISIEVSNPSLLD 300  
DB 241 YVTKTSIKIPSSHTLMKGSSTKYWSGNSSEPHFYSINVGGFFKLRSGEISIEVSNPSLLD 300

QY 301 PDODATYFGAFKVRDID 317  
DB 301 PDODATYFGAFKVRDID 317

RESULT 2  
US-08-995-659-13  
Sequence 13, Application US/08995659  
Patent No. 6242213

## GENERAL INFORMATION:

APPLICANT: Anderson, Dirk M.  
APPLICANT: Galibert, Laurent  
APPLICANT: Maraskovsky, Eugene  
TITLE OF INVENTION: Ligand for Receptor Activator of NF-kappaB  
NUMBER OF SEQUENCES: 19  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Immunex Corporation, Law Department  
STREET: 51 University Street  
CITY: Seattle  
STATE: WA  
COUNTRY: USA  
ZIP: 98101  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: Apple Power Macintosh  
OPERATING SYSTEM: Apple Operating System 7.5.5  
SOFTWARE: Microsoft Word for Power Macintosh 6.0.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/995,659  
FILING DATE: 22 DECEMBER 1997  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 60/064,671  
FILING DATE: 14 OCTOBER 1997  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/813,509  
FILING DATE: 07 MARCH 1997  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/772,330  
FILING DATE: 23 DECEMBER 1996  
CLASSIFICATION:  
ATTORNEY/AGENT INFORMATION:  
NAME: Perkins, Patricia Anne  
REGISTRATION NUMBER: 34,693  
REFERENCE/DOCKET NUMBER: 2852-A  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (206) 587-0430

TELEFAX: (206) 233-0644  
INFORMATION FOR SEQ ID NO: 13:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 317 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-995-659-13

Query Match 100.0%; Score 1685; DB 2; Length 317;  
Best Local Similarity 100.0%; Pred. No. 2e-163;  
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPIAHAPPAPPHQPPAASRSMFVALLGLGLGQV 60  
DB 1 MRRASRDYTKYLRGSEEMGGGPGAPHEGPIAHAPPAPPHQPPAASRSMFVALLGLGLGQV 60

QY 61 VCSVALFFYPRAQMDPNRISDGTGHCYRILRLHENDAFODTTLESODTKLIPDSCRIR 120  
DB 61 VCSVALFFYPRAQMDPNRISDGTGHCYRILRLHENDAFODTTLESODTKLIPDSCRIR 120

QY 121 QAFQGAOVKELQHVGSQHIRAEKAMVDGSMWDLAKRSKLEAOPFAHLTTINATDIPSGSH 180  
DB 121 QAFQGAOVKELQHVGSQHIRAEKAMVDGSMWDLAKRSKLEAOPFAHLTTINATDIPSGSH 180

QY 181 KVSLSWYHDSGMAKISNMTFSGNKLIVNODGFYLLYANICFRHETSGDLATEYLQLMV 240  
DB 181 KVSLSWYHDSGMAKISNMTFSGNKLIVNODGFYLLYANICFRHETSGDLATEYLQLMV 240

QY 241 YVTKTSIKIPSSHTLMKGSSTKYWSGNSSEPHFYSINVGGFFKLRSGEISIEVSNPSLLD 300  
DB 241 YVTKTSIKIPSSHTLMKGSSTKYWSGNSSEPHFYSINVGGFFKLRSGEISIEVSNPSLLD 300

QY 301 PDODATYFGAFKVRDID 317  
DB 301 PDODATYFGAFKVRDID 317

RESULT 3  
US-09-215-649A-13  
Sequence 13, Application US/09215649A  
Patent No. 6271349

## GENERAL INFORMATION:

APPLICANT: Anderson, Dirk M.  
APPLICANT: Galibert, Laurent  
APPLICANT: Maraskovsky, Eugene  
TITLE OF INVENTION: Receptor Activator of NF-kappaB  
NUMBER OF SEQUENCES: 19  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Immunex Corporation, Law Department  
STREET: 51 University Street  
CITY: Seattle  
STATE: WA  
COUNTRY: USA  
ZIP: 98101  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: Apple Power Macintosh  
OPERATING SYSTEM: Apple Operating System 7.5.5  
SOFTWARE: Microsoft Word for Power Macintosh 6.0.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/215,649A  
FILING DATE: 17-Dec-1998  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/996,139  
FILING DATE: <Unknown>  
APPLICATION NUMBER: USSN 08/813,509  
FILING DATE: 07 MARCH 1997  
APPLICATION NUMBER: USSN 08/772,330  
FILING DATE: 23 DECEMBER 1996  
ATTORNEY/AGENT INFORMATION:  
NAME: Perkins, Patricia Anne

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:35:06 ; Search time 218.262 Seconds  
(without alignments)  
1024.696 Million cell updates/sec

Title: US-09-211-297-39  
Perfect score: 1685  
Sequence: 1 MRRASRDYTKYLKRGSEMG.....LLDPDQATYFGAFKVRDID 317

Scoring table: BLOSUM62  
Gapop 10.0, Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :  
1: uniprot\_sprot.\*  
2: uniprot\_trembl.\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1685	100.0	317	1 TNF11_HUMAN	O14788 h tumor nec
2	1685	100.0	317	2 OST9Y4_HUMAN	O51944 homo sapien
3	1417.5	84.1	316	1 TNF11_MOUSE	O35235 m tumor nec
4	1396.5	82.9	318	1 TNF11_RAT	O98682 r tumor nec
5	1292	76.7	244	2 Q54A58_HUMAN	O54888 homo sapien
6	559.5	33.2	290	2 Q5H2R8_XENLA	O54888 xenopus lae
7	470	27.9	117	2 Q5X1H0_RABIT	O5X1H0 oryctolagus
8	273.5	16.2	289	2 Q4VSR6_PIG	O4VSR6 sus scrofa
9	266	15.8	317	2 Q7ZYX9_BRARE	O7ZYX9 brachydanio
10	265	15.7	304	2 Q7TIF2_CHICK	O7TIF2 gallus gall
11	262.5	15.6	292	2 Q5ZKX3_CHICK	O5ZKX3 gallus gall
12	251.5	14.9	281	1 TNF10_HUMAN	P50591 homo sapien
13	251.5	14.9	281	2 O61BA9_HUMAN	O61BA9 homo sapien
14	249.5	14.8	299	2 Q6DHG9_BRARE	O6DHG9 brachydanio
15	249.5	14.8	303	2 Q5XKX3_MOUSE	O5XKX3 mus musculu
16	248	14.7	291	1 TNF10_MOUSE	P50592 mus musculu
17	245.5	14.6	264	2 Q9DS94_TETNG	O9DS94 tetracodon n
18	240.5	14.3	214	2 Q9D255_BRARE	O9D255 brachydanio
19	234	13.9	300	2 Q5U675_HUMAN	O5U675 homo sapien
20	216.5	12.8	287	2 Q9QWT9_CHICK	O9QWT9 gallus gall
21	215.5	12.8	287	2 Q8K3G0_RAT	O8K3G0 rattus norv
22	211	12.5	285	2 Q4SK14_TETNG	O4SK14 tetracodon n
23	200	11.9	282	1 TNFL6_PIG	O98688 sus scrofa
24	194.5	11.5	280	2 Q61W5_FELCA	O61W5 felis silve
25	190.5	11.3	253	2 Q5CAQ0_CHICK	O5CAQ0 gallus gall
26	189	11.2	281	1 TNFL6_HUMAN	P48023 h tumor nec
27	189	11.2	281	2 Q53Z21_HUMAN	O53Z21 homo sapien
28	187.5	11.1	279	2 Q7TMY9_MOUSE	O7TMY9 mus musculu
29	186	11.0	280	1 TNFL6_MACFA	P63308 m tumor nec
30	186	11.0	280	1 TNFL6_MACMU	P63307 m tumor nec
31	186	11.0	280	1 TNFL6_MACNE	P63306 m tumor nec

32	184.5	10.9	252	2	O8K3Y8_MOUSE	O8K3Y8 mus musculu
33	184.5	10.9	279	1	TNPL6_MOUSE	P41047 mus musculu
34	184.5	10.9	279	1	O544E5_MOUSE	O544E5 mus musculu
35	182.5	10.8	278	2	Q4STX9_TETNG	O4STX9 tetracodon n
36	182.5	10.8	280	1	TNPL6_TETNG	O4STX9 tetracodon n
37	181	10.7	95	2	O6UML7_HUMAN	O6UML7 homo sapien
38	181	10.7	95	2	O6UML7_HUMAN	O6UML7 homo sapien
39	179.5	10.7	252	2	O80Y20_MOUSE	O80Y20 mus musculu
40	177.5	10.5	252	2	O8K3Y7_RAT	O8K3Y7 rattus norv
41	176.5	10.5	261	1	TNPL5_BOVIN	P51749 b tumor nec
42	175.5	10.4	278	1	TNPL5_CALJA	P36940 rattus norv
43	169.5	10.1	261	1	TNPL5_CALJA	O9Ddm3 c tumor nec
44	167.5	9.9	261	1	TNPL5_AORTA	O9Ddm3 a tumor nec
45	162	9.6	239	2	Q50L61_CHICK	Q50L61 gallus gall

## ALIGNMENTS

RESULT 1  
ID TNF11\_HUMAN STANDARD; PRT; 317 AA.  
AC O14788; O14723; Q96Q17; Q9P2Q3;  
DT 16-OCT-2001 (Rel. 40, Last sequence update)  
DT 16-OCT-2001 (Rel. 48, Last annotation update)  
DE Tumor necrosis factor ligand superfamily member 11 (Receptor activator  
DE of nuclear factor kappa B ligand) (RANKL) (TNF-related activation-  
DE induced cytokine) (TRANCE) (Osteoprotegerin ligand) (OPGL) (Osteoclast  
DE differentiation factor) (ODF) (Contains: Tumor necrosis factor ligand  
DE superfamily member 11, membrane form; Tumor necrosis factor ligand  
DE superfamily member 11, soluble form).  
GN Name=TNFSF11; Synonyms=OPGL, RANKL, TRANCE;  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;  
OC Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP NUCLEOTIDE SEQUENCE (ISOFORM 1).  
RC TISSUE=Bone marrow, and Peripheral blood;  
RX MEDLINE=98032977; PubMed=9367155; DOI=10.1038/36593;  
RA Anderson D.M., Maraskovsky E., Billingsley W.L., Dougan W.C.,  
RA Tomesko M.E., Roux E.R., Teepe M.C., Dubose R.F., Cosman D.,  
RA Galibert L.;  
RT "A homologue of the TNF receptor and its ligand enhance T-cell growth  
RT and dendritic-cell function.";  
RL Nature 390:175-179(1997).  
[2]  
RN NUCLEOTIDE SEQUENCE (ISOFORM 1).  
RP TISSUE=Lymph node;  
RX MEDLINE=98257661; PubMed=9568710; DOI=10.1016/S0092-8674(00)81569-X;  
RA Lacey D.L., Timms E., Tan H.-L., Kelley M.J., Dunstan C.R.,  
RA Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hu H.,  
RA Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.-X.,  
RA Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J.,  
RA Boyle W.J.;  
RT "Osteoprotegerin ligand is a cytokine that regulates osteoclast  
RT differentiation and activation.";  
RL Cell 93:165-176(1998).  
[3]  
RN NUCLEOTIDE SEQUENCE (ISOFORMS 1, 2 AND 3).  
RP Iwata T., Kuroyama H., Hirokawa K.;  
RT "Determination of human RANKL isoforms.";  
RL Submitted (JUN-2001) to the EMBL/GenBank/DBJ databases.  
[4]  
RN NUCLEOTIDE SEQUENCE (ISOFORM 2).  
RP TISSUE=Tongue;  
RX MEDLINE=2015237; PubMed=10708588; DOI=10.1006/dbrc.2000.2314;  
RA Nagai M., Yakumoto S., Sato N.;  
RT "Cancer cells responsible for humoral hypercalcemia express mRNA  
RT encoding a secreted form of ODF/TRANCE that induces osteoclast  
RT formation.";

RL Biochem. Biophys. Res. Commun. 269:532-536(2000).  
 RN [5]  
 RC NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).  
 RX TISSUE=Lung;  
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnae.242603899;  
 RX Struhsberg R.L., Felngold E.A., Grouse L.H., Derge J.G.,  
 RA Klausner R.D., Collins B.S., Wagner L., Shemen C.M., Schuler G.D.,  
 RA Altschul S.F., Zeeberg F., Buecor K.H., Schaefer C.F., Bhat N.K.,  
 RA Hopline R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
 RA Diachenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
 RA Brownstein M.J., Uedlin T.B., Toshiyuki S., Carninci P., Prange C.,  
 RA Raha S.S., Locantello N.A., Peters G.J., Abramson R.D., Mullanb S.J.,  
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
 RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
 RA Fahy J., Helton B., Kettelman M., Madan A., Rodrigues S., Sanchez A.,  
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
 RA Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smallos D.E.,  
 RA Schermer A., Schein J.E., Jones S.J.M., Marra M.A.,  
 RT "Generation and initial analysis of more than 15,000 full-length human  
 RT and mouse cDNA sequences.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
 RN [6]  
 RP NUCLEOTIDE SEQUENCE OF 73-317.  
 RC TISSUE=Thymocyte; PubMed=9312132; DOI=10.1074/jbc.272.40.25190;  
 RX MEDLINE=97460112; PubMed=97460112; DOI=10.1074/jbc.272.40.25190;  
 RX Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M.,  
 RA Kalichkov S., Cayani E., Bartlett F.S. III, Frankel W.N., Lee S.Y.,  
 RA Choi Y.;  
 RT "TRANCE is a novel ligand of the tumor necrosis factor receptor family  
 RT that activates c-Jun N-terminal kinase in T cells.";  
 RL J. Biol. Chem. 272:25190-25194(1997).  
 CC -1- FUNCTION: Cytokine that binds to TNFRSF11B/OPG and to  
 CC TNFRSF11A/RANK. Osteoclast differentiation and activation factor.  
 CC Augments the ability of dendritic cells to stimulate naive T-cell  
 CC proliferation. May be an important regulator of interactions  
 CC between T cells and dendritic cells and may play a role in the  
 CC regulation of the T cell-dependent immune response. May also play  
 CC an important role in enhanced bone-resorption in humoral  
 CC hypercalcemia of malignancy.  
 CC -1- SUBUNIT: Homotrimer (By similarity).  
 CC -1- SUBCELLULAR LOCATION: Type II membrane protein (isoforms 1 and 3);  
 CC Secreted (isoform 2). A soluble form of isoform 1 arises by  
 CC proteolytic processing (By similarity).  
 CC -1- ALTERNATIVE PRODUCTS:  
 CC Name=1;  
 CC IsoId=014788-1; Sequence=Displayed;  
 CC Name=2; Synonyms=SODP;  
 CC IsoId=014788-2; Sequence=VSP\_006447;  
 CC Name=3;  
 CC IsoId=014788-3; Sequence=VSP\_006446;  
 CC -1- TISSUE SPECIFICITY: Highest in the peripheral lymph nodes, weak in  
 CC spleen, peritoneal blood leukocytes, bone marrow, heart, placenta,  
 CC skeletal muscle, stomach and thyroid.  
 CC -1- INDUCTION: Up-regulated by T cell receptor stimulation.  
 CC -1- PTM: The soluble form of isoform 1 derives from the membrane form  
 CC by proteolytic processing (By similarity). The cleavage may be  
 CC catalyzed by ADAM17.  
 CC -1- SIMILARITY: Belongs to the tumor necrosis factor family.  
 CC -----  
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation-  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use as long as its content is in no way modified and this statement is not  
 CC removed.  
 CC EMBL; AF019047; AAB86811.1; -; mRNA.  
 DR EMBL; AF053712; AAC39731.1; -; mRNA.  
 DR EMBL; AB064269; BAB79694.1; -; mRNA.

DR EMBL; AB061227; BAB71768.1; -; mRNA.  
 DR EMBL; AB064270; BAB9695.1; -; mRNA.  
 DR EMBL; AB037599; BAA90488.1; -; mRNA.  
 DR EMBL; BC074823; AAH74823.1; -; mRNA.  
 DR EMBL; BC074850; AAH74850.1; -; mRNA.  
 DR EMBL; AF013171; AAC51762.1; -; mRNA.  
 DR HSSP; O35235; 1JY2.  
 DR SMR; O14788; 162-317.  
 DR Ensembl; ENSG00000120659; Homo sapiens.  
 DR HGNC; HGNC:11926; TNFRSF11.  
 DR MIM; 602642; -;  
 DR GO; GO:0005576; C:extracellular region; NAS.  
 DR GO; GO:0005887; C:integral to plasma membrane; NAS.  
 DR GO; GO:0005164; F:tumor necrosis factor receptor binding; NAS.  
 DR GO; GO:0006955; P:immune response; NAS.  
 DR GO; GO:0030316; P:osteoclast differentiation; NAS.  
 DR InterPro; IPR006052; TNF\_family.  
 DR InterPro; IPR003636; TNF\_subf.  
 DR Pfam; PF00229; TNF; 1.  
 DR ProDom; PD002012; TNF\_subf; 1.  
 DR SMART; SM00207; TNF; 1.  
 DR PROSITE; PS00459; TNF\_2; 1; FALSE\_NEG.  
 DR PROSITE; PS00459; TNF\_2; 1.  
 KW Alternative splicing; Cytokine; Developmental protein;  
 KW Differentiation; Glycoprotein; Receptor; Signal-anchor; Transmembrane.  
 FT CHAIN 1 317  
 FT Tumor necrosis factor ligand superfamily  
 FT member 11, membrane form.  
 FT CHAIN 140 317  
 FT Tumor necrosis factor ligand superfamily  
 FT member 11, soluble form (By similarity).  
 FT TOPO\_DOM 1 47  
 FT TRANSMEM 48 68  
 FT Signal-anchor for type II membrane  
 FT protein (Potential).  
 FT TOPO\_DOM 69 317  
 FT SITE 139 140  
 FT CARBOXD 171 171  
 FT CARBOXD 198 198  
 FT VARSPLIC 1 73  
 FT Missing (in isoform 2).  
 FT VARSPLIC 1 47  
 FT Missing (in isoform 3).  
 FT FTId=VSP\_006446.  
 FT CONFLICT 194 194 A -> G (in Ref. 6).  
 FT SEQUENCE 317 AA; 35478 MW; 76617646348097f CRC64;  
 SQ  
 Query Match 100.0%; Score 1685; DB 1; Length 317;  
 Best Local Similarity 100.0%; Pred. No. 6,5e-136;  
 Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MRRASRDYTKYLRSSEMGSGPAPHPGPRPAHPPPAPHPPPASRSMFVALLGIGLQGV 60  
 DB 1 MRRASRDYTKYLRSSEMGSGPAPHPGPRPAHPPPAPHPPPASRSMFVALLGIGLQGV 60  
 QY 61 VCSVALFFYPFAQMDPNRISDEGTHCTYRIILRLHENDPFODTTESODTKLIPDSCRIR 120  
 DB 61 VCSVALFFYPFAQMDPNRISDEGTHCTYRIILRLHENDPFODTTESODTKLIPDSCRIR 120  
 QY 61 VCSVALFFYPFAQMDPNRISDEGTHCTYRIILRLHENDPFODTTESODTKLIPDSCRIR 120  
 DB 61 VCSVALFFYPFAQMDPNRISDEGTHCTYRIILRLHENDPFODTTESODTKLIPDSCRIR 120  
 QY 121 QAFQAVQKEIQLHIVGSGHIAERKAMVDGSLDLAKSKLEAQPALHILINATDIPSSGH 180  
 DB 121 QAFQAVQKEIQLHIVGSGHIAERKAMVDGSLDLAKSKLEAQPALHILINATDIPSSGH 180  
 QY 121 QAFQAVQKEIQLHIVGSGHIAERKAMVDGSLDLAKSKLEAQPALHILINATDIPSSGH 180  
 DB 121 QAFQAVQKEIQLHIVGSGHIAERKAMVDGSLDLAKSKLEAQPALHILINATDIPSSGH 180  
 QY 181 KVSLSWTHDRGMAKISMTFSNGKLIVNODGFYLLVANTCPRHNETSGDLATEYLQIMV 240  
 DB 181 KVSLSWTHDRGMAKISMTFSNGKLIVNODGFYLLVANTCPRHNETSGDLATEYLQIMV 240  
 QY 181 KVSLSWTHDRGMAKISMTFSNGKLIVNODGFYLLVANTCPRHNETSGDLATEYLQIMV 240  
 DB 181 KVSLSWTHDRGMAKISMTFSNGKLIVNODGFYLLVANTCPRHNETSGDLATEYLQIMV 240  
 QY 241 YVTKTSIKIPSSHTLMGSGTKYKWSGNEEFYSLINVGFFPKLRSGERISIEVSPSLD 300  
 DB 241 YVTKTSIKIPSSHTLMGSGTKYKWSGNEEFYSLINVGFFPKLRSGERISIEVSPSLD 300  
 QY 241 YVTKTSIKIPSSHTLMGSGTKYKWSGNEEFYSLINVGFFPKLRSGERISIEVSPSLD 300  
 DB 241 YVTKTSIKIPSSHTLMGSGTKYKWSGNEEFYSLINVGFFPKLRSGERISIEVSPSLD 300  
 QY 301 PPDATYFGAFKVDID 317  
 DB 301 PPDATYFGAFKVDID 317  
 QY 301 PPDATYFGAFKVDID 317  
 DB 301 PPDATYFGAFKVDID 317  
 RESULT 2



protein) and to identify compounds that modulate binding of OPG binding protein to osteoclast differentiation and activation receptor (ODAR). The nucleic acid molecule encoding OPG binding protein can be used to detect OPG binding protein-encoding sequences, e.g. screening for related sequences, also to produce transgenic animal models, while complementary sequences are used for antisense regulation of OPG binding protein expression. Modulators of OPG binding protein, particularly soluble forms of OPG binding protein or Ab, are used to treat or prevent bone diseases, e.g. osteoporosis, bone loss caused by arthritis or metastases, hypercalcemia, Paget's disease, periodontal disease, osteoporosis, loosening of prostheses, optionally in combination with agents that promote bone growth

Sequence 317 AA;

Query Match 100.0%; Score 1685; DB 2; Length 317;  
Best Local Similarity 100.0%; Pred. No. 7.5e-154;  
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRASRDYTKYLKSGSEMGSGPGAPHEGRLAHPPPAPPAHPAASRSMPVALLGLGLGV 60  
DB 1 MRASRDYTKYLKSGSEMGSGPGAPHEGRLAHPPPAPPAHPAASRSMPVALLGLGLGV 60  
QY 61 VCSVALFFYFPAQMDPNRISBDGTHCIYRILRLHENDFODTTLESQDTKLIIPDSCRIR 120  
DB 61 VCSVALFFYFPAQMDPNRISBDGTHCIYRILRLHENDFODTTLESQDTKLIIPDSCRIR 120  
QY 121 QAFQGAQVQKELQHVSGQHIAEKAMVDSWLDLAKRSKLEAOPFAHLLTNATDIPSGSH 180  
DB 121 QAFQGAQVQKELQHVSGQHIAEKAMVDSWLDLAKRSKLEAOPFAHLLTNATDIPSGSH 180  
QY 181 KVSLSWYHDSGMWAKISNMTFSNGKLIYNODGFYLYANICFRHETSGDLATEYLQLMV 240  
DB 181 KVSLSWYHDSGMWAKISNMTFSNGKLIYNODGFYLYANICFRHETSGDLATEYLQLMV 240  
QY 241 VYTKTSIKIPSSHTLMKSGSTKYWSGSEFHFYSINVGFFPKLRSGBEISIEVNSPDL 300  
DB 241 VYTKTSIKIPSSHTLMKSGSTKYWSGSEFHFYSINVGFFPKLRSGBEISIEVNSPDL 300  
QY 301 PDDATYFGAFKVRDID 317  
DB 301 PDDATYFGAFKVRDID 317

RESULT 2

AAW69957 standard; protein; 317 AA.

AAW69957;

08-OCT-1998 (first entry)

NF-kB receptor activator RANK ligand (RANKL).

RANK; necrosis factor-kappa B; NF-kB; receptor activator; human;

immune response; inflammatory response; toxic shock; sepsis; RANKL;

RANK ligand; tumour necrosis factor; TNF.

Homo sapiens.

WO9828426-A2.

02-JUL-1998.

22-DEC-1997; 97WO-US023775.

23-DEC-1996; 96US-0053978P.

07-MAR-1997; 97US-00813509.

14-OCT-1997; 97US-0064671P.

(IMMUNEX CORP.

Anderson DM, Galibert LJ, Maraskovsky E;

WP1: 1998-377657/32.  
N-PSDB: AAV41378.  
New isolated ligand for receptor activator of NF-kappa B - used to develop products for augmenting an immune response for inhibiting an inflammatory response and for protection of cells.

Claim 27; Page 59-60; 80pp; English.

This represents a human RANKL, a ligand for the RANK (receptor activator of necrosis factor-kappa B (NF-kB)) polypeptide. RANK is a member of the tumour necrosis factor (TNF) family. A soluble RANK may be used for inhibiting activation of NF-kB, by contacting a cell expressing membrane-associated RANK with a soluble RANK which binds to RANK ligand (RANKL). RANKL polypeptides can activate RANK and can be used to induce maturation of dendritic cells and enhance their allo-stimulatory capacity, thereby augmenting an immune response. The soluble RANK polypeptide composition may also be used for regulating an immune or inflammatory response. Inhibition of NF-kB by RANK antagonists may be useful in ameliorating negative effects of an inflammatory response that result from triggering of RANK, e.g. in treating toxic shock or sepsis, graft-versus-host reactions, or acute inflammatory reactions. They can also be used in adjunct therapy for disease characterised by neoplastic cells that express RANK. RANKL polypeptides can also be used to identify inhibitors of RANK and thus inhibitors of an inflammatory response, and also for protecting RANK-expressing cells from the negative effects of chemotherapy or the presence of high levels of TNF-alpha. The products can also be used for detection and drug screening

Sequence 317 AA;

Query Match 100.0%; Score 1685; DB 2; Length 317;  
Best Local Similarity 100.0%; Pred. No. 7.5e-154;  
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRASRDYTKYLKSGSEMGSGPGAPHEGRLAHPPPAPPAHPAASRSMPVALLGLGLGV 60  
DB 1 MRASRDYTKYLKSGSEMGSGPGAPHEGRLAHPPPAPPAHPAASRSMPVALLGLGLGV 60  
QY 61 VCSVALFFYFPAQMDPNRISBDGTHCIYRILRLHENDFODTTLESQDTKLIIPDSCRIR 120  
DB 61 VCSVALFFYFPAQMDPNRISBDGTHCIYRILRLHENDFODTTLESQDTKLIIPDSCRIR 120  
QY 121 QAFQGAQVQKELQHVSGQHIAEKAMVDSWLDLAKRSKLEAOPFAHLLTNATDIPSGSH 180  
DB 121 QAFQGAQVQKELQHVSGQHIAEKAMVDSWLDLAKRSKLEAOPFAHLLTNATDIPSGSH 180  
QY 181 KVSLSWYHDSGMWAKISNMTFSNGKLIYNODGFYLYANICFRHETSGDLATEYLQLMV 240  
DB 181 KVSLSWYHDSGMWAKISNMTFSNGKLIYNODGFYLYANICFRHETSGDLATEYLQLMV 240  
QY 241 VYTKTSIKIPSSHTLMKSGSTKYWSGSEFHFYSINVGFFPKLRSGBEISIEVNSPDL 300  
DB 241 VYTKTSIKIPSSHTLMKSGSTKYWSGSEFHFYSINVGFFPKLRSGBEISIEVNSPDL 300  
QY 301 PDDATYFGAFKVRDID 317  
DB 301 PDDATYFGAFKVRDID 317

RESULT 3

AAW68293 standard; protein; 317 AA.

AAW68293;

08-OCT-1998 (first entry)

NF-kB receptor activator RANK ligand (RANKL).

RANK; necrosis factor-kappa B; NF-kB; receptor activator; human;

immune response; inflammatory response; toxic shock; sepsis; RANKL;



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using SW model

Run on: December 21, 2005, 12:47:51 / Search time 35.8574 Seconds  
(without alignment)  
850.612 Million cell updates/sec

Title: US-09-211-297-39  
Perfect score: 1685  
Sequence: 1 MRRASRDYTKYLRGSEEMG.....LIDPDQATYFGAFKVRDID 317

Scoring table: BLOSUM62  
Gapop 10.0, Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 45 summaries

Database : PIR 80: \*  
1: p1r1: \*  
2: p1r2: \*  
3: p1r3: \*  
4: p1r4: \*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query	Length	DB	ID	Description
1	189	11.2	281	2	I38707	Fas ligand - human
2	184.5	10.9	279	2	A53062	Fas ligand - mouse
3	176.5	10.5	261	2	S53090	CD40 ligand - bovi
4	175.5	10.4	278	2	A49286	Fas ligand - rat
5	158.5	9.4	261	2	I53476	CD40 ligand - huma
6	141.5	8.4	235	1	OMMSN	tumor necrosis fac
7	141	8.4	234	1	A25451	tumor necrosis fac
8	137	8.1	234	1	JH0529	tumor necrosis fac
9	137	7.9	233	1	QWHDN	tumor necrosis fac
10	132.5	7.9	235	2	I54490	tumor necrosis fac
11	131.5	7.8	235	2	JU0029	tumor necrosis fac
12	130.5	7.7	306	2	I49139	lymphotoxin-beta -
13	130	7.7	233	1	S22052	tumor necrosis fac
14	128	7.6	234	1	J01314	tumor necrosis fac
15	126.5	7.5	233	1	S24642	tumor necrosis fac
16	126	7.5	232	1	S12606	tumor necrosis fac
17	125.5	7.4	185	2	S52715	tumor necrosis fac
18	122	7.2	193	2	S06192	CD40 ligand - mous
19	120	7.1	260	2	S21738	tumor necrosis fac
20	117	6.9	233	2	S11688	tumor necrosis fac
21	117	6.9	244	2	A46066	lymphotoxin beta -
22	97.5	5.8	1464	1	CGHUIS	collagen alpha 1(I
23	94.5	5.6	664	1	CG4747	probable protein k
24	92.5	5.5	205	1	QWHDX	lymphotoxin alpha
25	92.5	5.5	450	2	S38114	hypothetical prote
26	91.5	5.4	3848	2	T17414	TiPC protein - sli
27	91	5.4	493	2	AC0937	probable GmR-fam1
28	90.5	5.4	1694	2	S50065	siadhesin - mou
29	90	5.3	730	2	JC1456	gelatinase B (EC 3

30	89.5	5.3	331	2	AF3526	homoprotocacthuc
31	89.5	5.3	379	2	A47659	farnesyl-protein t
32	89	5.3	202	1	B27303	tumor necrosis fac
33	89	5.3	440	2	I49681	glycerolaldehyde-3-p
34	89	5.3	479	2	A25052	fibrinogen beta ch
35	89	5.3	639	2	C83624	probable two-compo
36	88.5	5.3	565	2	C89893	hypothetical prote
37	88.5	5.3	578	2	S51379	probable phosphoes
38	88.5	5.3	684	2	T01267	leucine-rich repea
39	88.5	5.3	883	2	A49733	[heparan sulfate]-
40	87.5	5.2	610	2	T06690	galactonolactone d
41	87.5	5.2	1466	1	CGHUTL	collagen alpha 1(I
42	87	5.2	639	2	A32935	protein pI - Entlam
43	87	5.2	1114	2	JH0284	125K surface anti
44	87	5.2	1315	2	G96722	hypothetical prote
45	86.5	5.1	279	2	F72338	hypothetical prote

## ALIGNMENTS

RESULT 1  
138707  
Fas ligand - human  
C:Species: Homo sapiens (man)  
C:Date: 29-May-1998 #sequence revision 29-May-1998 #text\_change 09-Jul-2004  
C:Accession: I38707; J02340; S57565; I38554  
R:Takekoshi, T.; Tanaka, M.; Inazawa, J.; Abe, T.; Suda, T.; Nagata, S.  
Int. Immunol. 6, 1567-1574, 1994  
A:Title: Human Fas ligand: gene structure, chromosomal location and species specificity.  
A:Reference number: I38707; MUID:95127560; PMID:7826947  
A:Accession: I38707  
A:Status: preliminary; translated from GB/EMBL/DBJ  
A:Molecule type: DNA  
A:Residues: 1-281 <RES>  
A:Cross-references: UNIPARC:UPI000000D91A; GB:D38122; DDBJ:D29820; NID:G61892; PIDN:BAW  
R:Schatzlein, C.B.  
submitted to the EMBL Data Library, June 1995  
A:Reference number: S57565  
A:Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-281 <SCH>  
A:Cross-references: UNIPARC:UPI000000D91A; EMBL:X89102; NID:G887455; PID:G887456  
R:Allderson, M.R.; Tough, T.W.; Davis-Smith, T.; Brady, S.; Falk, B.; Schooley, K.A.; G  
J. Exp. Med. 181, 71-77, 1995  
A:Title: Fas ligand mediates activation-induced cell death in human T lymphocytes.  
A:Reference number: I38554; MUID:95105731; PMID:7528780  
A:Accession: I38554  
A:Status: preliminary; translated from GB/EMBL/DBJ  
A:Molecule type: mRNA  
A:Residues: 1-281 <RES>  
A:Cross-references: UNIPARC:UPI000000D91A; EMBL:U08137; NID:G624627; PIDN:MACS0071.1; P  
C:Genetic:  
A:Gene: FasL  
A:Introns: 151/1, 116/3  
C:Keywords: glycoprotein; transmembrane protein  
F:80-102/Domain: transmembrane #status predicted <TM>  
F:76,184,250,260/Binding site: carbohydrate (Aen) (covalent) #status predicted

Query Match 11.2% Score 189; DB 2; Length 281;  
Best Local Similarity 21.7%; Pred. No. 2e-08;  
Matches 69; Conservative 43; Mismatches 98; Indels 108; Gaps 11;  
22 PGAPHEPRLHAPPPAP---HQPAPASRS-----MFVALIGLIGLGVVCS 63

```
Db      46 PPPPPPPPLPPPPPPPLPPLPPLPKKRGHNSTGLCLLWPFMVLVALVGLG----- 100
Qy      64 VALFFPRQMPNRISEGTGHCYIRILNHNADQDTTLESQDTKLIPDSCKRIKQAF 123
Db      101 --MFQLFHQ-----KELAELESTSQMHTA----- 124
Qy      124 OGAVKELOHIVGSOHIRAEKAMVDGSMDLAKRSKLEAPPAHT--INATDIPSGSHK 181
Db      125 -SLEKQIGH-----PSPPEKKEIKRYAHLTGKSNRSM----- 159
Qy      182 VLSISSWYHGRWAKISNMTFSNGKLIYNODGEYIYANICFRHHETSGDLATEYLQLMVY 241
Db      160 ---LEWEDTYGIVLISGVKKKGGLVINEGTGLYFYVSKYFRGQSCNN-----LPLSHK 210
Qy      242 YKTKISIKIPSSHTLMKSGSTKY-----WSGSEHFHFYINVGFPFKLRSGEISIEVSN 295
Db      211 VYMRNSKYPQDLVIMWEGKMSYCTTGQMWARS-----YLGAVFNLTSAHLYVNVSE 263
Qy      296 PSLIDPDODATYFGAFKV 313
Db      264 LSLVNFESQTFPGLYKL 281
```

```
RESULT 2
A:3062
Fas ligand - mouse
C:Species: Mus musculus (house mouse)
C:Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 09-Jul-2004
C:Accession: A53062
R:Takahashi, T.; Tanaka, M.; Brannan, C.I.; Jenkins, N.A.; Copeland, N.G.; Suda, T.; Nag
Cell 76, 969-976, 1994
A:Title: Generalized lymphoproliferative disease in mice, caused by a point mutation in
A:Reference number: A53062; MUID:94185175; PMID:7511063
A:Accession: A53062
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-279 <TAK>
A:Cross-references: UNIPROT:P41047; UNIPARC:UPI0000004022; GB:U06948; NID:g473564; P1DN:
```

```
Query Match      10.9%; Score 184.5; DB 2; Length 279;
Best Local Similarity 21.7%; Pred. No. 4,9e-08;
Matches 70; Conservative 45; Mismatches 106; Indels 101; Gaps 11;

Qy      13 RSEEMGGGPGAPHGSRPLHAPRRPHOP-----PAASRSMVALLGL 57
Db      38 RRPDQRRPPRRPPVSLRPPSQRLPRLPLTKKKDHNTLMILVVFVFMVLVALVGMGL 97
Qy      58 GQVGSVALFFYFRAQMDPNRISEDTGHCYIRILNHNADQDTTLESQDTKLIPDSCR 117
Db      98 G-----MYQLFHL----- 105
Qy      118 RIKQAFQAVOKELQHI--VGSQHTRA--EKAMVDGSMDLAKRSKLEAPPAHTTNA 172
Db      106 -----QKELAELEFTNQSLKVSFEKQIANPS---TPSEKKEPRSVAILTGN- 150
Qy      173 TDIPSGSHKVSLS-SWYHGRWAKISNMTFSNGKLIYNODGEYIYANICFRHHETSD 231
Db      151 -----PHSRSLPLEMEDTYGTALISGVKKKGGLVINEGTGLYFYVSKYFRGQSCN--- 201
Qy      232 ATEYLQLMVYVTKTSIKIPSSHTLMKSGSTKYWSNSEHFHFYINVGFPFKLRSGEISI 291
Db      202 -NQPLNKKYMNNS--KYREDLVIMBEKRLNCT--TGQIMASSYLGAVFNLTSADHLV 257
Qy      292 EVSNPSLIDPDODATYFGAFKV 313
Db      258 NISQSLINFEESKTFPGLYKL 279
```

```
RESULT 3
S53090
CD40 ligand - bovine
C:Species: Bos primigenius taurus (cattle)
```

```
C:Date: 08-Jul-1995 #sequence_revision 21-Jul-1995 #text_change 09-Jul-2004
C:Accession: S53090
R:Mertens, B.E.L.C.; Murtiuk, M.
Submitted to the EMBL Data Library, February 1995
A:Description: Cloning of bovine CD40L and homology to bovine TNFA and TNFB.
A:Reference number: S53090
A:Accession: S53090
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-261 <MER>
A:Cross-references: UNIPROT:P51749; UNIPARC:UPI00001370A9; EMBL:Z48469; NID:g732569; P1DN:
```

```
Query Match      10.5%; Score 176.5; DB 2; Length 261;
Best Local Similarity 24.2%; Pred. No. 2,1e-07;
Matches 70; Conservative 54; Mismatches 122; Indels 43; Gaps 13;

Qy      33 PPPAPHPQPPAASRMFVALIGL-GQVGSVALFFYFRAQMDPNRISEDTGHCYIRIL 91
Db      8 PPSRSVATGPPVSKIRFMYLLTVFLITOMIGSALFAVYLHRLD--KIEDE-----R 57
Qy      92 RLHNADPQDT--TLSESQDTKLIPDSCKRIKQAFQAVOKELQHIIVGSOHIRAEKAVDG 149
Db      58 NLHEDFVFMKTIQRCKNGESLSLNCBEISRPFEDLVKQIMQ---NKEVKKKKRNF- 112
Qy      150 SMDLAKRSKLEAPPAHTLTINATDIPSGSHKVSLSWYHGRWAKISN--MTFSNGK-L 206
Db      113 -----MKGDQEPRIAAHVISEAS-----SKTYSVLQW-APKGYTSLNNLVTLENGKOL 161
Qy      207 IYNODGEYIYANICFRHHETSGDLATEYLQLMVYVTKTSIKIP--SSHTLMKSGSTKYW 264
Db      162 AVKRGQGEYIYVTVTFPCSNR-----ETLSQAFPIASLCKSPSGSERILLRAANTH-- 212
Qy      265 SGNSEHFHFYINVGFPFKLRSGEISIEVSNPSLIDPDODATYFGAFKV 313
Db      213 SSSKPCGQGSHTLGGVFELOSASVFVAVTDPDSQVSHGTFSTPGLLKL 261
```

```
RESULT 4
A49266
fas ligand - rat
C:Species: Rattus norvegicus (Norway rat)
C:Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 09-Jul-2004
C:Accession: A49266
R:Suda, T.; Takahashi, T.; Goletz, P.; Nagata, S.
Cell 75, 1169-1178, 1993
A:Title: Molecular cloning and expression of the fas ligand, a novel member of the tumor
A:Reference number: A49266; MUID:94084792; PMID:7505205
A:Accession: A49266
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-278 <SUD>
A:Cross-references: UNIPROT:P36940; UNIPARC:UPI00001370B5; GB:U03470; NID:g440178; P1DN:
```

```
Query Match      10.4%; Score 175.5; DB 2; Length 278;
Best Local Similarity 20.3%; Pred. No. 2,8e-07;
Matches 64; Conservative 47; Mismatches 106; Indels 99; Gaps 10;

Qy      21 GPGAPHGSRPLHAPRRPHOPPAASRM-----FVALIGLGL 57
Db      39 GPGQRRPPP--PPRPSPRLPPRSQRLPRLPLSKKDNITELMPLVIFMVLVALVGMGL 96
Qy      58 GQVGSVALFFYFRAQMDPNRISEDTGHCYIRILNHNADQDTTLESQDTKLIPDSCR 117
Db      97 G-----MYQLFQKELAELEFTNHSU--RVSSFEKQIANPSTPSTETKPPRSV----- 143
Qy      118 RIKQAFQAVOKELQHIIVGSOHIRAEKAMVDGSMDLAKRSKLEAPPAHTINATDIPS 177
Db      144 -----MYQLFQKELAELEFTNHSU--RVSSFEKQIANPSTPSTETKPPRSV----- 151
Qy      178 GSHKVSLSWYHGRWAKISNMTFSNGKLIYNODGEYIYANICFRHHETSGDLATEYLQ 237
Db      152 -SREIPL-EMEDTYGTALISGVKKKGGLVINEAGLYFYVSKYFRGQSCN-----SQPLS 205
```

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 13:02:07 ; Search time 174.61 Seconds  
(without alignments)  
758.559 Million cell updates/sec

Title: US-09-211-297-39

Sequence: 1 MRRASRDYTKYLGRSEMGCG.....LDDPDQATYFGAFKVRDID 317

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Published Applications\_AA\_Main:\*

- 1: /cgn2\_6/ptodaca/1/pubppaa/US07\_PUBCOMB.pep:\*
- 2: /cgn2\_6/ptodaca/1/pubppaa/US08\_PUBCOMB.pep:\*
- 3: /cgn2\_6/ptodaca/1/pubppaa/US09\_PUBCOMB.pep:\*
- 4: /cgn2\_6/ptodaca/1/pubppaa/US10A\_PUBCOMB.pep:\*
- 5: /cgn2\_6/ptodaca/1/pubppaa/US10B\_PUBCOMB.pep:\*
- 6: /cgn2\_6/ptodaca/1/pubppaa/US11\_PUBCOMB.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1685	100.0	317	3	US-09-813-329-7
2	1685	100.0	317	3	US-09-871-856-13
3	1685	100.0	317	3	US-09-957-944-6
4	1685	100.0	317	3	US-09-865-363-13
5	1685	100.0	317	3	US-09-871-291-13
6	1685	100.0	317	3	US-09-877-650-13
7	1685	100.0	317	3	US-09-933-915A-2
8	1685	100.0	317	4	US-10-151-071-10
9	1685	100.0	317	4	US-10-218-547-22
10	1685	100.0	317	4	US-10-405-878-13
11	1685	100.0	317	4	US-10-167-182-11
12	1685	100.0	317	4	US-10-310-793-28
13	1685	100.0	317	4	US-10-460-623-11
14	1685	100.0	317	4	US-10-289-456-79
15	1685	100.0	317	4	US-10-202-062-22
16	1685	100.0	317	4	US-10-664-801-2
17	1685	100.0	317	4	US-10-381-160-6
18	1685	100.0	317	4	US-10-799-345-12
19	1685	100.0	317	5	US-10-399-116-6
20	1685	100.0	317	5	US-10-802-133-13
21	1685	100.0	317	5	US-10-825-898-4
22	1685	100.0	317	5	US-10-854-300-11
23	1685	100.0	317	5	US-10-129-595-1
24	1685	100.0	317	5	US-10-451-200-6
25	1685	100.0	317	5	US-10-999-523-8
26	1685	100.0	317	6	US-11-028-780-22
27	1685	100.0	317	6	US-11-099-059-6

28	1685	100.0	317	6	US-11-135-521-11	Sequence 11, Appl
29	1685	100.0	317	6	US-11-142-736-7	Sequence 7, Appl
30	1424.5	84.5	316	3	US-09-957-944-8	Sequence 8, Appl
31	1424.5	84.5	316	4	US-10-799-345-10	Sequence 10, Appl
32	1424.5	84.5	316	6	US-11-099-059-8	Sequence 8, Appl
33	1422	84.4	270	4	US-10-289-456-80	Sequence 80, Appl
34	1417.5	84.1	316	3	US-09-079-569-7	Sequence 7, Appl
35	1417.5	84.1	316	3	US-09-873-829-4	Sequence 4, Appl
36	1417.5	84.1	316	3	US-09-933-915A-16	Sequence 16, Appl
37	1417.5	84.1	316	4	US-10-017-910-4	Sequence 2, Appl
38	1417.5	84.1	316	4	US-10-105-057-2	Sequence 2, Appl
39	1417.5	84.1	316	4	US-10-272-411-19	Sequence 19, Appl
40	1417.5	84.1	316	4	US-10-272-328A-19	Sequence 19, Appl
41	1417.5	84.1	316	4	US-10-326-052-2	Sequence 2, Appl
42	1417.5	84.1	316	4	US-10-167-182-1	Sequence 1, Appl
43	1417.5	84.1	316	4	US-10-460-623-1	Sequence 1, Appl
44	1417.5	84.1	316	4	US-10-664-801-4	Sequence 4, Appl
45	1417.5	84.1	316	4	US-10-664-801-6	Sequence 6, Appl

## ALIGNMENTS

```
RESULT 1
US-09-813-329-7
; Sequence 7, Application US/09813329
; Patent No. US20020012968A1
; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; TITLE OF INVENTION: No. US20020012968A1 Drosophila Tumor Necrosis Factor Class Mole
; FILE OR INVENTION: Variants Thereof
; FILE REFERENCE: D0016.NP
; CURRENT APPLICATION NUMBER: US/09/813,329
; PRIOR FILING DATE: 2001-03-20
; PRIOR APPLICATION NUMBER: 60/190,816
; PRIOR FILING DATE: 2000-03-21
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7
; LENGTH: 317
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
US-09-813-329-7
```

Query Match	100.0%	Score 1685	DB 3	Length 317
Best Local Similarity	100.0%	Pred. No. 4,9e-149	Mismatches 0	Indels 0
Matches 317	Conservative	0	Mismatches 0	Indels 0
QY	1	MRRASRDYTKYLGRSEMGCGPAPHEGRLHAPPPAPHPAPASRSMFVALIGLIGOV	60	Sequence 7, Appl
DB	1	MRRASRDYTKYLGRSEMGCGPAPHEGRLHAPPPAPHPAPASRSMFVALIGLIGOV	60	Sequence 7, Appl
QY	61	VCSVALFFYFRAQMDNRISEDDTHCIYRILRLHENAODPTTLESQDTKLIPDSGRKIK	120	Sequence 2, Appl
DB	61	VCSVALFFYFRAQMDNRISEDDTHCIYRILRLHENAODPTTLESQDTKLIPDSGRKIK	120	Sequence 2, Appl
QY	121	QAFQAVQKELQHVSSQHRAEKAMVDSWLDLAKRSKLEAPFAHLITINADIPSGH	180	Sequence 11, Appl
DB	121	QAFQAVQKELQHVSSQHRAEKAMVDSWLDLAKRSKLEAPFAHLITINADIPSGH	180	Sequence 11, Appl
QY	181	KVLSWYHIDRGNAKISNMTFSNGKLIYVODGGYVYIYANICFPHHETSGDLATYQLMV	240	Sequence 1, Appl
DB	181	KVLSWYHIDRGNAKISNMTFSNGKLIYVODGGYVYIYANICFPHHETSGDLATYQLMV	240	Sequence 1, Appl
QY	241	YVTKTSIKIPSSHTLMKSGSTKYWGNSEFFHYFINVGCFKLRSGEBISIEVSNPSILD	300	Sequence 6, Appl
DB	241	YVTKTSIKIPSSHTLMKSGSTKYWGNSEFFHYFINVGCFKLRSGEBISIEVSNPSILD	300	Sequence 6, Appl
QY	301	PDQATYFGAFKVRDID 317		Sequence 6, Appl
DB	301	PDQATYFGAFKVRDID 317		Sequence 6, Appl

```
RESULT 2
US-09-871-856-13
Sequence 13, Application US/09871856
Patent No. US20020081720A1
GENERAL INFORMATION:
APPLICANT: Anderson, Dirk M.
Maraskovsky, Eugene
Galibert, Laurent
TITLE OF INVENTION: Receptor Activator of NF-kappaB
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESS: Immunex Corporation, Law Department
STREET: 51 University Street
CITY: Seattle
STATE: WA
COUNTRY: USA
ZIP: 98101
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: Apple Power Macintosh
OPERATING SYSTEM: Apple Operating System 7.5.5
SOFTWARE: Microsoft Word for Power Macintosh 6.0.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/871,856
FILING DATE: 31-May-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/996,139
FILING DATE: <Unknown>
APPLICATION NUMBER: USSN 08/813,509
FILING DATE: 07 MARCH 1997
APPLICATION NUMBER: USSN 08/772,330
FILING DATE: 23 DECEMBER 1996
ATTORNEY/AGENT INFORMATION:
NAME: Perkins, Patricia Anne
REGISTRATION NUMBER: 34,693
REFERENCE/DOCKET NUMBER: 2851-A
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206)587-0430
TELEFAX: (206)233-0644
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 317 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-871-856-13
Query Match 100.0%; Score 1685; DB 3; Length 317;
Best Local Similarity 100.0%; Pred. No. 4.9e-149;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRRASRDYTKYLGRSEEMGGPGAPHEGPLHAPPPAPHPHOPPAASRSMFVALGLGLQGV 60
DB 1 MRRASRDYTKYLGRSEEMGGPGAPHEGPLHAPPPAPHPHOPPAASRSMFVALGLGLQGV 60
QY 61 VCSVALFFYFRAQMDPNRISBDGTHCIYRILRLHENAPODPTLESQDTKLIIPSCRIK 120
DB 61 VCSVALFFYFRAQMDPNRISBDGTHCIYRILRLHENAPODPTLESQDTKLIIPSCRIK 120
QY 121 QAFQGAQVQKELQHVGSQHIRAEKAMVDGSWLDLAKRSKLEAOPFAHLTINATDIPSGSH 180
DB 121 QAFQGAQVQKELQHVGSQHIRAEKAMVDGSWLDLAKRSKLEAOPFAHLTINATDIPSGSH 180
QY 181 KVSLSWYHDSRWAKISNMTFSGNGLIVNODGFYLLYANICFRHETSGDLATEYLQLMV 240
DB 181 KVSLSWYHDSRWAKISNMTFSGNGLIVNODGFYLLYANICFRHETSGDLATEYLQLMV 240
QY 241 VYTKTSIKIPSSHTLMKGGSTKYWGNSFHFYSINVGGFYFLKRSGBEISIEVSNPSILD 300
DB 241 VYTKTSIKIPSSHTLMKGGSTKYWGNSFHFYSINVGGFYFLKRSGBEISIEVSNPSILD 300
QY 301 PDODATYFGAFKVRDID 317
DB 301 PDODATYFGAFKVRDID 317
COMPUTER READABLE FORM:
```

```
QY 301 PDODATYFGAFKVRDID 317
DB 301 PDODATYFGAFKVRDID 317
RESULT 3
US-09-957-944-6
Sequence 6, Application US/09957944
Publication No. US20020086312A1
GENERAL INFORMATION:
APPLICANT: Dougall, William C.
TITLE OF INVENTION: SCREENING ASSAYS FOR AGONISTS AND ANTAGONISTS OF RECEPTOR ACTIVAT
FILE REFERENCE: 3109-A
CURRENT APPLICATION NUMBER: US/09/957,944
PRIOR FILING DATE: 2001-09-20
NUMBER OF SEQ ID NOS: 13
SOFTWARE: PatentIn version 3.1
SEQ ID NO 6
LENGTH: 317
TYPE: PRT
ORGANISM: Homo sapiens
US-09-957-944-6
Query Match 100.0%; Score 1685; DB 3; Length 317;
Best Local Similarity 100.0%; Pred. No. 4.9e-149;
Matches 317; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MRRASRDYTKYLGRSEEMGGPGAPHEGPLHAPPPAPHPHOPPAASRSMFVALGLGLQGV 60
DB 1 MRRASRDYTKYLGRSEEMGGPGAPHEGPLHAPPPAPHPHOPPAASRSMFVALGLGLQGV 60
QY 61 VCSVALFFYFRAQMDPNRISBDGTHCIYRILRLHENAPODPTLESQDTKLIIPSCRIK 120
DB 61 VCSVALFFYFRAQMDPNRISBDGTHCIYRILRLHENAPODPTLESQDTKLIIPSCRIK 120
QY 121 QAFQGAQVQKELQHVGSQHIRAEKAMVDGSWLDLAKRSKLEAOPFAHLTINATDIPSGSH 180
DB 121 QAFQGAQVQKELQHVGSQHIRAEKAMVDGSWLDLAKRSKLEAOPFAHLTINATDIPSGSH 180
QY 181 KVSLSWYHDSRWAKISNMTFSGNGLIVNODGFYLLYANICFRHETSGDLATEYLQLMV 240
DB 181 KVSLSWYHDSRWAKISNMTFSGNGLIVNODGFYLLYANICFRHETSGDLATEYLQLMV 240
QY 241 VYTKTSIKIPSSHTLMKGGSTKYWGNSFHFYSINVGGFYFLKRSGBEISIEVSNPSILD 300
DB 241 VYTKTSIKIPSSHTLMKGGSTKYWGNSFHFYSINVGGFYFLKRSGBEISIEVSNPSILD 300
QY 301 PDODATYFGAFKVRDID 317
DB 301 PDODATYFGAFKVRDID 317
RESULT 4
US-09-865-363-13
Sequence 13, Application US/09865363
Publication No. US20020086826A1
GENERAL INFORMATION:
APPLICANT: Anderson, Dirk M.
Maraskovsky, Eugene
Galibert, Laurent
TITLE OF INVENTION: Ligand for Receptor Activator of NF-kappaB
CORRESPONDENCE ADDRESS:
ADDRESS: Immunex Corporation, Law Department
STREET: 51 University Street
CITY: Seattle
STATE: WA
COUNTRY: USA
ZIP: 98101
COMPUTER READABLE FORM:
```



US-10-821-234-1288  
; Sequence 1288, Application US/10821234  
; Publication No. US20050255114A1  
; GENERAL INFORMATION:  
; APPLICANT: Labat, Ivan  
; APPLICANT: Stache-Crain, Birgit  
; APPLICANT: Andarmant, Susan  
; APPLICANT: Tang, Y. Tom  
; TITLE OF INVENTION: Methods for Diagnosis and Treatment of Preeclampsia  
; FILE REFERENCE: 821A  
; CURRENT APPLICATION NUMBER: US/10/821,234  
; CURRENT FILING DATE: 2004-04-07  
; PRIOR APPLICATION NUMBER: US 60/462,047  
; PRIOR FILING DATE: 2003-04-07  
; NUMBER OF SEQ ID NOS: 1704  
; SOFTWARE: pc\_seq\_genes Version 1.0  
; SEQ ID NO 1288  
; LENGTH: 281  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-821-234-1288

Query Match 14.9%; Score 251.5; DB 6; Length 281;  
Best Local Similarity 24.1%; Pred. No. 1.7e-16;  
Matches 71; Conservative 61; Mismatches 117; Indels 45; Gaps 10;  
QY 42 PAASRMFVALLGLGQVVCVALFFYPRAQMD--PNRISDGTCHCIYRILRLHENDAF 99  
DB 10 PSLGQTCVLIVITVLLQSLCAVATYYFTNELKQMDKYSKGIACF-----LKED--- 61  
QY 100 QDTLESQDTKLIPDSCRRIKOAFQAVQKELQHIIVGSOHIAEKAMVDGWLDAKRSK 159  
DB 62 -DSYWDPNDESMNSPCQVWK-----QLRQLVRKMLIRTSEETI-----STVQEKQ 107  
QY 160 LEAOPF-----AHLT-----INATDIPSGSHKVSLS---SSWYHDR-GMAKISNM 199  
DB 108 QNISPLVREGRQVRAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSFLSNL 167  
QY 200 TFSNGKLIVNODGFYLLVYLANICFRHHETSGDLATEYLQLMVYVTKSIKIPSSHTLMKG 259  
DB 168 HLRNGELVHKEGFYIYSQYTFRQBEIKENTKDKQVQIYKTT-SYDPDILMLMSA 226  
QY 260 STKYWSGEFFHFSINVGFFKLRSGEISIEVNSPLDPPDQATYFGAFKV 313  
DB 227 RNSCWSKDAEYGLVSIYGGIFELKENDRIFVSVTNEHLIDMDHSAFFGAFV 280

RESULT 3  
US-11-077-272-2  
; Sequence 2, Application US/11077272  
; Publication No. US20050244927A1  
; GENERAL INFORMATION:  
; APPLICANT: LEUNG, MOON-LAM SUSAN  
; APPLICANT: SMARTZ, JAMES R.  
; TITLE OF INVENTION: PROCESS FOR PRODUCING POLYPEPTIDES  
; FILE REFERENCE: P2019R1  
; CURRENT APPLICATION NUMBER: US/11/077,272  
; CURRENT FILING DATE: 2005-03-10  
; PRIOR APPLICATION NUMBER: US 60/552,678  
; PRIOR FILING DATE: 2004-03-11  
; NUMBER OF SEQ ID NOS: 7  
; SEQ ID NO 2  
; LENGTH: 281  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-11-077-272-2

Query Match 14.7%; Score 247.5; DB 7; Length 281;  
Best Local Similarity 24.1%; Pred. No. 4e-16;  
Matches 71; Conservative 60; Mismatches 118; Indels 45; Gaps 10;  
QY 42 PAASRMFVALLGLGQVVCVALFFYPRAQMD--PNRISDGTCHCIYRILRLHENDAF 99  
DB 10 PSLGQTCVLIVITVLLQSLCAVATYYFTNELKQMDKYSKGIACF-----LKED--- 61  
QY 100 QDTLESQDTKLIPDSCRRIKOAFQAVQKELQHIIVGSOHIAEKAMVDGWLDAKRSK 159  
DB 62 -DSYWDPNDESMNSPCQVWK-----QLRQLVRKMLIRTSEETI-----STVQEKQ 107  
QY 160 LEAOPF-----AHLT-----INATDIPSGSHKVSLS---SSWYHDR-GMAKISNM 199  
DB 108 QNISPLVREGRQVRAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSFLSNL 167  
QY 200 TFSNGKLIVNODGFYLLVYLANICFRHHETSGDLATEYLQLMVYVTKSIKIPSSHTLMKG 259  
DB 168 HLRNGELVHKEGFYIYSQYTFRQBEIKENTKDKQVQIYKTT-SYDPDILMLMSA 226  
QY 260 STKYWSGEFFHFSINVGFFKLRSGEISIEVNSPLDPPDQATYFGAFKV 313  
DB 227 RNSCWSKDAEYGLVSIYGGIFELKENDRIFVSVTNEHLIDMDHSAFFGAFV 280

DB 10 PSLGQTCVLIVITVLLQSLCAVATYYFTNELKQMDKYSKGIACF-----LKED--- 61  
QY 100 QDTLESQDTKLIPDSCRRIKOAFQAVQKELQHIIVGSOHIAEKAMVDGWLDAKRSK 159  
DB 62 -DSYWDPNDESMNSPCQVWK-----QLRQLVRKMLIRTSEETI-----STVQEKQ 107  
QY 160 LEAOPF-----AHLT-----INATDIPSGSHKVSLS---SSWYHDR-GMAKISNM 199  
DB 108 QNISPLVREGRQVRAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSFLSNL 167  
QY 200 TFSNGKLIVNODGFYLLVYLANICFRHHETSGDLATEYLQLMVYVTKSIKIPSSHTLMKG 259  
DB 168 HLRNGELVHKEGFYIYSQYTFRQBEIKENTKDKQVQIYKTT-SYDPDILMLMSA 226  
QY 260 STKYWSGEFFHFSINVGFFKLRSGEISIEVNSPLDPPDQATYFGAFKV 313  
DB 227 RNSCWSKDAEYGLVSIYGGIFELKENDRIFVSVTNEHLIDMDHSAFFGAFV 280

RESULT 4  
US-11-082-544-10  
; Sequence 10, Application US/11082544  
; Publication No. US20050249706A1  
; GENERAL INFORMATION:  
; APPLICANT: Bermudes, G.  
; APPLICANT: King, I.  
; APPLICANT: Clairmont, C.  
; APPLICANT: Belcourt, M.  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR  
; FILE REFERENCE: 8002-059  
; CURRENT APPLICATION NUMBER: US/11/082,544  
; CURRENT FILING DATE: 2005-03-17  
; PRIOR APPLICATION NUMBER: US/09/645,415  
; PRIOR FILING DATE: 2000-08-24  
; PRIOR APPLICATION NUMBER: 60/157,581  
; PRIOR FILING DATE: 1999-10-04  
; PRIOR APPLICATION NUMBER: 60/157,637  
; PRIOR FILING DATE: 1999-10-04  
; NUMBER OF SEQ ID NOS: 61  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 10  
; LENGTH: 266  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Fusion construct  
US-11-082-544-10

Query Match 14.0%; Score 235.5; DB 7; Length 266;  
Best Local Similarity 25.3%; Pred. No. 5e-15;  
Matches 65; Conservative 51; Mismatches 98; Indels 43; Gaps 9;  
QY 77 NRISDGTCHCIYRILRLHENDAFQDTLESQDTKLIPDSCRRIKOAFQAVQKELQHIIVG 136  
DB 32 DKYSKGIACF-----LKED-----DSYWDPNDESMNSPCQVWK-----QLRQLVR 74  
QY 137 SQHRAEKAMVDGWLDAKRSKLEAOPF-----AHLT-----INATDIPSGSHK 181  
DB 75 KMLIRTSEETI-----STVQEKQNISPLVREGRQVRAAHITGTRGRSNTLSSPNSKNE 129  
QY 182 VSL-----SSWYHDR-GMAKISNMTFNSNGKLIVNODGFYLLVYLANICFRHHETSGDLATEYL 236  
DB 130 KALGRKINSWESSRSGHSFLSNLHLRNGELVHKEGFYIYSQYTFRQBEIKENTKDK 189  
QY 237 QLMVYVTKSIKIPSSHTLMKGSTKYWSGEFFHFSINVGFFKLRSGEISIEVNSP 296  
DB 190 QMVQIYKTT-SYDPDILMLMSARNSCSKDAEYGLVSIYGGIFELKENDRIFVSVTNE 248  
QY 297 SLDDPDQATYFGAFKV 313  
DB 249 HLIDMDHSAFFGAFV 265

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:34:10 ; Search time 169.402 Seconds  
(without alignments)  
645.834 Million cell updates/sec

Title: US-09-211-297-39\_COPY\_69\_317

Sequence: 1 YFRAGMDPNRISEDTCTHCITY.....LIDPDQATVRCAGFVRDID 249

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :  
1: Genesegp1980a:\*  
2: genesegp1990a:\*  
3: genesegp2000a:\*  
4: genesegp2001a:\*  
5: genesegp2002a:\*  
6: genesegp2003a:\*  
7: genesegp2003bs:\*  
8: genesegp2004a:\*  
9: genesegp2005a:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match Length	ID	Description
1	1319	100.0	249 5	ABG94282 Human RAN
2	1319	100.0	249 5	ABG80594 Human rec
3	1319	100.0	249 7	ADJ82115 Protein f
4	1319	100.0	250 6	ADA50079 Human wll
5	1319	100.0	270 7	ADJ82113 Protein f
6	1319	100.0	317 2	AAW83018 Osteoclas
7	1319	100.0	317 2	AAW83195 Human ost
8	1319	100.0	317 2	AAW69957 NF-kB rec
9	1319	100.0	317 2	AAW68293 NF-kB rec
10	1319	100.0	317 2	AAW68293 Human rec
11	1319	100.0	317 3	AAW84417 Amino aci
12	1319	100.0	317 4	AAE04426 Human rec
13	1319	100.0	317 4	AAE01993 Human ful
14	1319	100.0	317 5	ABW08134 Human RAN
15	1319	100.0	317 5	AAE26103 Human RAN
16	1319	100.0	317 5	ABG31631 Human RAN
17	1319	100.0	317 5	AAU78285 Human TRA
18	1319	100.0	317 5	AAU01906 C neoform
19	1319	100.0	317 5	ADR29336 Human RAN
20	1319	100.0	317 6	ABP55108 Human ost
21	1319	100.0	317 6	AAE31364 Human rec
22	1319	100.0	317 6	ABR42314 Human RAN
23	1319	100.0	317 7	ADB16988 Human rec
24	1319	100.0	317 7	ADC35204 Human TNF

25	1319	100.0	317 7	ADC73002	Adc73002 Human RAN
26	1319	100.0	317 7	ADC78268	Adc78268 Human RAN
27	1319	100.0	317 7	ABW02277	Abw02277 Human RAN
28	1319	100.0	317 7	ADG46723	Adg46723 Protein f
29	1319	100.0	317 7	ADJ82112	Adj82112 Human rec
30	1319	100.0	317 8	ADM96241	Adm96241 Human RAN
31	1319	100.0	317 8	ADT08155	Adt08155 Human RAN
32	1319	100.0	317 8	ADW06570	Adw06570 Novel bro
33	1319	100.0	317 9	ADW09029	Adw09029 Human rec
34	1319	100.0	317 9	ADY16469	Ady16469 PRO polyp
35	1319	100.0	317 9	ADY74714	Ady74714 Human rec
36	1319	100.0	317 9	ADZ12661	Adz12661 Human can
37	1319	100.0	317 9	ADY97756	Ady97756 Human RAN
38	1316	99.8	250 6	ADA50095	Ada50095 Human RAN
39	1316	99.8	250 6	ADA50094	Ada50094 Human RAN
40	1316	99.8	250 6	ADA50102	Ada50102 Human RAN
41	1316	99.8	250 6	ADA50098	Ada50098 Human RAN
42	1315	99.7	250 6	ADA50101	Ada50101 Human RAN
43	1315	99.7	250 6	ADA50089	Ada50089 Human RAN
44	1315	99.7	250 6	ADA50086	Ada50086 Human RAN
45	1315	99.7	250 6	ADA50099	Ada50099 Human RAN

## ALIGNMENTS

RESULT 1  
ABG94282  
ID ABG94282 standard; protein; 249 AA.

XX ABG94282;

DT 10-DEC-2002 (first entry)

XX Human RANKL extracellular domain.

KW Human; mouse; rat; antimicrobial; antiallergic; immunomodulatory;

KW cytotoxic; antiviral; antidiabetic; hypoglycaemic; antigen array;

XX vaccine; infectious disease.

OS Homo sapiens.

PN WO200256905-A2.

PD 25-JUL-2002.

PF 21-JAN-2002; 2002WO-1B000166.

PR 19-JAN-2001; 2001US-0262379P.

PR 04-MAY-2001; 2001US-0288549P.

PR 05-OCT-2001; 2001US-0326998P.

PR 07-NOV-2001; 2001US-0331045P.

PA (CYTO-) CYTOS BIOTECHNOLOGY AG.

PI Renner WA, Bachmann M, Tissot A, Maurer P, Lechner F, Sebbel P;

PT Ploseck C;

DR WPI; 2002-627351/67.

PT Molecular antigen array used in the production of vaccines for infectious diseases.

PS Disclosure; Page 420; 441pp; English.

CC This invention relates to a novel ordered and repetitive antigen array used in the production of vaccines for infectious diseases. The invention also discloses a composition comprising a non-natural molecular scaffold comprising a core particle selected from a core particle of a non-natural origin and a core particle of natural origin and an organiser comprising at least one first attachment site, where the organiser is connected to the core particle by at least one covalent bond. Also disclosed is an antigen or antigenic determinant with at least one second attachment

CC site, where the antigen or antigenic determinant is amyloid beta peptide  
 CC (Abeta1-42) or its fragment and where the second attachment site is  
 CC selected from an attachment site not naturally occurring with the antigen  
 CC or antigenic determinant and an attachment site naturally occurring with  
 CC the antigen or antigenic determinant, where the second attachment site is  
 CC capable of association through at least one non-peptide bond to the first  
 CC attachment site and where the antigen or antigenic determinant and the  
 CC scaffold interact through the association to form an ordered and  
 CC repetitive antigen array. The invention also comprises a coat protein  
 CC capable of forming a capsid which comprises mutant Qbeta coat proteins  
 CC having an amino acid sequence selected from five amino acid sequences  
 CC fully defined in the specification. The compounds of the invention may  
 CC have antimicrobial, antiallergic, immunomodulatory, cytostatic,  
 CC antiviral, antidiabetic, or hypoglycaemic activities and may be used in  
 CC immunisation and as a vaccine. The present sequence represents a protein  
 CC sequence used to create the compositions of the invention

CC Sequence 249 AA;

Query Match 100.0%; Score 1319; DB 5; Length 249;  
 Best Local Similarity 100.0%; Pred. No. 9,4e-129;  
 Matches 249; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 YFRAQMDPNRISSEGTGHCYRIILRLHENADPDPTLLESQDTKLIPDSGRRIKQAFQAVQ 60  
 DB 1 YFRAQMDPNRISSEGTGHCYRIILRLHENADPDPTLLESQDTKLIPDSGRRIKQAFQAVQ 60  
 QY 61 KELQHVSGQHIRAEKAMVDGSMWDLAKRSKLEAPPAHLITNATDIPSGSHKYSLSWY 120  
 DB 61 KELQHVSGQHIRAEKAMVDGSMWDLAKRSKLEAPPAHLITNATDIPSGSHKYSLSWY 120  
 QY 121 HDRGMAKISNMTFSGNKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMVYVTKTSIK 180  
 DB 121 HDRGMAKISNMTFSGNKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMVYVTKTSIK 180  
 QY 181 IPSSHITLMKSGSTKYWNGSEFHFYSINVGFFPKRSGEISIEVSNPSLDDPDODATYF 240  
 DB 181 IPSSHITLMKSGSTKYWNGSEFHFYSINVGFFPKRSGEISIEVSNPSLDDPDODATYF 240  
 QY 241 GAFKYRDIID 249  
 DB 241 GAFKYRDIID 249

RESULT 2

ABG80594  
 ID ABG80594 standard; protein; 249 AA.

XX ABG80594;

DT 29-NOV-2002 (first entry)

DE Human receptor activator of NFkB ligand, RANKL, extracellular part.

XX Molecular antigen array; vaccine; antigen; antimicrobial;  
 KM molecular scaffold; amyloid beta; Abeta 1-42; influenza;  
 KM gratic versus host disease; IGE-mediated allergic reaction; anaphylaxis;  
 KM allergic respiratory distress syndrome; ARDS; Crohn's disease;  
 KM allergic asthma; acute lymphoblastic leukaemia; non-Hodgkin's lymphoma;  
 KM Grave's disease; systemic lupus erythematosus; osteoporosis;  
 KM inflammatory immune disease; myasthenia gravis; multiple sclerosis;  
 KM immunoproliferative disease lymphadenopathy; Alzheimer's disease;  
 KM angioimmunoproliferative lymphadenopathy; immunoblastic lymphadenopathy;  
 KM rheumatoid arthritis; diabetes; infectious disease; factor Xa;  
 KM enterokinase; cysteine-containing linker.

XX Homo sapiens.

XX WO200256907-A2.

XX 25-JUL-2002.

XX 21-JAN-2002; 2002WO-1B000168.

XX 19-JAN-2001; 2001US-0262379P.  
 PR 04-MAY-2001; 2001US-0288549P.  
 PR 05-OCT-2001; 2001US-0326998P.  
 PR 07-NOV-2001; 2001US-0331045P.  
 PA (CYTO-) CYTOS BIOTECHNOLOGY AG.  
 PA (NOVS) NOVARTIS PHARMA AG.  
 PA (MAUR/) MAURER P.  
 PA (LECH/) LECHNER F.  
 PA (ORTM/) ORTMANN R.  
 PA (LUEB/) LUEBEND R.  
 PA (STAU/) STAUFENBIEL M.  
 PA (PREY/) PREY P.  
 FI Maurer P, Lechner F, Ortmann R, Lueend R, Staufenbiel M, Frey P;  
 PI Renner WA, Bachmann M, Tissot A, Seibel P, Plossek C;  
 DR WPI, 2002-636514/68.  
 XX Molecular antigen array used in the production of vaccines for infectious  
 PT diseases.

PS Disclosure; Page 397; 418pp; English.

CC The invention relates to a composition comprising: (a) a non-natural  
 CC molecular scaffold comprising: (i) a core particle selected from: (1) a  
 CC core particle of a non-natural origin; and (2) a core particle of natural  
 CC origin; and (ii) an organiser comprising at least one first attachment  
 CC site, where the organiser is connected to the core particle by at least  
 CC one covalent bond; (b) an antigen or antigenic determinant with at least  
 CC one second attachment site, where the antigen or antigenic determinant is  
 CC amyloid beta peptide (Abeta 1-42) or its fragment, and where the second  
 CC attachment site is selected from: (i) an attachment site not naturally  
 CC occurring with the antigen or antigenic determinant; and (ii) an  
 CC attachment site naturally occurring with the antigen or antigenic  
 CC determinant, where the second attachment site is capable of association  
 CC through at least one non-peptide bond to the first attachment site; and  
 CC where the antigen or antigenic determinant and the scaffold interact  
 CC through the association to form an ordered and repetitive antigen array.  
 CC Also included is a process for producing a non-naturally occurring  
 CC ordered and repetitive antigen array. The composition is used in  
 CC immunisation and as a vaccine for diseases such as influenza, graft  
 CC versus host disease, IGE-mediated allergic reactions, anaphylaxis, adult  
 CC respiratory distress syndrome (ARDS), Crohn's disease, allergic asthma,  
 CC acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, Grave's disease,  
 CC systemic lupus erythematosus, inflammatory immune diseases, myasthenia  
 CC gravis, immunoproliferative disease lymphadenopathy,  
 CC angioimmunoproliferative lymphadenopathy, immunoblastic lymphadenopathy,  
 CC rheumatoid arthritis, diabetes, multiple sclerosis, Alzheimer's disease,  
 CC osteoporosis and infectious diseases. The present sequence is an antigen  
 CC for use in the array of the invention. The antigen is modified to possess  
 CC a cleavage site (enterokinase or factor Xa) and a cysteine-containing N-  
 CC or C-terminal linker peptide which serves as the attachment point to a  
 CC virus like particle or bacterial protein (the scaffold protein)

XX Sequence 249 AA;

Query Match 100.0%; Score 1319; DB 5; Length 249;  
 Best Local Similarity 100.0%; Pred. No. 9,4e-129;  
 Matches 249; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 YFRAQMDPNRISSEGTGHCYRIILRLHENADPDPTLLESQDTKLIPDSGRRIKQAFQAVQ 60  
 DB 1 YFRAQMDPNRISSEGTGHCYRIILRLHENADPDPTLLESQDTKLIPDSGRRIKQAFQAVQ 60  
 QY 61 KELQHVSGQHIRAEKAMVDGSMWDLAKRSKLEAPPAHLITNATDIPSGSHKYSLSWY 120  
 DB 61 KELQHVSGQHIRAEKAMVDGSMWDLAKRSKLEAPPAHLITNATDIPSGSHKYSLSWY 120  
 QY 121 HDRGMAKISNMTFSGNKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMVYVTKTSIK 180  
 DB 121 HDRGMAKISNMTFSGNKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMVYVTKTSIK 180



A; Cross-references: UNIPROT:P41047; UNIPARC:UPI0000004022; GB:U06948; NID:g47

	Query Match	11.9%	Score 157;	DB 2;	Length 279;
	Beet Local Similarity	25.9%	Pred. No. 3e-06;		
	Matches	50;	Conservative	38;	Mismatches 81; Indels 24; Gaps 8;
Oy	59 VQKELOHI--VGSQHIRA---EKAMVDGSMWLDLAKRSKLEAPFAHLTINATDIPSGSHK	113	:	:	:
Dd	105 LÖKELAEIAREFTNGSLKXVSFEKOJANPS-----TPSEKKERSRVAHLGN-----PHS	153	:	:	:
Oy	114 VSLS-SWYHDGRMAKISNMTFSNGKLIVNOGGFYILYLIANTIFRHHETSGLDATEYLQMLV	172	:	:	:
Dd	154 RSIPLMEWDVTGYALGISGVKKKGGLVIINEGLYFVVSKVFYRQSCGSC---NOPLNHKV	209	:	:	:
Oy	173 YVTKTSIKIPISSHTLMKMGSTKYWSNGNSEPFHYSLNVGCFKLRSGEIEISLVENPSSLID	232	:	:	:
Dd	210 YMRNS--KYRPEDVLIMEEKRNLNYCT-TGOIWAHSSYLGAIVNLITSADHLVYNIGQLSLIN	266	:	:	:
Oy	233 PDQDATYTGAFKV	245	:	:	:
Dd	267 FEESTKTFPGLYTL	279	:	:	:

RESULT 3

CD340 ligand - human

N:Alternate names: glycoprotein 39; hCD40-L protein; T-cell antigen gp39; TRAP protein

C:Species: Homo sapiens (man)

C:Date: 02-Jul-1996 #sequence revision 02-Jul-1996 #text change 09-Jul-2004

C:Accession: S28017; JH0793; S26594; S28852; I53476; S25684; S30593

R:Holtenbaugh, D.; Grosmitre, L.S.; Kullas, C.D.; Chalupny, N.J.; Braesch-Andersen, S.; EMBO J. 11, 4313-4321, 1992

A:Title: The human T cell antigen gp39, a member of the TNF gene family, is a ligand for

A:Reference number: S28017; MUID:93049181; PMID:1385114

A:Accession: S28017

A:Residues: 1-261 <HOL>

A:Molecule type: mRNA

A:Cross-references: UNIPROT: P29965; UNIPARC:UPI00000315E7; EMBL: Z15017; NID: g38483; PIDD: R:SP1499, M.K.; Armitage, R.J.; Strockbine, L.; Clifford, K.N.; Macduff, B.W.; Sato, T

U. Exp. Med. 176, 1543-1550, 1992

A:Title: Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin

A:Reference number: JH0793; MUID:93094757; PMID:1281209

A:Accession: JH0793

A:Molecule type: mRNA

A:Residues: 1-261 <SPR>

A:Cross-references: UNIPARC:UPI00000315E7; GB:X67878; NID: g38411; PIDD: CAA48077.1; PTD: S: A:Experimental source: peripheral blood T-cell

R: Graf, D.; Korthauer, U.; Mages, H.W.; Senger, G.; Krocsek, R.A.

Eur. J. Immunol. 22, 3191-3194, 1992

A:Title: Cloning of TRAP, a ligand for CD40 on human T cells.

A:Reference number: S26594; MUID:93076854; PMID:1280226

A:Accession: S26594

A:Status: preliminary

A:Molecule type: mRNA

A:Residues: 1-261 <GRA>

A:Cross-references: UNIPARC:UPI00000315E7; EMBL: X68550; NID: g37269; PIDD: CAA46554.1; PIR: R:Gauchat, J.F.; Aubry, J.P.; Mazzei, G.; Life, P.; Jomote, T.; Elson, G.; Bonnefoy, J

FEBS Lett. 315, 259-266, 1993

A:Title: Human CD40-ligand: molecular cloning, cellular distribution and regulation of e

A:Reference number: S28852; MUID:93138085; PMID:7678552

A:Accession: S28852

A:Molecule type: mRNA

A:Residues: 1-261 <GAU>

A:Cross-references: UNIPARC:UPI00000315E7; EMBL: L07414; NID: g180123; PIDD: AAA55662.1; PIR: A:Note: the sequence from Fig. 3 is inconsistent with that from Fig. 2 in having 6-Gln

C:Genetics:

A:Gene: GDB: CD40LG; HIGM1; IMD3

A:Cross-references: GDB: 120632; OMIM: 308230

A:Map position: Xq26-Xq26

C:Keywords: glycoprotein; transmembrane protein

F:13-44/Domain: transmembrane #status predicted <TM>

F:45-261/Domain: extracellular #status predicted <EXT>

F:6-240/Binding site: carbohydrate (Asn) (covalent) #status predicted

[illegible]

```

RESULT 4
138707
Fas ligand - human
C:Species: Homo sapiens (nan)
C.Date: 29-May-1998 #sequence revision 29-May-1998 #text_change 09-Jul-2004
C.Accession: 138707; J02310; S57565; I38554
R:Takahashi, T.; Tanaka, M.; Inazawa, J.; Abe, T.; Suda, T.; Nagata, S.
Int. Immunol. 6, 1567-1574, 1994
A>Title: Human Fas ligand: gene structure, chromosomal location and species specificity.
A.Reference number: 138707; MUID:95127560; PMID:7826947
A.Accession: 138707
A>Status: preliminary; translated from GB/EMBL/DBD
A.Molecule type: mRNA
A.Residues: 1-281 <RES>
A.Cross-references: UNIPROT:P48023; UNIPARC:UPI000000D91A; EMBL:U11621; NID:G595430; PID:
R.Mitch, E.; Hayashi, N.; Iio, S.; Takehara, T.; Hijioke, T.; Kasehara, A.; Fuesamoto, H.;
Biochem. Biophys. Res. Commun. 204, 468-474, 1994
A>Title: Role of Fas ligand in apoptosis induced by hepatitis C virus infection.
A.Reference number: J02340; MUID:95071350; PMID:780502
A.Accession: J02340
A.Molecule type: DNA
A.Residues: 1-281 <MIT>
A.Cross-references: UNIPARC:UPI000000D91A; GB:D38122; DDBJ:298820; NID:G601892; PIDN:BAAC
R.Schaezelin, C.E.
submitted to the EMBL Data Library, June 1995
A.Reference number: S57565
A.Accession: S57565
A.Status: preliminary
A.Molecule type: mRNA
A.Residues: 1-281 <SCH>
A.Cross-references: UNIPARC:UPI000000D91A; EMBL:X89102; NID:9887455; PID:9887456
R.Alderson, M.R.; Tough, T.W.; Davis-Smith, T.; Braddy, S.; Falk, B.; Schooley, K.A.; Go
J. Exp. Med. 181, 71-77, 1995
A>Title: Fas ligand mediates activation-induced cell death in human T lymphocytes.
A.Reference number: I38554; MUID:95105731; PMID:7528780
A.Accession: I38554
A.Status: preliminary; translated from GB/EMBL/DBD
A.Molecule type: mRNA
A.Residues: 1-281 <RE2>
A.Cross-references: UNIPARC:UPI000000D91A; EMBL:U08137; NID:9624627; PIDN:AAC50071.1; PI
C:Genetics:
A:Gene: FasL
A:Introns: 151/1; 116/3
C.Keywords: glycoprotein; transmembrane protein
F:80-102/Domain: transmembrane #status predicted <TM>
F:76,184,250,260/Binding site: carbohydrate (Aa) (covalent) #status predicted
Query Match 11.3%; Score 149.5; DB 2; Length 281;
Best Local Similarity 23.9%; Pred. No. 1,4e-05;
Matches 47; Conservative 33; Mismatches 74; Gaps 6;

```

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:35:06 ; Search time 171.443 Seconds  
(without alignment)  
1024.696 Million cell updates/sec

Title: US-09-211-297-39\_COPY\_69\_317  
Perfect score: 1319  
Sequence: 1 YFRAQMDPRISEDGTICV.....LDDPDQATYFGAFKVRDID 249

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :  
1: uniprot\_05.80.\*  
2: uniprot\_sprot.\*  
3: uniprot\_trembl.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1319	100.0	317	1	TNFI1_HUMAN
2	1319	100.0	317	2	Q5T9Y4_HUMAN
3	1292	98.0	244	2	O54A98_HUMAN
4	1127	85.4	316	1	TNFI1_MOUSE
5	1118	84.8	318	1	TNFI1_RAT
6	482	36.5	290	2	Q5H2R8_XENLA
7	470	35.6	117	2	Q5XLH0_BRARI
8	253.5	19.2	317	2	Q7ZYX9_BRARI
9	252.5	18.1	289	2	Q4VSR6_PIG
10	242	18.3	304	2	Q7T1P2_CHICK
11	241.5	18.3	303	2	Q5XKX3_MOUSE
12	240.5	18.2	214	2	Q9DD55_BRARI
13	239.5	18.2	292	2	Q5ZKX3_CHICK
14	238.5	18.1	291	1	TNFI1_MOUSE
15	238	18.0	264	2	Q4S9Q4_TETNG
16	237	18.0	299	2	Q6DHG9_BRARI
17	236.5	17.9	281	1	TNFI1_HUMAN
18	236.5	17.9	281	2	Q61BA9_HUMAN
19	219	16.6	300	2	Q5U675_HUMAN
20	216.5	16.4	287	2	Q90W79_CHICK
21	211	16.0	285	2	Q4SKU4_TETNG
22	207.5	15.7	287	2	Q8K3G0_RAT
23	184.5	14.0	252	2	Q8K3Y8_MOUSE
24	181	13.7	95	2	Q6UWL7_HUMAN
25	181	13.7	95	2	Q6UY13_HUMAN
26	179.5	13.6	252	2	Q80Y20_MOUSE
27	177.5	13.5	252	2	Q8K3Y7_RAT
28	172.5	13.1	253	2	Q5CAQ0_CHICK
29	171	13.0	278	2	Q4STY9_CHICK
30	162	12.3	239	2	Q50L61_CHICK
31	160	12.1	207	2	Q58G74_CHICK

32	160	12.1	279	2	Q7TMV9_MOUSE
33	158	12.0	98	2	Q4T6H7_TETNG
34	157.5	11.9	282	1	TNFI6_PIG
35	157	11.9	261	1	TNFI6_BOVIN
36	157	11.9	279	1	TNFI6_MOUSE
37	157	11.9	279	2	Q544E3_MOUSE
38	156.5	11.9	192	2	Q5VJK8_MOUSE
39	156.5	11.9	251	2	Q8VFE9_HUMAN
40	155	11.8	280	2	Q861W5_FELCA
41	150	11.4	261	1	TNFI5_AOTTR
42	150	11.4	261	1	TNFI5_CALJA
43	150	11.4	261	1	TNFI5_HUMAN
44	149.5	11.3	280	1	TNFI6_MACPA
45	149.5	11.3	280	1	TNFI6_MACMU

## ALIGNMENTS

RESULT 1  
ID TNFI1\_HUMAN STANDARD; PRT; 317 AA.  
AC 014788; 014723; Q96Q17; Q9P2Q3;  
DT 16-OCT-2001 (Rel. 40, Created)  
DT 16-OCT-2001 (Rel. 40, Last sequence update)  
DT 13-SEP-2005 (Rel. 48, Last annotation update)  
DE Tumor necrosis factor ligand superfamily member 11 (Receptor activator  
DE of nuclear factor kappa B ligand) (RANKL) (TNF-related activation-  
DE induced cytokine) (TRANCE) (Osteoprotegerin ligand) (OPGL) (Osteoclast  
DE differentiation factor) (ODF) (Contains: Tumor necrosis factor ligand  
DE superfamily member 11, membrane form; Tumor necrosis factor ligand  
DE superfamily member 11, soluble form).  
GN Name=TNFSF11; Synonyms=OPGL, RANKL, TRANCE;  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;  
OC Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP NUCLEOTIDE SEQUENCE (ISOFORM 1).  
RC TISSUE=Bone marrow, and Peripheral blood;  
RX MEDLINE=98032977; PubMed=936755; DOI=10.1038/36593;  
RA Anderson D.M., Maraskovsky E., Billingsley W.L., Dougan W.C.,  
RA Tometsko M.E., Roux E.R., Teepe M.C., Dubose R.F., Cosman D.,  
RA Gilbert L.;  
RT "A homologue of the TNF receptor and its ligand enhance T-cell growth  
RT and dendritic-cell function.";  
RL Nature 390:175-179(1997).  
[2]  
RN NUCLEOTIDE SEQUENCE (ISOFORM 1).  
RP TISSUE=Lymph node;  
RX MEDLINE=9827661; PubMed=9568710; DOI=10.1016/S0092-8674(00)81569-X;  
RA Lacey D.L., Timms E., Tan H.-L., Kelley M.J., Dunstan C.R.,  
RA Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H.,  
RA Sullivan J., Hawkins N., Davy E., Caporale C., Eli A., Qian Y.-X.,  
RA Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J.,  
RA Boyle W.J.;  
RT "Osteoprotegerin ligand is a cytokine that regulates osteoclast  
RT differentiation and activation.";  
RL Cell 93:165-176(1998).  
[3]  
RN NUCLEOTIDE SEQUENCE (ISOFORMS 1, 2 AND 3).  
RP Ikeda T., Kuroyama H., Hirokawa K.;  
RT "Determination of human RANKL isoforms.";  
RL Submitted (JUN-2001) to the EMBL/GenBank/DBJ databases.  
[4]  
RN NUCLEOTIDE SEQUENCE (ISOFORM 2).  
RP TISSUE=tongue;  
RX MEDLINE=2015237; PubMed=10708588; DOI=10.1006/bbrc.2000.2314;  
RA Nagai M., Yakumoto S., Sato N.;  
RT "Cancer cells responsible for humoral hypercalcemia express mRNA  
RT encoding a secreted form of ODF/TRANCE that induces osteoclast  
RT formation.";

RL Biochem. Biophys. Res. Commun. 269:532-536(2000).

RP [5]

RN NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).

RC TISSUE=Lung;

RX MEDLINE=2238257; PubMed=12477932; DOI=10.1073/pnae.242603899;

RA Strusberg R.L., Felngold E.A., Grouse L.H., Derge J.G.,

RA Kleauer R.D., Collins F.S., Wagner L., Shemen C.M., Schuler G.D.,

RA Altschul S.F., Zeeberg B., Buecker K.H., Scheffer C.F., Bhat N.K.,

RA Hopfing R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,

RA Diachenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,

RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Schetz T.E.,

RA Brownstein M.J., Uedlin T.B., Toshiyuki S., Carninci P., Prange C.,

RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,

RA Bosak S.A., McSwain P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,

RA Richards S., Morley K.C., Hale S., Garcia A.M., Gay L.J., Hulik S.W.,

RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,

RA Fanev J., Helton E., Kettelman W., Madan A., Rodrigues S., Sanchez A.,

RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,

RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,

RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,

RA Buterfield V.S.N., Krzywinski M.I., Skalska U., Smalins D.E.,

RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.,

RT "Generation and initial analysis of more than 15,000 full-length human

RT and mouse cDNA sequences.";

RT Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).

RL [6]

RN NUCLEOTIDE SEQUENCE OF 73-317.

RP TISSUE=Thymocyte.

RX MEDLINE=97460112; PubMed=9312132; DOI=10.1074/jbc.272.40.25190;

RA Wong B.R., Rho J., Aron J., Robinson E., Orlinick J., Chao M.,

RA Kalichkov S., Cayan E., Bartlett F.S. III, Frankel W.N., Lee S.Y.,

RA Choi Y.;

RT "TRANCE is a novel ligand of the tumor necrosis factor receptor family

RT that activates c-Jun N-terminal kinase in T cells.";

RL J. Biol. Chem. 272:25190-25194(1997).

CC -1- FUNCTION: Cytokine that binds to TNFRSF11B/OPG and to

CC TNFRSF11A/RANK. Osteoclast differentiation and activation factor.

CC Augments the ability of dendritic cells to stimulate naive T-cell

CC proliferation. May be an important regulator of interactions

CC between T cells and dendritic cells and may play a role in the

CC regulation of the T cell-dependent immune response. May also play

CC an important role in enhanced bone-resorption in humoral

CC hypercalcemia of malignancy.

CC -1- SUBUNIT: Homotrimer (By similarity).

CC -1- SUBCELLULAR LOCATION: Type II membrane protein (isoforms 1 and 3);

CC Secreted (isoform 2). A soluble form of isoform 1 arises by

CC proteolytic processing (By similarity).

CC -1- ALTERNATIVE PRODUCTS:

CC Event=Alternative splicing; Named isoforms=3;

CC Name=1;

CC IsoId=014788-1; Sequence=Displayed;

CC Name=2; Synonyms=SDPF;

CC IsoId=014788-2; Sequence=VSP\_006447;

CC Name=3;

CC IsoId=014788-3; Sequence=VSP\_006446;

CC -1- TISSUE SPECIFICITY: Highest in the peripheral lymph nodes, weak in

CC spleen, peripheral blood leukocytes, bone marrow, heart, placenta,

CC skeletal muscle, stomach and thyroid.

CC -1- INDUCTION: Up-regulated by T cell receptor stimulation.

CC -1- PTM: The soluble form of isoform 1 derives from the membrane form

CC by proteolytic processing (By similarity). The cleavage may be

CC catalyzed by ADAM17.

CC -1- SIMILARITY: Belongs to the tumor necrosis factor family.

CC -----

CC This Swiss-Prot entry is copyright. It is produced through a collaboration

CC between the Swiss Institute of Bioinformatics and the EMBL outstation-

CC the European Bioinformatics Institute. There are no restrictions on its

CC use as long as its content is in no way modified and this statement is not

CC removed.

CC

CC EMBL, AF019047; AAB86811.1; -; mRNA.

DR EMBL, AF053712; AAC39731.1; -; mRNA.

DR EMBL, AB064269; BAB79694.1; -; mRNA.

DR EMBL, AB061227; BAB71768.1; -; mRNA.

DR EMBL, AB064270; BAB79695.1; -; mRNA.

DR EMBL, AB037599; BAA90488.1; -; mRNA.

DR EMBL, BC074823; AAT74823.1; -; mRNA.

DR EMBL, BC074850; AAT74850.1; -; mRNA.

DR EMBL, AF013171; AAC51762.1; -; mRNA.

DR HSSP, O35235; 1J72.

DR SMR, O14788; 162-317.

DR Ensembl, ENSG00000120659; Homo sapiens.

DR HGNC, HGNC:11926; TNFRSF11.

DR MIM, 602642; -.

DR GO, GO:0005576; C:extracellular region; NAS.

DR GO, GO:0005887; C:integral to plasma membrane; NAS.

DR GO, GO:0005164; F:tumor necrosis factor receptor binding; NAS.

DR GO, GO:0006955; P:immune response; NAS.

DR GO, GO:0030316; P:osteoclast differentiation; NAS.

DR InterPro, IPR006052; TNF\_family.

DR InterPro, IPR003636; TNF\_subf.

DR Pfam, PF00229; TNF; 1.

DR ProDom, PD002012; TNF\_subf; 1.

DR SMART, SM00207; TNF; 1.

DR PROSITE, PS00251; TNF\_1; FALSE\_NEG.

DR PROSITE, PS00049; TNF\_2; 1.

KW Alternative splicing; Cytokine; Developmental protein;

KW Differentiation; Glycoprotein; Receptor; Signal-anchor; Transmembrane.

FT CHAIN 1 317

FT Tumor necrosis factor ligand superfamily

FT member 11, membrane form.

FT CHAIN 140 317

FT Tumor necrosis factor ligand superfamily

FT member 11, soluble form (By similarity).

FT TOPO\_DOM 1 47

FT Cytoplasmic (Potential).

FT TRANSMEM 48 68

FT Signal-anchor for type II membrane

FT protein (Potential).

FT TOPO\_DOM 69 317

FT Extracellular (Potential).

FT SITE 139 140

FT Cleavage (By similarity).

FT CARBOHYD 171 171

FT N-linked (GlcNAc...) (Potential).

FT CARBOHYD 198 198

FT N-linked (GlcNAc...) (Potential).

FT VASPLIC 1 73

FT Missing (in isoform 2).

FT VASPLIC 1 47

FT Missing (in isoform 3).

FT /Frid=VSP\_006447.

FT /Frid=VSP\_006446.

FT /Frid=VSP\_006445.

FT CONFLICT 194 194 A->G (in Ref. 6).

FT SEQUENCE 317 AA; 35478 MW; 76617646348097F CRC64;

SO QUERY MATCH

Best Local Similarity 100.0%; Score 1319; DB 1; Length 317;

Matches 249; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 YFRAQMDPNRISDEGTHCTYRILRLHENAQRDPTTLESQDTKLIIPDSCRRIKQAFQAVQ 60

DB 69 YFRAQMDPNRISDEGTHCTYRILRLHENAQRDPTTLESQDTKLIIPDSCRRIKQAFQAVQ 128

QY 61 KELGHIVGSHIRAEKAMVDGSMWDLAKRSKLEAOPFAHLTINTNDIPSGSHKVSLSMW 120

DB 129 KELGHIVGSHIRAEKAMVDGSMWDLAKRSKLEAOPFAHLTINTNDIPSGSHKVSLSMW 188

QY 121 HDRGMAKISNMTFSGNGKLIIVQDGFYLYANICRRHETSGDLATEYLQLVVYTKTSIK 180

DB 189 HDRGMAKISNMTFSGNGKLIIVQDGFYLYANICRRHETSGDLATEYLQLVVYTKTSIK 248

QY 181 IPSSHTLMKGGSTKYWSGNSFFHYYSINVGGFFLKLRSGEISIEVSNPSLLDPPQDATYF 240

DB 249 IPSSHTLMKGGSTKYWSGNSFFHYYSINVGGFFLKLRSGEISIEVSNPSLLDPPQDATYF 308

QY 241 GAFYVRDID 249

DB 309 GAFYVRDID 317

RESULT 2

OST9Y4 HUMAN

ID OST9Y4 HUMAN PRELIMINARY; PRT; 317 AA.

AC OST9Y4;

DT 01-FEB-2005 (TRENDELREL 29, Created)

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using SW model

Run on: December 21, 2005, 12:44:31 ; Search time 42.4525 Seconds  
(without alignments)  
484.925 Million cell updates/sec

Title: US-09-211-297-39\_COPY\_69\_317

Perfect score: 1319  
Sequence: 1 YFRAGMDPNRISEDTGHCY.....LLDPDQATYFGAFKVRDID 249

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 45 summaries

Database : Issued\_Patents\_AA:\*  
1: /cgn2\_6/prodata/1/1aa/5.COMB.pep.\*  
2: /cgn2\_6/prodata/1/1aa/6.COMB.pep.\*  
3: /cgn2\_6/prodata/1/1aa/H.COMB.pep.\*  
4: /cgn2\_6/prodata/1/1aa/PCTUS.COMB.pep.\*  
5: /cgn2\_6/prodata/1/1aa/R.COMB.pep.\*  
6: /cgn2\_6/prodata/1/1aa/backfillset.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1319	100.0	317	2	US-08-996-139-13 Sequence 13, Appl
2	1319	100.0	317	2	US-08-995-659-13 Sequence 13, Appl
3	1319	100.0	317	2	US-09-215-649A-13 Sequence 4, Appl
4	1319	100.0	317	2	US-09-052-521C-4 Sequence 13, Appl
5	1319	100.0	317	2	US-09-577-800-13 Sequence 13, Appl
6	1319	100.0	317	2	US-09-466-496-13 Sequence 13, Appl
7	1319	100.0	317	2	US-09-871-856-13 Sequence 13, Appl
8	1319	100.0	317	2	US-09-871-291-13 Sequence 13, Appl
9	1319	100.0	317	2	US-09-396-937-2 Sequence 2, Appl
10	1319	100.0	317	2	US-09-865-363-13 Sequence 13, Appl
11	1319	100.0	317	2	US-09-868-459-13 Sequence 13, Appl
12	1319	100.0	317	2	US-09-957-944-6 Sequence 6, Appl
13	1319	100.0	317	2	US-08-996-139-11 Sequence 11, Appl
14	1319	100.0	317	2	US-08-995-659-11 Sequence 11, Appl
15	1319	100.0	317	2	US-08-995-659-11 Sequence 11, Appl
16	1319	100.0	317	2	US-08-995-659-11 Sequence 11, Appl
17	1319	100.0	317	2	US-08-995-659-11 Sequence 11, Appl
18	1319	100.0	317	2	US-08-995-659-11 Sequence 11, Appl
19	1319	100.0	317	2	US-08-995-659-11 Sequence 11, Appl
20	1319	100.0	317	2	US-08-995-659-11 Sequence 11, Appl
21	1319	100.0	317	2	US-08-995-659-11 Sequence 11, Appl
22	1319	100.0	317	2	US-08-995-659-11 Sequence 11, Appl
23	1319	100.0	317	2	US-08-995-659-11 Sequence 11, Appl
24	1319	100.0	317	2	US-08-995-659-11 Sequence 11, Appl
25	1319	100.0	317	2	US-08-995-659-11 Sequence 11, Appl
26	1319	100.0	317	2	US-08-995-659-11 Sequence 11, Appl
27	1319	100.0	317	2	US-08-995-659-11 Sequence 11, Appl

28	1127	85.4	316	2	US-08-989-362-2 Sequence 2, Appl
29	1127	85.4	316	2	US-09-052-521C-2 Sequence 2, Appl
30	1127	85.4	316	2	US-09-671-658A-2 Sequence 2, Appl
31	1127	85.4	316	2	US-09-396-937-4 Sequence 4, Appl
32	1127	85.4	316	2	US-09-396-937-6 Sequence 6, Appl
33	771	58.5	187	2	US-09-396-937-8 Sequence 8, Appl
34	769	58.3	173	2	US-09-396-937-10 Sequence 10, Appl
35	759	57.5	173	2	US-09-396-937-12 Sequence 12, Appl
36	721.5	54.7	188	2	US-09-396-937-14 Sequence 14, Appl
37	711.5	53.9	182	2	US-09-396-937-16 Sequence 16, Appl
38	691	52.4	173	2	US-09-396-937-18 Sequence 18, Appl
39	670	50.8	173	2	US-09-396-937-20 Sequence 20, Appl
40	538	40.8	109	2	US-09-911-777-8 Sequence 8, Appl
41	418	31.7	77	2	US-09-632-287A-11 Sequence 11, Appl
42	418	31.7	77	2	US-10-286-696-11 Sequence 11, Appl
43	363	27.5	77	2	US-09-632-287A-10 Sequence 10, Appl
44	363	27.5	77	2	US-10-286-696-10 Sequence 10, Appl
45	238.5	18.1	291	1	US-08-670-354-6 Sequence 6, Appl

## ALIGNMENTS

RESULT 1  
US-08-996-139-13

Sequence 13, Application US/08996139

Patent No. 6017729

GENERAL INFORMATION:  
APPLICANT: Anderson, Dirk M.

APPLICANT: Galibert, Laurent

APPLICANT: Marakovsky, Eugene

TITLE OF INVENTION: Receptor Activator of NF-kappaB

NUMBER OF SEQUENCES: 19

CORRESPONDENCE ADDRESSES:

ADDRESSER: Immunex Corporation, Law Department

STREET: 51 University Street

CITY: Seattle

STATE: WA

COUNTRY: USA

ZIP: 98101

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: Apple Power Macintosh

OPERATING SYSTEM: Apple Operating System 7.5.5

SOFTWARE: Microsoft Word for Power Macintosh 6.0.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/996,139

FILING DATE: 22 DECEMBER 1997

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: USSN 60/064,671

FILING DATE: 14 OCTOBER 1997

PRIOR APPLICATION DATA:

APPLICATION NUMBER: USSN 08/813,509

FILING DATE: 07 MARCH 1997

PRIOR APPLICATION DATA:

APPLICATION NUMBER: USSN 08/772,330

FILING DATE: 23 DECEMBER 1996

ATTORNEY/AGENT INFORMATION:

NAME: Perkins, Patricia Anne

REGISTRATION NUMBER: 34,693

REFERENCE/DOCKET NUMBER: 2851-A

TELECOMMUNICATION INFORMATION:

TELEPHONE: (206)587-0430

TELEFAX: (206)233-0644

INFORMATION FOR SEQ ID NO: 13:

SEQUENCE CHARACTERISTICS:

LENGTH: 317 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: protein

US-08-996-139-13

Query Match 100.0%; Score 1319; DB 2; Length 317;  
Best Local Similarity 100.0%; Pred. No. 1.7e-139;  
Matches 249; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 YFRAQMDPNRISSEGTGHCYIRILRLHENDPQDTTLESQDTKLIPDSGRRIKQAFQGAQV 60  
DB 69 YFRAQMDPNRISSEGTGHCYIRILRLHENDPQDTTLESQDTKLIPDSGRRIKQAFQGAQV 128

QY 61 KELQHVOSQHIRAEKAMVDGSMWLDLAKRSKLEAQPFAHLITINATDIPSGSHKYSLSMW 120  
DB 129 KELQHVOSQHIRAEKAMVDGSMWLDLAKRSKLEAQPFAHLITINATDIPSGSHKYSLSMW 188

QY 121 HDRGMAKISNMTFSGNGLIVNODGFYYLYANICFRHHETSGDLATEYQLMWVYTKTSIK 180  
DB 189 HDRGMAKISNMTFSGNGLIVNODGFYYLYANICFRHHETSGDLATEYQLMWVYTKTSIK 248

QY 181 IPSSHTLMKGGSTKYWGSNSEFHFYSINVGFPLKRSGEISIEVSNPSLLDPQDATYF 240  
DB 249 IPSSHTLMKGGSTKYWGSNSEFHFYSINVGFPLKRSGEISIEVSNPSLLDPQDATYF 308

QY 241 GAFKVRDID 249  
DB 309 GAFKVRDID 317

RESULT 2  
US-08-995-659-13  
Sequence 13, Application US/08995659  
Patent No. 6242213  
GENERAL INFORMATION:  
APPLICANT: Anderson, Dirk M.  
APPLICANT: Marakovsky, Eugene  
TITLE OF INVENTION: Ligand for Receptor Activator of NF-kappaB  
NUMBER OF SEQUENCES: 19  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Immunex Corporation, Law Department  
STREET: 51 University Street  
CITY: Seattle  
STATE: WA  
COUNTRY: USA  
ZIP: 98101  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: Apple Power Macintosh  
OPERATING SYSTEM: Apple Operating System 7.5.5  
SOFTWARE: Microsoft Word for Power Macintosh 6.0.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/995,659  
FILING DATE: 22 DECEMBER 1997  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USN 60/064,671  
FILING DATE: 14 OCTOBER 1997  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USN 08/813,509  
FILING DATE: 07 MARCH 1997  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: USSN 08/772,330  
FILING DATE: 23 DECEMBER 1996  
CLASSIFICATION:  
ATTORNEY/AGENT INFORMATION:  
NAME: Perkins, Patricia Anne  
REGISTRATION NUMBER: 34,693  
REFERENCE/DOCKET NUMBER: 2852-A  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (206)587-0430  
TELEFAX: (206)233-0644  
INFORMATION FOR SEQ ID NO: 13:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 317 amino acids

TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-995-659-13

Query Match 100.0%; Score 1319; DB 2; Length 317;  
Best Local Similarity 100.0%; Pred. No. 1.7e-139;  
Matches 249; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 YFRAQMDPNRISSEGTGHCYIRILRLHENDPQDTTLESQDTKLIPDSGRRIKQAFQGAQV 60  
DB 69 YFRAQMDPNRISSEGTGHCYIRILRLHENDPQDTTLESQDTKLIPDSGRRIKQAFQGAQV 128

QY 61 KELQHVOSQHIRAEKAMVDGSMWLDLAKRSKLEAQPFAHLITINATDIPSGSHKYSLSMW 120  
DB 129 KELQHVOSQHIRAEKAMVDGSMWLDLAKRSKLEAQPFAHLITINATDIPSGSHKYSLSMW 188

QY 121 HDRGMAKISNMTFSGNGLIVNODGFYYLYANICFRHHETSGDLATEYQLMWVYTKTSIK 180  
DB 189 HDRGMAKISNMTFSGNGLIVNODGFYYLYANICFRHHETSGDLATEYQLMWVYTKTSIK 248

QY 181 IPSSHTLMKGGSTKYWGSNSEFHFYSINVGFPLKRSGEISIEVSNPSLLDPQDATYF 240  
DB 249 IPSSHTLMKGGSTKYWGSNSEFHFYSINVGFPLKRSGEISIEVSNPSLLDPQDATYF 308

QY 241 GAFKVRDID 249  
DB 309 GAFKVRDID 317

RESULT 3  
US-09-215-649A-13  
Sequence 13, Application US/09215649A  
Patent No. 6271349  
GENERAL INFORMATION:  
APPLICANT: Anderson, Dirk M.  
APPLICANT: Galibert, Laurent  
TITLE OF INVENTION: Receptor Activator of NF-kappaB  
NUMBER OF SEQUENCES: 19  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Immunex Corporation, Law Department  
STREET: 51 University Street  
CITY: Seattle  
STATE: WA  
COUNTRY: USA  
ZIP: 98101  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: Apple Power Macintosh  
OPERATING SYSTEM: Apple Operating System 7.5.5  
SOFTWARE: Microsoft Word for Power Macintosh 6.0.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/215,649A  
FILING DATE: 17-Dec-1998  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/996,139  
FILING DATE: <Unknown>  
APPLICATION NUMBER: USSN 08/813,509  
FILING DATE: 07 MARCH 1997  
APPLICATION NUMBER: USSN 08/772,330  
FILING DATE: 23 DECEMBER 1996  
ATTORNEY/AGENT INFORMATION:  
NAME: Perkins, Patricia Anne  
REGISTRATION NUMBER: 34,693  
REFERENCE/DOCKET NUMBER: 2851-A  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (206)587-0430  
TELEFAX: (206)233-0644  
INFORMATION FOR SEQ ID NO: 13:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 317 amino acids

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 13:02:07 / Search time 137.154 Seconds  
(without alignments)  
758.559 Million cell updates/sec

Title: US-09-211-297-39\_COPY\_69\_317

Perfect score: 1319  
Sequence: 1 YFRQMDPNRISBDTHCTIR.....LDDPDATYGAFAKVRDID 249

Scoring table: BLOSUM62  
Gapop 10.0, Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-Processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications\_AA\_Main:\*  
1: /cgn2\_6/prodata/1/pubppaa/US07\_PUBSCOMB.pep.\*  
2: /cgn2\_6/prodata/1/pubppaa/US08\_PUBSCOMB.pep.\*  
3: /cgn2\_6/prodata/1/pubppaa/US09\_PUBSCOMB.pep.\*  
4: /cgn2\_6/prodata/1/pubppaa/US10\_PUBSCOMB.pep.\*  
5: /cgn2\_6/prodata/1/pubppaa/US10\_PUBSCOMB.pep.\*  
6: /cgn2\_6/prodata/1/pubppaa/US11\_PUBSCOMB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1319	100.0	249	US-10-050-902-221	Sequence 221, App
2	1319	100.0	249	US-10-050-898-221	Sequence 221, App
3	1319	100.0	249	US-10-289-456-82	Sequence 82, App1
4	1319	100.0	250	US-10-338-785A-1	Sequence 1, App1
5	1319	100.0	250	US-10-611-363-1	Sequence 80, App1
6	1319	100.0	270	US-10-289-456-80	Sequence 7, App1
7	1319	100.0	317	US-09-813-329-7	Sequence 13, App1
8	1319	100.0	317	US-09-871-856-13	Sequence 6, App1
9	1319	100.0	317	US-09-957-944-6	Sequence 13, App1
10	1319	100.0	317	US-09-865-293-13	Sequence 13, App1
11	1319	100.0	317	US-09-871-291-13	Sequence 13, App1
12	1319	100.0	317	US-09-871-650-13	Sequence 13, App1
13	1319	100.0	317	US-09-933-815A-2	Sequence 2, App1
14	1319	100.0	317	US-10-151-071-10	Sequence 10, App1
15	1319	100.0	317	US-10-218-547-22	Sequence 22, App1
16	1319	100.0	317	US-10-405-878-13	Sequence 11, App1
17	1319	100.0	317	US-10-167-182-11	Sequence 28, App1
18	1319	100.0	317	US-10-310-793-28	Sequence 11, App1
19	1319	100.0	317	US-10-460-623-11	Sequence 79, App1
20	1319	100.0	317	US-10-289-456-79	Sequence 22, App1
21	1319	100.0	317	US-10-202-062-22	Sequence 2, App1
22	1319	100.0	317	US-10-664-801-2	Sequence 6, App1
23	1319	100.0	317	US-10-381-160-6	Sequence 12, App1
24	1319	100.0	317	US-10-799-345-12	Sequence 6, App1
25	1319	100.0	317	US-10-399-115-6	Sequence 13, App1
26	1319	100.0	317	US-10-802-133-13	Sequence 4, App1
27	1319	100.0	317	US-10-825-898-4	Sequence 4, App1

## ALIGNMENTS

28	1319	100.0	317	5	US-10-854-300-11	Sequence 11, App1
29	1319	100.0	317	5	US-10-129-595-1	Sequence 1, App1
30	1319	100.0	317	5	US-10-451-200-6	Sequence 6, App1
31	1319	100.0	317	5	US-10-999-523-8	Sequence 8, App1
32	1319	100.0	317	6	US-11-028-780-22	Sequence 22, App1
33	1319	100.0	317	6	US-11-099-059-6	Sequence 6, App1
34	1319	100.0	317	6	US-11-135-521-11	Sequence 11, App1
35	1319	100.0	317	6	US-11-142-726-7	Sequence 17, App1
36	1301	98.6	246	4	US-10-167-182-17	Sequence 17, App1
37	1301	98.6	246	4	US-10-460-623-17	Sequence 17, App1
38	1301	98.6	246	5	US-10-854-300-17	Sequence 17, App1
39	1301	98.6	246	6	US-11-135-521-17	Sequence 17, App1
40	1293	98.0	245	3	US-09-873-829-2	Sequence 2, App1
41	1293	98.0	245	4	US-10-017-910-2	Sequence 2, App1
42	1292	98.0	244	3	US-09-933-915A-10	Sequence 10, App1
43	1292	98.0	244	4	US-10-210-951-42	Sequence 42, App1
44	1292	98.0	244	4	US-10-050-902-222	Sequence 222, App
45	1292	98.0	244	4	US-10-050-898-222	Sequence 222, App

RESULT 1									
US-10-050-902-221									
Sequence 221, Application US/10050902									
Publication No. US20030175290A1									
GENERAL INFORMATION:									
APPLICANT: Renner, Wolfgang A.									
APPLICANT: Bachmann, Martin									
APPLICANT: Tissot, Alain									
APPLICANT: Maurer, Patrick									
APPLICANT: Legner, Franziska									
APPLICANT: Seibel, Peter									
APPLICANT: Piossek, Christine									
TITLE OF INVENTION: Molecular Antigen Array									
FILE REFERENCE: 1700.0190004									
CURRENT APPLICATION NUMBER: US/10/050,902									
CURRENT FILING DATE: 2002-01-18									
PRIOR APPLICATION NUMBER: US 60/262,379									
PRIOR FILING DATE: 2001-01-19									
PRIOR APPLICATION NUMBER: US 60/288,549									
PRIOR FILING DATE: 2001-05-04									
PRIOR APPLICATION NUMBER: US 60/326,998									
PRIOR FILING DATE: 2001-10-05									
PRIOR APPLICATION NUMBER: US 60/331,045									
PRIOR FILING DATE: 2001-11-07									
NUMBER OF SEQ ID NOS: 350									
SOFTWARE: PatentIn Ver. 2.1									
SEQ ID NO 221									
LENGTH: 249									
TYPE: PR									
ORGANISM: Homo sapiens									
US-10-050-902-221									
Query Match									
Best Local Similarity 100.0%; Pred. No. 5.3e-122;									
Matches 249; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
Qy	1	YFRQMDPNRISBDTHCTIRILRLHENDFODTTLESODTKLIPDSRRIRKQAFGAVQ	60						
Db	1	YFRQMDPNRISBDTHCTIRILRLHENDFODTTLESODTKLIPDSRRIRKQAFGAVQ	60						
Qy	61	KELOHTVGSQHIRAEKAMVDGSLDAKRSKLEAOPFAHLTTNADIPGSHKVSLSMW	120						
Db	61	KELOHTVGSQHIRAEKAMVDGSLDAKRSKLEAOPFAHLTTNADIPGSHKVSLSMW	120						
Qy	121	HDRGAKISNMTSNGKLIVNODGFYLYANICFRHETSGDLATYLLQMYVTTSIK	180						
Db	121	HDRGAKISNMTSNGKLIVNODGFYLYANICFRHETSGDLATYLLQMYVTTSIK	180						
Qy	181	IPSHITMGKSGTKYSGNSEFHFYSINVGFKLSGGEISIEVNSPILDDPDATYF	240						
Db	181	IPSHITMGKSGTKYSGNSEFHFYSINVGFKLSGGEISIEVNSPILDDPDATYF	240						

Db 181 IPSSHLMKGGSTKYWSGNSSEFFHYSINVGGFFKLRSGBEISIEVSNPSLLDPDQATYF 240  
QY 241 GAFKVRDID 249  
Db 241 GAFKVRDID 249

RESULT 2  
US-10-050-898-221

/ Sequence 221, Application US/10050898  
/ Publication No. US2003017571A1  
/ GENERAL INFORMATION:  
/ APPLICANT: Renner, Wolfgang A.  
/ APPLICANT: Bachmann, Martin  
/ APPLICANT: Tissot, Alain  
/ APPLICANT: Maurer, Patrick  
/ APPLICANT: Lechner, Franziska  
/ APPLICANT: Seibel, Peter  
/ APPLICANT: Ploesek, Christine  
/ APPLICANT: Ortman, Rainer  
/ APPLICANT: Luond, Rainer  
/ APPLICANT: Staufenbiel, Matthias  
/ APPLICANT: Frey, Peter  
/ TITLE OF INVENTION: Molecular Antigen Array  
/ FILE REFERENCE: 1700.0190005  
/ CURRENT APPLICATION NUMBER: US/10/050,898  
/ PRIOR FILING DATE: 2002-01-18  
/ PRIOR APPLICATION NUMBER: US 60/262,379  
/ PRIOR FILING DATE: 2001-01-19  
/ PRIOR APPLICATION NUMBER: US 60/288,549  
/ PRIOR FILING DATE: 2001-05-04  
/ PRIOR APPLICATION NUMBER: US 60/326,998  
/ PRIOR FILING DATE: 2001-10-05  
/ PRIOR APPLICATION NUMBER: US 60/331,045  
/ PRIOR FILING DATE: 2001-11-07  
/ NUMBER OF SEQ ID NOS: 350  
/ SOFTWARE: Patentin Ver. 2.1  
/ SEQ ID NO 221  
/ LENGTH: 249  
/ TYPE: PRT  
/ ORGANISM: Homo sapiens  
US-10-050-898-221

Query Match 100.0%; Score 1319; DB 4; Length 249;  
Best Local Similarity 100.0%; Pred. No. 5,3e-122;  
Matches 249; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 YFRAQMDPNRISSEGTGTCIYRIILRLHENADPQDTTLESQDTKLIPDSCRRIKQAFQGA VQ 60  
Db 1 YFRAQMDPNRISSEGTGTCIYRIILRLHENADPQDTTLESQDTKLIPDSCRRIKQAFQGA VQ 60  
QY 61 KELQHVGSQHIRAEKAMVDGSMWLDLAKRSKLEADQPAHLITINATDIPSGSHKYSLSMW 120  
Db 61 KELQHVGSQHIRAEKAMVDGSMWLDLAKRSKLEADQPAHLITINATDIPSGSHKYSLSMW 120  
QY 121 HDRGMAKISNMTFSGNGKLIYNQDGFYYLYANICFRHHETSGDLATEYIQLMYYVTKTSIK 180  
Db 121 HDRGMAKISNMTFSGNGKLIYNQDGFYYLYANICFRHHETSGDLATEYIQLMYYVTKTSIK 180  
QY 181 IPSSHLMKGGSTKYWSGNSSEFFHYSINVGGFFKLRSGBEISIEVSNPSLLDPDQATYF 240  
Db 181 IPSSHLMKGGSTKYWSGNSSEFFHYSINVGGFFKLRSGBEISIEVSNPSLLDPDQATYF 240  
QY 241 GAFKVRDID 249  
Db 241 GAFKVRDID 249

RESULT 3  
US-10-289-456-82  
/ Sequence 82, Application US/10289456  
/ Publication No. US2004003321A1  
/ GENERAL INFORMATION:

/ APPLICANT: Bachmann, Martin  
/ APPLICANT: Maurer, Patrick  
/ APPLICANT: Spohn, Gunther  
/ TITLE OF INVENTION: Antigen Arrays for Treatment of Bone Disease  
/ FILE REFERENCE: 1700.0330001  
/ CURRENT APPLICATION NUMBER: US/10/289,456  
/ PRIOR FILING DATE: 2002-11-07  
/ PRIOR APPLICATION NUMBER: PCT/IB02/00166  
/ PRIOR FILING DATE: 2002-01-21  
/ PRIOR APPLICATION NUMBER: US 10/050,902  
/ PRIOR FILING DATE: 2002-01-18  
/ PRIOR APPLICATION NUMBER: US 60/396,635  
/ PRIOR FILING DATE: 2002-07-19  
/ PRIOR APPLICATION NUMBER: US 60/331,045  
/ PRIOR FILING DATE: 2001-11-07  
/ NUMBER OF SEQ ID NOS: 170  
/ SOFTWARE: Patentin version 3.2  
/ SEQ ID NO 82  
/ LENGTH: 249  
/ TYPE: PRT  
/ ORGANISM: Homo sapiens  
US-10-289-456-82

Query Match 100.0%; Score 1319; DB 4; Length 249;  
Best Local Similarity 100.0%; Pred. No. 5,3e-122;  
Matches 249; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 YFRAQMDPNRISSEGTGTCIYRIILRLHENADPQDTTLESQDTKLIPDSCRRIKQAFQGA VQ 60  
Db 1 YFRAQMDPNRISSEGTGTCIYRIILRLHENADPQDTTLESQDTKLIPDSCRRIKQAFQGA VQ 60  
QY 61 KELQHVGSQHIRAEKAMVDGSMWLDLAKRSKLEADQPAHLITINATDIPSGSHKYSLSMW 120  
Db 61 KELQHVGSQHIRAEKAMVDGSMWLDLAKRSKLEADQPAHLITINATDIPSGSHKYSLSMW 120  
QY 121 HDRGMAKISNMTFSGNGKLIYNQDGFYYLYANICFRHHETSGDLATEYIQLMYYVTKTSIK 180  
Db 121 HDRGMAKISNMTFSGNGKLIYNQDGFYYLYANICFRHHETSGDLATEYIQLMYYVTKTSIK 180  
QY 181 IPSSHLMKGGSTKYWSGNSSEFFHYSINVGGFFKLRSGBEISIEVSNPSLLDPDQATYF 240  
Db 181 IPSSHLMKGGSTKYWSGNSSEFFHYSINVGGFFKLRSGBEISIEVSNPSLLDPDQATYF 240  
QY 241 GAFKVRDID 249  
Db 241 GAFKVRDID 249

RESULT 4  
US-10-338-785A-1

/ Sequence 1, Application US/10338785A  
/ Publication No. US20030219864A1  
/ GENERAL INFORMATION:  
/ APPLICANT: Desjarlais, John R.  
/ APPLICANT: Hubert, Rene S.  
/ TITLE OF INVENTION: No. US20030219864A1 Variants of RANKL Protein  
/ FILE REFERENCE: A-71486  
/ CURRENT APPLICATION NUMBER: US/10/338,785A  
/ PRIOR FILING DATE: 2003-01-06  
/ PRIOR APPLICATION NUMBER: US 60/345,805  
/ PRIOR FILING DATE: 2002-01-04  
/ PRIOR APPLICATION NUMBER: US 60/373,453  
/ PRIOR FILING DATE: 2002-04-17  
/ NUMBER OF SEQ ID NOS: 6  
/ SOFTWARE: Patentin version 3.2  
/ SEQ ID NO 1  
/ LENGTH: 250  
/ TYPE: PRT  
/ ORGANISM: Homo sapiens  
/ PUBLICATION INFORMATION:  
/ DATABASE ACCESSION NUMBER: Genbank Acc. No. US20030219864A1 AAB86811  
/ DATABASE ENTRY DATE: 1997-11-21



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using SW model

Run on: December 21, 2005, 13:03:52 ; Search time 7.75574 Seconds  
(without alignments)  
228.978 Million cell updates/sec

Title: US-09-211-297-39\_COPY\_69\_317

Perfect score: 1319  
Sequence: 1 YFRAGMDPNRISDGTCTCT.....LIDPDQATYFGAFKVRDID 249

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 53982 seqs, 7132107 residues

Total number of hits satisfying chosen parameters: 53982

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Published Applications\_AA\_New.\*  
1: /cgn2\_6/prodata/2/pubppaa/US09\_NEW\_PUB.pep.\*  
2: /cgn2\_6/prodata/2/pubppaa/US06\_NEW\_PUB.pep.\*  
3: /cgn2\_6/prodata/2/pubppaa/US07\_NEW\_PUB.pep.\*  
4: /cgn2\_6/prodata/2/pubppaa/PCT\_NEW\_PUB.pep.\*  
5: /cgn2\_6/prodata/2/pubppaa/US09\_NEW\_PUB.pep.\*  
6: /cgn2\_6/prodata/2/pubppaa/US10\_NEW\_PUB.pep.\*  
7: /cgn2\_6/prodata/2/pubppaa/US11\_NEW\_PUB.pep.\*  
8: /cgn2\_6/prodata/2/pubppaa/US60\_NEW\_PUB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	538	40.8	109	7	US-11-065-669-8
2	236.5	17.9	281	6	US-10-821-234-1288
3	235.5	17.9	266	7	US-11-082-544-10
4	232.5	17.6	281	7	US-11-077-372-2
5	232.5	17.6	391	7	US-11-105-172-4
6	147.5	11.2	359	7	US-11-105-172-2
7	134	10.2	240	6	US-10-987-663-6
8	133	10.1	157	7	US-11-010-954-1
9	133	10.1	157	7	US-11-053-750-1
10	133	10.1	157	7	US-11-053-749-1
11	133	10.1	157	7	US-11-108-001-12
12	133	10.1	158	7	US-11-082-544-4
13	133	10.1	164	7	US-11-108-001-2
14	133	10.1	180	7	US-11-082-544-8
15	92.5	7.0	177	6	US-10-999-866-61
16	92.5	7.0	205	6	US-10-995-561-1028
17	92.5	7.0	205	6	US-10-995-561-1029
18	86.5	6.6	104	7	US-11-065-669-5
19	85	6.4	220	7	US-11-054-515-3233
20	77.5	5.9	290	7	US-11-054-515-3231
21	77	5.8	200	6	US-10-524-198-2
22	76.5	5.8	219	7	US-11-054-515-3237
23	76.5	5.8	243	7	US-11-054-515-3236
24	74.5	5.6	239	7	US-11-054-515-3232
25	74.5	5.6	943	6	US-10-475-204-34

26	73.5	5.6	207	7	US-11-054-515-3234	Sequence 3234, Ap
27	73	5.5	188	7	US-11-054-515-3235	Sequence 3235, Ap
28	73	5.5	536	6	US-10-131-826A-490	Sequence 490, Ap
29	72	5.5	389	7	US-11-088-686-1	Sequence 1, Appl
30	72	5.5	389	7	US-11-088-686-3	Sequence 3, Appl
31	72	5.5	389	7	US-11-088-686-5	Sequence 5, Appl
32	72	5.5	389	7	US-11-088-686-7	Sequence 7, Appl
33	72	5.5	389	7	US-11-088-686-9	Sequence 9, Appl
34	72	5.5	389	7	US-11-088-686-11	Sequence 11, Appl
35	72	5.5	389	7	US-11-088-686-13	Sequence 13, Appl
36	71.5	5.4	1001	6	US-10-467-962B-81	Sequence 81, Appl
37	71.5	5.4	1151	7	US-11-128-420-10	Sequence 10, Appl
38	71.5	5.4	1467	6	US-10-507-956-1	Sequence 1, Appl
39	71	5.4	447	7	US-11-112-882-4	Sequence 4, Appl
40	70.5	5.3	369	7	US-11-055-832-32	Sequence 42, Appl
41	70.5	5.3	585	6	US-10-878-556A-42	Sequence 3, Appl
42	70	5.3	152	6	US-10-742-634-3	Sequence 17, Appl
43	70	5.3	178	6	US-10-742-634-17	Sequence 3229, Ap
44	70	5.3	266	7	US-11-054-515-3229	Sequence 24, Appl
45	70	5.3	285	6	US-10-131-826A-24	

## ALIGNMENTS

RESULT 1  
US-11-065-669-8  
; Sequence 8, Application US/11065669  
; Publication No. US2005024441A1  
; GENERAL INFORMATION:  
; APPLICANT: Mackay, Fabienne  
; APPLICANT: Kalled, Susan  
; TITLE OF INVENTION: BAF, INHIBITORS THEREOF AND THEIR USE IN THE  
; FILE REFERENCE: 08201.0024-0400  
; CURRENT APPLICATION NUMBER: US/11/065,669  
; CURRENT FILING DATE: 2005-02-24  
; PRIOR APPLICATION NUMBER: 10/045,574  
; PRIOR FILING DATE: 2001-11-07  
; PRIOR APPLICATION NUMBER: 09/911,777  
; PRIOR FILING DATE: 2001-07-24  
; PRIOR APPLICATION NUMBER: 60/143,228  
; PRIOR FILING DATE: 2001-07-09  
; PRIOR APPLICATION NUMBER: PCT/US00/01788  
; PRIOR FILING DATE: 2000-01-25  
; PRIOR APPLICATION NUMBER: 60/117,169  
; PRIOR FILING DATE: 1999-01-25  
; NUMBER OF SEQ ID NOS: 26  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 8  
; LENGTH: 109  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-11-065-669-8

Query Match 40.8%; Score 538; DB 7; Length 109;  
Best Local Similarity 75.5%; Pred. No. 1.4e-46;  
Matches 108; Conservative 0; Mismatches 1; Indels 34; Gaps 2;

QY	93	EAQPAHLTINADIPSGSHKVSLSWYHDGRWAKTSNMTFNSGKLIIVNODGFYYLYANI	152
DB	1	EAQPAHLTINADIPSGSHKVSLSWYHDGRWAKTSNMTFNSGKLIIVNODGFYYLYANI	43
QY	153	CFPHHETSGDLATEYQLMYYVTKTSIKIPSSHTLMKGSSTKYSGNSEPHFYSINVGCF	212
DB	44	CFPHHETSGDLATEYQLMYYVTKTSIKIPSSHTLMKGSSTKYSGNSEPHFYSINVGCF	86
QY	213	FKLRSGEISIEVSNPSILDPPQ	235
DB	87	FKLRSGEISIEVSNPSILDPPQ	109

RESULT 2

```
US-10-821-234-1288
; Sequence 1288, Application US/10821234
; Publication No. US20050255114A1
; GENERAL INFORMATION:
; APPLICANT: Labat, Ivan
; APPLICANT: Stache-Crain, Birgit
; APPLICANT: Andarmani, Susan
; APPLICANT: Tang, Y. Tom
; TITLE OF INVENTION: Methods for Diagnosis and Treatment of Preeclampsia
; FILE REFERENCE: 821A
; CURRENT APPLICATION NUMBER: US/10/821,234
; CURRENT FILING DATE: 2004-04-07
; PRIOR APPLICATION NUMBER: US 60/462,047
; PRIOR FILING DATE: 2003-04-07
; NUMBER OF SEQ ID NOS: 1704
; SOFTWARE: pc_seq_genes Version 1.0
; SEQ ID NO 1288
; LENGTH: 281
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-821-234-1288

Query Match          17.9%; Score 236.5; DB 6; Length 281;
Best Local Similarity 25.1%; Pred. No. 3.1e-16;
Matches 67; Conservative 53; Mismatches 102; Indels 45; Gaps 10;

QY 1 YFRAQMD--PNRISEGDGHCIRILRLHENDFODTTLESODTKLIPDSCRRIKQAFQGA 58
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
DB 37 YFTNELKQMDKRYSGIACF-----LKED-----DSYWDPNDESMNSPCQVVKM----- 82

QY 59 VQKELOHIVGSOHIRAEKAMVDGSMWLDAKRSKLEAOPF-----AHLT-----IN 103
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
DB 83 ---QLRQLVRKMIILRTSEETI-----STVQEKQONISPLVREGRQVAAHITGRGRSN 134
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
QY 104 ATDIPSGSHKVSLS---SSWYHDR-GWAKISNMTFSNGKLIVNODGFYLYANICFRHHE 158
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
DB 135 TLLSPNKGKAEKALGRKINSWESSRSGHSFLSNLHRLNGELVIRHEKGFYIYSQTYFRQE 194
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
QY 159 TSGDLATEYLQLMVYVTKTSIKIPSHITLMKSGSTKYWGSNEPFFYSINVGPFKLKSG 218
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
DB 195 EIKENTKNDKQMVQYIYKTYT-SYDPDILMKSAARNSCWSKDAEYGLYSIYGQIFELKEN 253
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
QY 219 EISIEVSNPSLLDPDODATYFGAFKV 245
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
DB 254 DRIFVSVTNEHLIDMDHEASFFGAFLV 280
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||

RESULT 3
US-11-082-544-10
; Sequence 10, Application US/11082544
; Publication No. US20050249706A1
; GENERAL INFORMATION:
; APPLICANT: Bermudez, G.
; APPLICANT: King, I.
; APPLICANT: Clairmont, C.
; APPLICANT: Lin, S.
; APPLICANT: Belcourt, M.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR
; FILE REFERENCE: 8002-059
; CURRENT APPLICATION NUMBER: US/11/082,544
; CURRENT FILING DATE: 2005-03-17
; PRIOR APPLICATION NUMBER: US/09/645,415
; PRIOR FILING DATE: 2000-08-24
; PRIOR APPLICATION NUMBER: 60/157,581
; PRIOR FILING DATE: 1999-10-04
; PRIOR APPLICATION NUMBER: 60/157,637
; PRIOR FILING DATE: 1999-10-04
; NUMBER OF SEQ ID NOS: 61
; SOFTWARE: FaalSEQ for Windows Version 3.0
; SEQ ID NO 10
; LENGTH: 266
; TYPE: PRT
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Fusion construct
US-11-082-544-10

Query Match          17.9%; Score 235.5; DB 7; Length 266;
Best Local Similarity 25.3%; Pred. No. 3.6e-16;
Matches 65; Conservative 51; Mismatches 98; Indels 43; Gaps 9;

QY 9 NRISEDGHCIRILRLHENDFODTTLESODTKLIPDSCRRIKQAFQGAQKLOHIVG 68
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
DB 32 DKYSKGIACF-----LKED-----DSYWDPNDESMNSPCQVVKM-----QLRQLVR 74

QY 69 SQHIRAEKAMVDGSMWLDAKRSKLEAOPF-----AHLT-----INATDIPSGSHK 113
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
DB 75 KMIILRTSEETI-----STVQEKQONISPLVREGRQVAAHITGRGRSNLTSSPNSKNE 129
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
QY 114 VSL---SSWYHDR-GWAKISNMTFSNGKLIVNODGFYLYANICFRHHE TSGDLATEYL 168
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
DB 130 KALGRKINSWESSRSGHSFLSNLHRLNGELVIRHEKGFYIYSQTYFRQEIKENTKNDK 189
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
QY 169 QLMYVYVTKTSIKIPSHITLMKSGSTKYWGSNEPFFYSINVGPFKLKSGSEI SIEVSNP 228
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
DB 190 QMVQYIYKTYT-SYDPDILMKSAARNSCWSKDAEYGLYSIYGQIFELKENDRIFVSVTNE 248
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
QY 229 SLDPDODATYFGAFKV 245
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
DB 249 HLIDMDHEASFFGAFLV 265
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||

RESULT 4
US-11-077-272-2
; Sequence 2, Application US/11077272
; Publication No. US20050244927A1
; GENERAL INFORMATION:
; APPLICANT: LEUNG, WOON-LAM SUSAN
; APPLICANT: SMARTZ, JAMES R.
; TITLE OF INVENTION: PROCESS FOR PRODUCING POLYPEPTIDES
; FILE REFERENCE: P2019R1
; CURRENT APPLICATION NUMBER: US/11/077,272
; CURRENT FILING DATE: 2005-03-10
; PRIOR APPLICATION NUMBER: US 60/552,678
; PRIOR FILING DATE: 2004-03-11
; NUMBER OF SEQ ID NOS: 7
; SEQ ID NO 2
; LENGTH: 281
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-077-272-2

Query Match          17.6%; Score 232.5; DB 7; Length 281;
Best Local Similarity 25.1%; Pred. No. 7.6e-16;
Matches 67; Conservative 52; Mismatches 103; Indels 45; Gaps 10;

QY 1 YFRAQMD--PNRISEGDGHCIRILRLHENDFODTTLESODTKLIPDSCRRIKQAFQGA 58
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
DB 37 YFTNELKQMDKRYSGIACF-----LKED-----DSYWDPNDESMNSPCQVVKM----- 82

QY 59 VQKELOHIVGSOHIRAEKAMVDGSMWLDAKRSKLEAOPF-----AHLT-----IN 103
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
DB 83 ---QLRQLVRKMIILRTSEETI-----STVQEKQONISPLVREGRQVAAHITGRGRSN 134
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
QY 104 ATDIPSGSHKVSLS---SSWYHDR-GWAKISNMTFSNGKLIVNODGFYLYANICFRHHE 158
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
DB 135 TLLSPNKGKAEKALGRKINSWESSRSGHSFLSNLHRLNGELVIRHEKGFYIYSQTYFRQE 194
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
QY 159 TSGDLATEYLQLMVYVTKTSIKIPSHITLMKSGSTKYWGSNEPFFYSINVGPFKLKSG 218
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
DB 195 EIKENTKNDKQMVQYIYKTYT-SYDPDILMKSAARNSCWSKDAEYGLYSIYGQIFELKEN 253
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
QY 219 EISIEVSNPSLLDPDODATYFGAFKV 245
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
DB 254 DRIFVSVTNEHLIDMDHEASFFGAFLV 280
   ||::||::||::||::||::||::||::||::||::||::||::||::||::||::||
```

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model

Run on: December 21, 2005, 12:44:31 ; Search time 2.89836 Seconds  
(without alignments)  
484.925 Million cell updates/sec

Title: US-09-211-297-34

Perfect score: 84  
Sequence: 1 VYVVKTSIKIPSHNLM 17

Scoring table: BLOSUM62  
Gapop 10.0, Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Issued Patents AA:  
1: /cgn2\_6/prodata/1/1aa/5-COMB.pep.\*  
2: /cgn2\_6/prodata/1/1aa/6-COMB.pep.\*  
3: /cgn2\_6/prodata/1/1aa/H-COMB.pep.\*  
4: /cgn2\_6/prodata/1/1aa/BCUUS-COMB.pep.\*  
5: /cgn2\_6/prodata/1/1aa/RE-COMB.pep.\*  
6: /cgn2\_6/prodata/1/1aa/backfilltest.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	84	100.0	17	2 US-09-052-521C-35	Sequence 35, Appl
2	84	100.0	173	2 US-09-396-937-10	Sequence 10, Appl
3	84	100.0	173	2 US-09-396-937-12	Sequence 12, Appl
4	84	100.0	173	2 US-09-396-937-18	Sequence 18, Appl
5	84	100.0	187	2 US-09-396-937-8	Sequence 8, Appl
6	84	100.0	188	2 US-09-396-937-14	Sequence 14, Appl
7	84	100.0	234	2 US-08-996-139-11	Sequence 11, Appl
8	84	100.0	234	2 US-08-995-659-11	Sequence 11, Appl
9	84	100.0	234	2 US-09-215-649A-11	Sequence 11, Appl
10	84	100.0	234	2 US-09-577-800-11	Sequence 11, Appl
11	84	100.0	234	2 US-09-577-800-11	Sequence 11, Appl
12	84	100.0	234	2 US-09-466-496-11	Sequence 11, Appl
13	84	100.0	234	2 US-09-871-856-11	Sequence 11, Appl
14	84	100.0	234	2 US-09-871-291-11	Sequence 11, Appl
15	84	100.0	234	2 US-09-877-650-11	Sequence 11, Appl
16	84	100.0	234	2 US-09-865-363-11	Sequence 11, Appl
17	84	100.0	234	2 US-09-688-459-11	Sequence 11, Appl
18	84	100.0	316	1 US-08-882-842-7	Sequence 7, Appl
19	84	100.0	316	2 US-08-969-362-2	Sequence 2, Appl
20	84	100.0	316	2 US-09-052-521C-2	Sequence 2, Appl
21	84	100.0	316	2 US-09-671-658A-2	Sequence 2, Appl
22	84	100.0	316	2 US-09-396-937-4	Sequence 4, Appl
23	84	100.0	316	2 US-09-396-937-6	Sequence 6, Appl
24	84	100.0	316	2 US-09-987-944-8	Sequence 8, Appl
25	84	100.0	317	2 US-08-996-139-13	Sequence 13, Appl
26	84	100.0	317	2 US-08-995-659-13	Sequence 13, Appl
27	84	100.0	317	2 US-09-215-649A-13	Sequence 13, Appl

## ALIGNMENTS

28	74	88.1	317	2	US-09-052-521C-4	Sequence 4, Appl
29	74	88.1	317	2	US-09-577-780-13	Sequence 13, Appl
30	74	88.1	317	2	US-09-577-800-13	Sequence 13, Appl
31	74	88.1	317	2	US-09-466-496-13	Sequence 13, Appl
32	74	88.1	317	2	US-09-871-856-13	Sequence 13, Appl
33	74	88.1	317	2	US-09-871-291-13	Sequence 13, Appl
34	74	88.1	317	2	US-09-877-650-13	Sequence 13, Appl
35	74	88.1	317	2	US-09-865-363-13	Sequence 13, Appl
36	74	88.1	317	2	US-09-688-459-13	Sequence 13, Appl
37	74	88.1	317	2	US-09-957-944-6	Sequence 6, Appl
38	74	88.1	317	2	US-09-957-944-6	Sequence 6, Appl
39	71	84.5	182	2	US-09-396-937-16	Sequence 16, Appl
40	69	82.1	173	2	US-09-396-937-20	Sequence 20, Appl
41	54	64.3	12	2	US-09-628-665-23	Sequence 23, Appl
42	54	64.3	12	2	US-09-628-665-23	Sequence 23, Appl
43	53	63.1	109	2	US-09-911-777-8	Sequence 8, Appl
44	50	59.5	10	2	US-09-628-665-6	Sequence 6, Appl
45	50	59.5	11	2	US-09-628-665-5	Sequence 5, Appl

RESULT 1  
US-09-052-521C-35  
; Sequence 35, Application US/09052521C

; Patent No. 6316408

; GENERAL INFORMATION:

; APPLICANT: Boyle, William J.

; TITLE OF INVENTION: Osteoprotegerin Binding Proteins and Receptors

; FILE REFERENCE: A-451Bv

; CURRENT APPLICATION NUMBER: US/09/052,521C

; PRIOR FILING DATE: 1998-03-30

; PRIOR APPLICATION NUMBER: 08/880,855

; PRIOR FILING DATE: 1997-06-23

; PRIOR APPLICATION NUMBER: 08/842,842

; NUMBER OF SEQ ID NOS: 40

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 35

; LENGTH: 17

; TYPE: PRT

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Synthetic

US-09-052-521C-35

Query Match 100.0%; Score 84; DB 2; Length 17;

Best Local Similarity 100.0%; Pred. No. 1.7e-07; Mismatches 0; Indels 0; Gaps 0;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VYVVKTSIKIPSHNLM 17

DB 1 VYVVKTSIKIPSHNLM 17

RESULT 2

US-09-396-937-10

; Sequence 10, Application US/09396937

; Patent No. 6645500

; GENERAL INFORMATION:

; APPLICANT: M&E Biotech A/S

; APPLICANT: HALKIER, Torben

; APPLICANT: HANING, Jesper

; TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand

; FILE REFERENCE: 22021 P1

; CURRENT APPLICATION NUMBER: US/09/396,937

; CURRENT FILING DATE: 1999-09-15

; NUMBER OF SEQ ID NOS: 35

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 10

LENGTH: 173  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: DNA encoding  
OTHER INFORMATION: murine OPGL, residues 158-316, fused to His tag  
US-09-396-937-10

Query Match 100.0%; Score 84; DB 2; Length 173;  
Best Local Similarity 100.0%; Pred. No. 2.1e-06;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VVVVKTSLKIPSSHNLM 17  
|||  
Db 96 VVVVKTSLKIPSSHNLM 112

RESULT 3  
US-09-396-937-12  
Sequence 12, Application US/09396937  
Patent No. 6645500  
GENERAL INFORMATION:  
APPLICANT: M&B Biotech A/S  
APPLICANT: HALKIER, Torben  
APPLICANT: HAANING, Jesper  
TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand  
FILE REFERENCE: 22021 PC 1  
CURRENT APPLICATION NUMBER: US/09/396,937  
CURRENT FILING DATE: 1999-09-15  
NUMBER OF SEQ ID NOS: 35  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 12  
LENGTH: 173  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Fusion of  
OTHER INFORMATION: murine OPGL, residues 158-316 with C to S  
OTHER INFORMATION: mutation, and His tag  
US-09-396-937-12

Query Match 100.0%; Score 84; DB 2; Length 173;  
Best Local Similarity 100.0%; Pred. No. 2.1e-06;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VVVVKTSLKIPSSHNLM 17  
|||  
Db 96 VVVVKTSLKIPSSHNLM 112

RESULT 4  
US-09-396-937-18  
Sequence 18, Application US/09396937  
Patent No. 6645500  
GENERAL INFORMATION:  
APPLICANT: M&B Biotech A/S  
APPLICANT: HALKIER, Torben  
APPLICANT: HAANING, Jesper  
TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand  
FILE REFERENCE: 22021 PC 1  
CURRENT APPLICATION NUMBER: US/09/396,937  
CURRENT FILING DATE: 1999-09-15  
NUMBER OF SEQ ID NOS: 35  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 18  
LENGTH: 173  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Fusion between  
OTHER INFORMATION: murine OPGL, residues 158-316 with tetanus toxoid

OTHER INFORMATION: P2 epitope introduced, and His tag  
US-09-396-937-18

Query Match 100.0%; Score 84; DB 2; Length 173;  
Best Local Similarity 100.0%; Pred. No. 2.1e-06;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VVVVKTSLKIPSSHNLM 17  
|||  
Db 96 VVVVKTSLKIPSSHNLM 112

RESULT 5  
US-09-396-937-8  
Sequence 8, Application US/09396937  
Patent No. 6645500  
GENERAL INFORMATION:  
APPLICANT: M&B Biotech A/S  
APPLICANT: HALKIER, Torben  
APPLICANT: HAANING, Jesper  
TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand  
FILE REFERENCE: 22021 PC 1  
CURRENT APPLICATION NUMBER: US/09/396,937  
CURRENT FILING DATE: 1999-09-15  
NUMBER OF SEQ ID NOS: 35  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 8  
LENGTH: 187  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Synthetic PCR  
OTHER INFORMATION: product with optimum codons for E. coli and P.  
OTHER INFORMATION: pasteuris expression  
US-09-396-937-8

Query Match 100.0%; Score 84; DB 2; Length 187;  
Best Local Similarity 100.0%; Pred. No. 2.3e-06;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VVVVKTSLKIPSSHNLM 17  
|||  
Db 110 VVVVKTSLKIPSSHNLM 126

RESULT 6  
US-09-396-937-14  
Sequence 14, Application US/09396937  
Patent No. 6645500  
GENERAL INFORMATION:  
APPLICANT: M&B Biotech A/S  
APPLICANT: HALKIER, Torben  
APPLICANT: HAANING, Jesper  
TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand  
FILE REFERENCE: 22021 PC 1  
CURRENT APPLICATION NUMBER: US/09/396,937  
CURRENT FILING DATE: 1999-09-15  
NUMBER OF SEQ ID NOS: 35  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 14  
LENGTH: 188  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Fusion of  
OTHER INFORMATION: murine OPGL, residues 158-316 modified by  
OTHER INFORMATION: introduction of tetanus toxoid P30 epitope, and  
OTHER INFORMATION: His tag  
US-09-396-937-14

Query Match 100.0%; Score 84; DB 2; Length 188;

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model

Run on: December 21, 2005, 13:02:07 ; Search time 9.36393 Seconds  
(without alignments)  
758.559 Million cell updates/sec

Title: US-09-211-297-34

Perfect score: 84  
Sequence: 1 VYVVKTSIKIPSSHNLM 17

Scoring table: BLOSUM62  
Gapop 10.0, Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database: Published Applications\_AA\_Main:\*  
1: /cgn2\_6/prodata/1/pubppaa/US07\_PUBCOMB.pep:\*  
2: /cgn2\_6/prodata/1/pubppaa/US08\_PUBCOMB.pep:\*  
3: /cgn2\_6/prodata/1/pubppaa/US09\_PUBCOMB.pep:\*  
4: /cgn2\_6/prodata/1/pubppaa/US10\_PUBCOMB.pep:\*  
5: /cgn2\_6/prodata/1/pubppaa/US11\_PUBCOMB.pep:\*  
6: /cgn2\_6/prodata/1/pubppaa/US11\_PUBCOMB.pep:\*  
  
Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	length	DB ID	Description
1	84	100.0	17	US-10-825-898-35	Sequence 35, Appl
2	84	100.0	18	US-10-825-898-36	Sequence 36, Appl
3	84	100.0	160	US-09-779-050A-14	Sequence 14, Appl
4	84	100.0	170	US-09-791-153A-76	Sequence 76, Appl
5	84	100.0	170	US-10-289-456-99	Sequence 99, Appl
6	84	100.0	173	US-10-664-801-10	Sequence 10, Appl
7	84	100.0	173	US-10-664-801-12	Sequence 12, Appl
8	84	100.0	173	US-10-664-801-18	Sequence 18, Appl
9	84	100.0	187	US-10-664-801-8	Sequence 8, Appl
10	84	100.0	188	US-10-664-801-14	Sequence 14, Appl
11	84	100.0	193	US-10-289-456-96	Sequence 96, Appl
12	84	100.0	193	US-10-050-902-224	Sequence 224, App
13	84	100.0	199	US-10-050-998-224	Sequence 224, App
14	84	100.0	199	US-10-289-456-86	Sequence 86, Appl
15	84	100.0	244	US-10-167-182-16	Sequence 16, Appl
16	84	100.0	244	US-10-460-623-16	Sequence 16, Appl
17	84	100.0	244	US-10-854-300-16	Sequence 16, Appl
18	84	100.0	244	US-11-125-521-16	Sequence 16, Appl
19	84	100.0	247	US-10-050-902-223	Sequence 223, App
20	84	100.0	247	US-10-050-998-223	Sequence 223, App
21	84	100.0	247	US-10-289-456-85	Sequence 85, Appl
22	84	100.0	249	US-10-338-785A-3	Sequence 3, Appl
23	84	100.0	249	US-10-611-363-3	Sequence 3, Appl
24	84	100.0	294	US-09-871-856-11	Sequence 11, Appl
25	84	100.0	294	US-09-865-363-11	Sequence 11, Appl
26	84	100.0	294	US-09-871-291-11	Sequence 11, Appl
27	84	100.0	294	US-09-877-650-11	Sequence 11, Appl

28	84	100.0	294	4	US-10-405-878-11	Sequence 11, Appl
29	84	100.0	294	5	US-10-802-133-11	Sequence 11, Appl
30	84	100.0	316	3	US-09-957-944-8	Sequence 8, Appl
31	84	100.0	316	3	US-09-079-569-7	Sequence 7, Appl
32	84	100.0	316	3	US-09-873-829-4	Sequence 4, Appl
33	84	100.0	316	3	US-09-933-915A-16	Sequence 16, Appl
34	84	100.0	316	4	US-10-017-910-4	Sequence 4, Appl
35	84	100.0	316	4	US-10-105-057-2	Sequence 2, Appl
36	84	100.0	316	4	US-10-272-411-19	Sequence 19, Appl
37	84	100.0	316	4	US-10-272-328A-19	Sequence 19, Appl
38	84	100.0	316	4	US-10-326-052-2	Sequence 2, Appl
39	84	100.0	316	4	US-10-167-182-1	Sequence 1, Appl
40	84	100.0	316	4	US-10-460-623-1	Sequence 1, Appl
41	84	100.0	316	4	US-10-664-801-4	Sequence 4, Appl
42	84	100.0	316	4	US-10-664-801-6	Sequence 6, Appl
43	84	100.0	316	4	US-10-799-345-10	Sequence 10, Appl
44	84	100.0	316	5	US-10-825-898-2	Sequence 2, Appl
45	84	100.0	316	5	US-10-854-300-1	Sequence 1, Appl

## ALIGNMENTS

RESULT 1  
US-10-825-898-35  
Sequence 35, Application US/10825898  
Publication No. US20050003400A1  
GENERAL INFORMATION:  
APPLICANT: BOYLE, WILLIAM  
TITLE OF INVENTION: OSTEOPROTEGERIN BINDING PROTEINS AND RECEPTORS  
FILE REFERENCE: A-451K REV 09-10-03 54SEQ  
CURRENT APPLICATION NUMBER: US/10/825,898  
PRIOR FILING DATE: 2004-04-15  
PRIOR APPLICATION NUMBER: US/10/825,898  
PRIOR FILING DATE: 2004-04-15  
PRIOR APPLICATION NUMBER: US 09/052,521  
PRIOR FILING DATE: 1998-03-30  
PRIOR APPLICATION NUMBER: US 08/880,855  
PRIOR FILING DATE: 1997-06-23  
PRIOR APPLICATION NUMBER: US 08/842,842  
PRIOR FILING DATE: 1997-04-16  
NUMBER OF SEQ ID NOS: 54  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 35  
LENGTH: 17  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Synthetic Oligonucleotide  
US-10-825-898-35  
  
Query Match 100.0%; Score 84; DB 5; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.5e-07;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 VYVVKTSIKIPSSHNLM 17  
Db 1 VYVVKTSIKIPSSHNLM 17  
  
RESULT 2  
US-10-825-898-36  
Sequence 36, Application US/10825898  
Publication No. US20050003400A1  
GENERAL INFORMATION:  
APPLICANT: BOYLE, WILLIAM  
TITLE OF INVENTION: OSTEOPROTEGERIN BINDING PROTEINS AND RECEPTORS  
FILE REFERENCE: A-451K REV 09-10-03 54SEQ  
CURRENT APPLICATION NUMBER: US/10/825,898  
PRIOR FILING DATE: 2004-04-15  
PRIOR APPLICATION NUMBER: US 09/052,521  
PRIOR FILING DATE: 2004-04-15  
PRIOR APPLICATION NUMBER: US 09/052,521

```

; PRIOR FILING DATE: 1998-03-30
; PRIOR APPLICATION NUMBER: US 08/880,855
; PRIOR FILING DATE: 1997-06-23
; PRIOR APPLICATION NUMBER: US 08/842,842
; PRIOR FILING DATE: 1997-04-16
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 36
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-10-825-898-36
```

```
Query Match          100.0%; Score 84; DB 5; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.6e-07;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1 VYVVKTSIKIPSSHNL 17
        |||||
Db      1 VYVVKTSIKIPSSHNL 17
```

```

RESULT 3
US-09-779-050A-14
; Sequence 14, Application US/09779050A
; Patent No. US20020160416A1
; GENERAL INFORMATION:
; APPLICANT: BOYLE, WILLIAM
; APPLICANT: HSU, HAILING
; TITLE OF INVENTION: RECEPTOR FROM TNF FAMILY
; FILE REFERENCE: A-570B
; CURRENT APPLICATION NUMBER: US/09/779,050A
; CURRENT FILING DATE: 2001-02-12
; PRIOR APPLICATION NUMBER: 60/181,800
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 52
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 14
; LENGTH: 160
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-779-050A-14
```

```
Query Match          100.0%; Score 84; DB 3; Length 160;
Best Local Similarity 100.0%; Pred. No. 1.8e-06;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1 VYVVKTSIKIPSSHNL 17
        |||||
Db      83 VYVVKTSIKIPSSHNL 99
```

```

RESULT 4
US-09-791-153A-76
; Sequence 76, Application US/09791153A
; Publication No. US20030103878A1
; GENERAL INFORMATION:
; APPLICANT: Deshpande, Rajendra
; APPLICANT: Hitz, Anna
; APPLICANT: Boyle, William
; APPLICANT: Sullivan, John
; TITLE OF INVENTION: SELECTIVE BINDING AGENTS OF OSTEOPROTEGERIN BINDING PROTEIN
; FILE REFERENCE: A-633A
; CURRENT APPLICATION NUMBER: US/09/791,153A
; CURRENT FILING DATE: 2001-07-17
; PRIOR APPLICATION NUMBER: 09/511,139
; PRIOR FILING DATE: 2000-02-23
; NUMBER OF SEQ ID NOS: 154
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 76
; LENGTH: 170
```

```

; TYPE: PRT
; ORGANISM: Mus musculus
US-09-791-153A-76
```

```
Query Match          100.0%; Score 84; DB 3; Length 170;
Best Local Similarity 100.0%; Pred. No. 1.9e-06;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1 VYVVKTSIKIPSSHNL 17
        |||||
Db      93 VYVVKTSIKIPSSHNL 109
```

```

RESULT 5
US-10-289-456-99
; Sequence 99, Application US/10289456
; Publication No. US2004003211A1
; GENERAL INFORMATION:
; APPLICANT: Bachmann, Martin
; APPLICANT: Maurer, Patrick
; APPLICANT: Spohn, Gunther
; TITLE OF INVENTION: Antigen Arrays for Treatment of Bone Disease
; FILE REFERENCE: 1700.0330001
; CURRENT APPLICATION NUMBER: US/10/289,456
; CURRENT FILING DATE: 2002-11-07
; PRIOR APPLICATION NUMBER: PCT/IB02/00166
; PRIOR FILING DATE: 2002-01-21
; PRIOR APPLICATION NUMBER: US 10/050,902
; PRIOR FILING DATE: 2002-01-18
; PRIOR APPLICATION NUMBER: US 60/396,635
; PRIOR FILING DATE: 2002-07-19
; PRIOR APPLICATION NUMBER: US 60/331,045
; PRIOR FILING DATE: 2001-11-07
; NUMBER OF SEQ ID NOS: 170
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 99
; LENGTH: 170
; TYPE: PRT
; ORGANISM: Mus sp.
US-10-289-456-99
```

```
Query Match          100.0%; Score 84; DB 4; Length 170;
Best Local Similarity 100.0%; Pred. No. 1.9e-06;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1 VYVVKTSIKIPSSHNL 17
        |||||
Db      84 VYVVKTSIKIPSSHNL 100
```

```

RESULT 6
US-10-664-801-10
; Sequence 10, Application US/10664801
; Publication No. US20040115199A1
; GENERAL INFORMATION:
; APPLICANT: M&S Biotech A/S
; APPLICANT: HALKIER, Torben
; APPLICANT: HAANING, Jesper
; TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand
; FILE REFERENCE: 22021 PC 1
; CURRENT APPLICATION NUMBER: US/10/664,801
; CURRENT FILING DATE: 2003-09-17
; PRIOR APPLICATION NUMBER: US/09/396,937
; PRIOR FILING DATE: 1999-09-15
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 173
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: DNA encoding
```

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OW protein - protein search, using bw model

Run on: December 21, 2005, 13:03:52; Search time 0.529508 Seconds  
(without alignments)  
228.978 Million cell updates/sec

Title: US-09-211-297-34

Perfect score: 84

Sequence: 1 VYVVKTSIKIPSSHNL 17

Scoring table:

BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 53982 seqs, 7132107 residues

Total number of hits satisfying chosen parameters: 53982

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: Published Applications AA\_New.\*  
1: /cgn2\_6/ptodata/2/pubpaa/US08\_NEW\_PUB\_PEP.\*  
2: /cgn2\_6/ptodata/2/pubpaa/US06\_NEW\_PUB\_PEP.\*  
3: /cgn2\_6/ptodata/2/pubpaa/US07\_NEW\_PUB\_PEP.\*  
4: /cgn2\_6/ptodata/2/pubpaa/PCT\_NEW\_PUB\_PEP.\*  
5: /cgn2\_6/ptodata/2/pubpaa/US05\_NEW\_PUB\_PEP.\*  
6: /cgn2\_6/ptodata/2/pubpaa/US10\_NEW\_PUB\_PEP.\*  
7: /cgn2\_6/ptodata/2/pubpaa/US11\_NEW\_PUB\_PEP.\*  
8: /cgn2\_6/ptodata/2/pubpaa/US60\_NEW\_PUB\_PEP.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	53	63.1	109	7 US-11-065-669-8	Sequence 8, Appl
2	37	44.0	717	6 US-10-793-626-3022	Sequence 3022, Ap
3	35	41.7	269	6 US-10-821-234-1684	Sequence 1684, Ap
4	34	40.5	113	6 US-10-793-626-3282	Sequence 3282, Ap
5	34	40.5	351	6 US-10-467-657-5088	Sequence 5088, Ap
6	33.5	39.9	374	7 US-11-060-023-10	Sequence 10, Appl
7	33	39.3	39	6 US-10-467-657-2174	Sequence 2174, Ap
8	33	39.3	96	6 US-10-467-657-8984	Sequence 8984, Ap
9	33	39.3	155	7 US-11-069-642-97	Sequence 97, Appl
10	33	39.3	198	7 US-11-069-642-25	Sequence 25, Appl
11	33	39.3	208	6 US-10-880-388-81	Sequence 81, Appl
12	33	39.3	238	7 US-11-069-642-127	Sequence 127, Appl
13	33	39.3	431	7 US-11-069-642-1	Sequence 1, Appl
14	33	39.3	437	7 US-11-069-642-92	Sequence 92, Appl
15	33	39.3	438	7 US-11-069-642-47	Sequence 47, Appl
16	33	39.3	438	7 US-11-069-642-49	Sequence 49, Appl
17	33	39.3	438	7 US-11-069-642-51	Sequence 51, Appl
18	33	39.3	438	7 US-11-069-642-53	Sequence 53, Appl
19	33	39.3	438	7 US-11-069-642-55	Sequence 55, Appl
20	33	39.3	438	7 US-11-069-642-57	Sequence 57, Appl
21	33	39.3	438	7 US-11-069-642-59	Sequence 59, Appl
22	33	39.3	438	7 US-11-069-642-61	Sequence 61, Appl
23	33	39.3	438	7 US-11-069-642-63	Sequence 63, Appl
24	33	39.3	438	7 US-10-131-826A-310	Sequence 310, Appl
25	33	39.3	619	6 US-10-763-712A-35	Sequence 35, Appl

26	33	39.3	734	7 US-11-093-274-40	Sequence 40, Appl
27	33	39.3	949	7 US-11-077-550-68	Sequence 68, Appl
28	33	39.3	1420	7 US-11-077-550-110	Sequence 110, Appl
29	32	38.1	64	6 US-10-467-657-7122	Sequence 7122, Appl
30	32	38.1	101	7 US-11-053-076-51	Sequence 51, Appl
31	32	38.1	111	7 US-11-053-076-163	Sequence 163, Appl
32	32	38.1	215	6 US-10-793-626-596	Sequence 596, Appl
33	32	38.1	215	6 US-10-793-626-8258	Sequence 8258, Appl
34	32	38.1	257	6 US-10-467-662B-73	Sequence 73, Appl
35	32	38.1	317	6 US-10-689-742-166	Sequence 166, Appl
36	32	38.1	356	7 US-11-055-822-972	Sequence 972, Appl
37	32	38.1	437	7 US-11-082-389-180	Sequence 180, Appl
38	32	38.1	437	7 US-11-082-389-180	Sequence 180, Appl
39	32	38.1	477	7 US-11-055-822-1050	Sequence 1050, Appl
40	32	38.1	477	7 US-11-055-822-1050	Sequence 1050, Appl
41	32	38.1	478	6 US-10-793-626-768	Sequence 768, Appl
42	32	38.1	567	6 US-10-131-826A-476	Sequence 476, Appl
43	32	38.1	1234	6 US-10-467-657-4224	Sequence 4224, Appl
44	32	38.1	2725	7 US-11-113-424-52	Sequence 52, Appl
45	31	36.9	102	7 US-11-053-076-162	Sequence 162, Appl

## ALIGNMENTS

RESULT 1  
US-11-065-669-8  
; Sequence 8, Application US/11065669  
; Publication No. US2005024411A1  
; GENERAL INFORMATION:  
; APPLICANT: Mackay, Sienne  
; APPLICANT: Kalled, Susan  
; TITLE OF INVENTION: BAPF, INHIBITORS THEREOF AND THEIR USE IN THE  
; TITLE OF INVENTION: MODULATION OF B-CELL RESPONSE  
; FILE REFERENCE: 08201.0024-04000  
; CURRENT APPLICATION NUMBER: US/11/065,669  
; CURRENT FILING DATE: 2005-02-24  
; PRIOR APPLICATION NUMBER: 10/045,574  
; PRIOR FILING DATE: 2001-11-07  
; PRIOR APPLICATION NUMBER: 09/911,777  
; PRIOR FILING DATE: 2001-07-24  
; PRIOR APPLICATION NUMBER: 60/143,228  
; PRIOR FILING DATE: 2001-07-09  
; PRIOR APPLICATION NUMBER: PCT/US00/01788  
; PRIOR FILING DATE: 2000-01-25  
; PRIOR APPLICATION NUMBER: 60/117,169  
; PRIOR FILING DATE: 1999-01-25  
; NUMBER OF SEQ ID NOS: 26  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 8  
; LENGTH: 109  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-11-065-669-8  
Query Match 63.1%; Score 53; DB 7; Length 109;  
Best Local Similarity 91.7%; Pred. No. 0.0067;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1 VYVVKTSIKIPS 12  
DB 63 VYVVKTSIKIPS 74  
RESULT 2  
US-10-793-626-3022  
; Sequence 3022, Application US/10793626  
; Publication No. US2005025478A1  
; GENERAL INFORMATION:  
; APPLICANT: KIMBERLY, WILLIAM JOHN  
; TITLE OF INVENTION: STAPHYLOCOCCUS EPIDERMIDIS NUCLEIC ACIDS AND PROTEINS  
; FILE REFERENCE: PU3480US  
; CURRENT APPLICATION NUMBER: US/10/793,626

```

; CURRENT FILING DATE: 2004-03-04
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
; OTHER INFORMATION: amino acid sequence
; PRIOR FILING DATE: 1999-11-09
; NUMBER OF SEQ ID NOS: 4472
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3022
; LENGTH: 717
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
; OTHER INFORMATION: amino acid sequence
US-10-793-626-3022

Query Match          44.0%; Score 37; DB 6; Length 717;
Best Local Similarity 46.2%; Pred. No. 39;
Matches 6; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Oy      2 YVVKTSIKIPSSH 14
Db      198 YVKGKVKILNNH 210

RESULT 3
US-10-821-234-1684
; Sequence 1684, Application US/10821234
; Publication No. US20050255114A1
; GENERAL INFORMATION:
; APPLICANT: Labat, Ivan
; APPLICANT: Stache-Crain, Birgit
; APPLICANT: Andarmani, Susan
; APPLICANT: Tang, Y. Tom
; TITLE OF INVENTION: Methods for Diagnosis and Treatment of Preeclampsia
; FILE REFERENCE: 821A
; CURRENT APPLICATION NUMBER: US/10/821,234
; CURRENT FILING DATE: 2004-04-07
; PRIOR APPLICATION NUMBER: US 60/462,047
; PRIOR FILING DATE: 2003-04-07
; NUMBER OF SEQ ID NOS: 1704
; SOFTWARE: pc_seq_genes Version 1.0
; SEQ ID NO 1684
; LENGTH: 269
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-821-234-1684

Query Match          41.7%; Score 35; DB 6; Length 269;
Best Local Similarity 50.0%; Pred. No. 28;
Matches 6; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Oy      6 TSIKIPSSHNM 17
Db      186 TDIKIATGHNTI 197

RESULT 4
US-10-793-626-3282
; Sequence 3282, Application US/10793626
; Publication No. US20050255478A1
; GENERAL INFORMATION:
; APPLICANT: KIMMERLY, WILLIAM JOHN
; TITLE OF INVENTION: STAPHYLOCOCCUS EPIDERMIDIS NUCLEIC ACIDS AND PROTEINS
; FILE REFERENCE: PUJ480US
; CURRENT APPLICATION NUMBER: US/10/793,626
; CURRENT FILING DATE: 2004-03-04
; PRIOR APPLICATION NUMBER: 60/164,258
; PRIOR FILING DATE: 1999-11-09
; NUMBER OF SEQ ID NOS: 4472
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3282
; LENGTH: 113
; TYPE: PRT
; ORGANISM: Artificial Sequence
```

```

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
; OTHER INFORMATION: amino acid sequence
US-10-793-626-3282

Query Match          40.5%; Score 34; DB 6; Length 113;
Best Local Similarity 42.9%; Pred. No. 16;
Matches 6; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

Oy      1 YVVKTSIKIPSSH 14
Db      56 VSVASTLMKLPNTH 69

RESULT 5
US-10-467-657-5088
; Sequence 5088, Application US/10467657
; Publication No. US20050260581A1
; GENERAL INFORMATION:
; APPLICANT: CHIRON SPA
; APPLICANT: FONTANA Maria Rita
; APPLICANT: PIZZA Mariagrazia
; APPLICANT: MASIGNANI Vega
; APPLICANT: MONACI Elisabetta
; TITLE OF INVENTION: GONOCOCCAL PROTEINS AND NUCLEIC ACIDS
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/10/467,657
; CURRENT FILING DATE: 2003-08-11
; PRIOR APPLICATION NUMBER: GB-0103424.8
; PRIOR FILING DATE: 2001-02-12
; NUMBER OF SEQ ID NOS: 9218
; SOFTWARE: SeqWIn99, version 1.04
; SEQ ID NO 5088
; LENGTH: 351
; TYPE: PRT
; ORGANISM: Neisseria gonorrhoeae
US-10-467-657-5088

Query Match          40.5%; Score 34; DB 6; Length 351;
Best Local Similarity 40.0%; Pred. No. 58;
Matches 6; Conservative 4; Mismatches 5; Indels 0; Gaps 0;

Oy      2 YVVKTSIKIPSSH 16
Db      275 HIINPNKRPIRSHNL 289

RESULT 6
US-11-060-023-10
; Sequence 10, Application US/11060023
; Publication No. US20050255531A1
; GENERAL INFORMATION:
; APPLICANT: Aventis Pharma Deutschland GmbH
; TITLE OF INVENTION: Process for identifying modulators of G protein coupled
; FILE REFERENCE: AVE D-2000/A033 englisch
; CURRENT APPLICATION NUMBER: US/11/060,023
; CURRENT FILING DATE: 2005-02-17
; PRIOR APPLICATION NUMBER: US/09/899,295
; PRIOR FILING DATE: 2003-07-06
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 374
; TYPE: PRT
; ORGANISM: Mus musculus
US-11-060-023-10

Query Match          39.9%; Score 33.5; DB 7; Length 374;
Best Local Similarity 47.1%; Pred. No. 76;
Matches 8; Conservative 4; Mismatches 2; Indels 3; Gaps 1;

Oy      1 YVVKTSI--KIPSSH 14
```





CC modulate binding of OPG binding protein to osteoclast differentiation and  
 CC activation receptor (ODAR). The nucleic acid molecule encoding OPG  
 CC binding protein can be used to detect OPG binding protein-encoding  
 CC sequences, e.g. screening for related sequences, also to produce  
 CC transgenic animal models, while complementary sequences are used for  
 CC antisense regulation of OPG binding protein expression. Modulators of OPG  
 CC binding protein, particularly soluble forms of OPG binding protein or Ab,  
 CC are used to treat or prevent bone diseases, e.g. osteoporosis, bone loss  
 CC caused by arthritis or metastases, hypercalcaemia, Paget's disease,  
 CC periodontal disease, osteoporosis, loosening of prostheses, optionally in  
 CC combination with agents that promote bone growth

CC Sequence 17 AA:

Query Match 100.0%; Score 84; DB 2; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 1.4e-07;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VYVVKTSIKIPSSHNLM 17  
 |||||  
 DB 1 VYVVKTSIKIPSSHNLM 17

RESULT 2  
 AAM83199  
 ID AAM83199 standard; peptide; 18 AA.  
 XX

AC AAM83199;

DT 11-FEB-1999 (first entry)

DE Murine osteoprotegerin binding protein EF loop-Cys peptide.

XX Osteoprotegerin binding protein; OPG binding protein; arthritis;  
 KM osteoporosis; osteoclast maturation; bone disease; metastasis; ODAR;  
 KM hypercalcaemia; osteoclast differentiation and activation receptor;  
 KM Paget's disease.

XX Mus sp.

XX MO9846751-A1.

XX 22-OCT-1998.

XX 15-APR-1998; 98WO-US007584.

XX 16-APR-1997; 97US-00842842.

XX 23-JUN-1997; 97US-00880855.

XX 30-MAR-1998; 98US-00052521.

XX (AMGE-) AMGEN INC.

XX Boyle WJ;

XX WPI, 1998-594578/50.

XX Nucleic acid encoding osteoprotegerin binding protein - useful for, e.g.  
 PT treating bone diseases by modulating osteoclast differentiation and for  
 PT diagnosis.

XX Example 11; Page 55; 47pp; English.

XX The present sequence represents peptide from murine osteoprotegerin (OPG)  
 CC binding protein. Host cells transfected with vectors containing nucleic  
 CC acid molecules encoding OPG binding protein are used to produce  
 CC recombinant OPG binding protein. OPG binding protein is used in binding  
 CC assays to determine osteoprotegerin (OG) in biological samples; to screen  
 CC for specific binding agents (particularly agonists and antagonists,  
 CC including intracellular proteins); to raise Ab (useful in immunoassays  
 CC for detection of OPG binding protein) and to identify compounds that  
 CC modulate binding of OPG binding protein to osteoclast differentiation and  
 CC activation receptor (ODAR). The nucleic acid molecule encoding OPG  
 CC binding protein can be used to detect OPG binding protein-encoding

CC sequences, e.g. screening for related sequences, also to produce  
 CC transgenic animal models, while complementary sequences are used for  
 CC antisense regulation of OPG binding protein expression. Modulators of OPG  
 CC binding protein, particularly soluble forms of OPG binding protein or Ab,  
 CC are used to treat or prevent bone diseases, e.g. osteoporosis, bone loss  
 CC caused by arthritis or metastases, hypercalcaemia, Paget's disease,  
 CC periodontal disease, osteoporosis, loosening of prostheses, optionally in  
 CC combination with agents that promote bone growth

CC Sequence 18 AA:

Query Match 100.0%; Score 84; DB 2; Length 18;  
 Best Local Similarity 100.0%; Pred. No. 1.4e-07;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VYVVKTSIKIPSSHNLM 17  
 |||||  
 DB 1 VYVVKTSIKIPSSHNLM 17

RESULT 3  
 AAY91023  
 ID AAY91023 standard; protein; 139 AA.  
 XX  
 XX AAY91023;

XX 05-SEP-2000 (first entry)

DT Mouse OBM protein sequence SEQ ID NO:8.

DE Mouse, osteoclastogenesis inhibitory factor binding molecule; OCIF; OBM;

XX osteoclast; bone absorption promoting factor; vitamin D3; PTH;  
 KM parathyroid hormone.

XX Mus sp.

XX JP2000102390-A.

XX 11-APR-2000.

XX 30-SEP-1998; 98JP-00292971.

XX 30-SEP-1998; 98JP-00292971.

XX (SNOW) SNOW BRAND MILK PROD CO LTD.

XX (YSNE-) YS NEW TECHNOLOGY KENKYUSHO.

XX WPI, 2000-332087/29.

XX N-PSDB; AAA39155.

XX A DNA and preparation of a protein by using it.

XX Example 2; Page 14; 18pp; Japanese.

XX The present invention describes a genomic DNA encoding a protein having  
 CC an activity of supporting or promoting differentiation and maturation of  
 CC osteoclasts. The genomic DNA encoding a protein has the following  
 CC properties: (a) combines specifically with osteoclastogenesis inhibitory  
 CC factor (OCIF) and has a high affinity; (b) shows a molecular weight (mw)  
 CC of 30,000 to 40,000 by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide  
 CC gel electrophoresis) under a nonreductive condition and the apparent mw  
 CC when crosslinked with monomer type OCIF is 90,000 to 110,000; and (c) has  
 CC an activity of supporting or promoting differentiation and maturation of  
 CC osteoclast in the co-culture of mouse osteoblast-like stroma cell and  
 CC mouse spleen cell in the presence of a bone absorption promoting factor  
 CC such as active type vitamin D3 and parathyroid hormone (PTH). The protein  
 CC can be used as a drug and a research reagent. The present sequence  
 CC represents a mouse OCIF binding molecule (OBM) from the present invention

XX Sequence 139 AA:

Query Match 100.0%; Score 84; DB 3; Length 139;  
 Best Local Similarity 100.0%; Pred. No. 1.5e-06;

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:47:51 ; Search time 1.92295 Seconds  
(without alignments)  
850.612 Million cell updates/sec

Title: US-09-211-297-34

Perfect score: 84

Sequence: 1 VYVVKTSIKIPSSHNL 17

Scoring table: BLOSUM62  
Gapop 10.0, Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database: PIR 80: \*  
1: p1r1: \*  
2: p1r2: \*  
3: p1r3: \*  
4: p1r4: \*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	45	53.6	206	2 G86279	Fla117_27 protein
2	44.5	53.0	311	2 B70441	ribose-phosphate d
3	43	51.2	232	1 I83349	CS6 subunits chape
4	43	51.2	377	2 S67448	hypothetical prote
5	41	48.8	612	2 A13493	oligopeptide-bind
6	40	47.6	115	2 F81358	probable periplasm
7	40	47.6	311	2 C23701	olfactory receptor
8	40	47.6	1235	2 T17457	SARA protein - Afr
9	39.5	47.0	917	2 T05430	hypothetical prote
10	39	46.4	176	2 C86824	hypothetical prote
11	39	46.4	262	2 T49066	hypothetical prote
12	39	46.4	288	2 B98278	hypothetical prote
13	39	46.4	288	2 A13005	conserved hypothet
14	39	46.4	334	2 A70101	hypothetical prote
15	39	46.4	360	2 T15639	hypothetical prote
16	39	46.4	603	2 T40528	palmitoyl-protein
17	39	46.4	659	2 F72568	probable acylamino
18	39	46.4	799	2 B71478	probable cell divi
19	39	46.4	1109	2 B71478	DNA-directed RNA p
20	39	46.4	1227	2 T48028	hypothetical prote
21	39	46.4	1802	2 S69703	HKX1 protein precu
22	38.5	45.8	400	2 A46297	beta-1,6-N-acetyl
23	38.5	45.8	699	2 T16109	hypothetical prote
24	38	45.2	135	2 PNO550	G protein-coupled
25	38	45.2	294	2 B69445	conserved hypothet
26	38	45.2	332	2 H84129	sugar ABC transpor
27	38	45.2	510	1 S15620	LI protein - human
28	38	45.2	672	2 E90294	hypothetical prote
29	38	45.2	899	2 G71453	hypothetical prote

30	38	45.2	1038	2 S52522	hypothetical prote
31	38	45.2	1517	2 T38912	hypothetical integ
32	37.5	44.6	119	2 AH3459	hypothetical prote
33	37	44.0	72	2 AB2528	hypothetical prote
34	37	44.0	76	2 AH2120	hypothetical prote
35	37	44.0	174	2 F97114	uncharacterized co
36	37	44.0	291	2 S28299	hypothetical prote
37	37	44.0	307	2 T34143	hypothetical prote
38	37	44.0	327	2 G83921	hypothetical prote
39	37	44.0	334	2 E75153	glyceraledehyde 3-p
40	37	44.0	370	2 S52699	hypothetical prote
41	37	44.0	377	2 AB0087	probable flagellar
42	37	44.0	433	2 AD1164	H+-transporting AT
43	37	44.0	433	2 AD1523	UDP-N-acetylmuramo
44	37	44.0	452	2 UT6561	nicotinic acetylch
45	37	44.0	506	1 ACRYG1	

## ALIGNMENTS

RESULT 1  
G86279  
Fla117\_27 protein - Arabidopsis thaliana  
C:Species: Arabidopsis thaliana (mouse-ear cress)  
C:Date: 02-Mar-2001 #sequence\_revision 02-Mar-2001 #text\_change 09-Jul-2004  
C:Accession: G86279  
R:Theologos, A.; Becker, J.R.; Palm, C.J.; Federpiet, N.A.; Kaul, S.; White, O.; Alonso, J.; Chung, M.K.; Conn, L.; Conway, A.B.; Conway, A.R.; Creasy, T.H.; Dewart, K.; Jensen, N.F.; Hughes, B.; Hulzar, L.  
Nature 408, 816-820, 2000  
A:Authors: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin, E.; Kim, C.; Li, J.H.; Li, Y.; Lin, X.; Liu, S.X.; Liu, Z.A.; Lueros, J.S.; Maiti, R.; Marziani, Rizzo, M.; Rooney, T.; Rowley, D.; Sakano, H.  
A:Authors: Salzberg, S.L.; Schwartz, J.R.; Shinn, P.; Southwick, A.M.; Sun, H.; Tallon, K.; Wu, D.; Yu, G.; Fraser, C.M.; Venter, J.C.; Davis, R.W.  
A:title: Sequence and analysis of chromosome 1 of the plant Arabidopsis.  
A:Reference number: A6141; MUID:21016719; PMID:11130712  
A:Accession: G86279  
A:Status: preliminary  
A:Stature: preliminary  
A:Molecule type: DNA  
A:Residues: 1-206 <STO>  
A:Cross-references: UNIPROT:Q9M9R4; UNIPARC:UPI000000A0A22; GB:AE005172; NID:97262692; PI C:Genetics:  
A:Map position: 1  
Query Match  
Best Local Similarity 53.6%; Score 45; DB 2; Length 206;  
Matches 10; Conservative 0; Mismatches 6; Indels 0; Gaps 0;  
QY 1 VYVVKTSIKIPSSHNL 16  
DB 142 VYFVATSPFNPSYHRL 157  
RESULT 2  
B70441  
ribose-phosphate diphosphokinase (EC 2.7.6.1) - Aquifex aeolicus  
N:Alternate names: phosphoribosylpyrophosphate synthetase  
C:Species: Aquifex aeolicus  
C:Date: 08-May-1998 #sequence\_revision 08-May-1998 #text\_change 09-Jul-2004  
C:Accession: B70441  
R:Decker, G.; Warren, P.V.; Gaasterland, T.; Young, W.G.; Lenox, A.L.; Graham, D.E.; V.  
Nature 392, 353-358, 1998  
A:title: The complete genome of the hyperthermophilic bacterium Aquifex aeolicus.  
A:Reference number: A70300; MUID:98196666; PMID:9537320  
A:Status: preliminary; nucleic acid sequence not shown; translation not shown  
A:Molecule type: DNA  
A:Residues: 1-311 <AOF>  
A:Cross-references: UNIPROT:Q67556; UNIPARC:UPI000005668B; GB:AE000748; NID:92983960; PI A:Experimental source: strain VFS





RX MEDLINE=98188248; PubMed=9520411; DOI=10.1073/pnas.95.7.3597;  
 RA Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinoshita M., Tsuda E.,  
 RA Mochizuki S.-I., Tomoyasu A., Yano K., Soto M., Murakami A.,  
 RA Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T.;  
 RT Osteoclast differentiation factor is a ligand for  
 RT osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical  
 RT to TRANCE/RANKL.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 95:3597-3602(1998).  
 RL [5]  
 RP NUCLEOTIDE SEQUENCE (ISOFORM 1).  
 RC STRAIN=129;  
 RX MEDLINE=99214075; PubMed=10196481; DOI=10.1016/S0378-1119(99)00025-6;  
 RA Kodaira K., Kodaira K., Mizuno A., Yasuda H., Shima N., Murakami A.,  
 RA Ueda M., Higashio K.;  
 RT Cloning and characterization of the gene encoding mouse osteoclast  
 RT differentiation factor.";  
 RL Gene 230:121-127(1999).  
 RL [6]  
 RP NUCLEOTIDE SEQUENCE (ISOFORMS 1; 2 AND 3).  
 RX MEDLINE=21150053; PubMed=11250921; DOI=10.1210/en.142.4.1419;  
 RA Ikeda T., Kasai M., Utsuyama M., Hirokawa K.;  
 RT Determination of three isoforms of the receptor activator of nuclear  
 RT factor-kappaB ligand and their differential expression in bone and  
 RT thymus.";  
 RL Endocrinology 142:1419-1426(2001).  
 RL [7]  
 RP PROTEIN SEQUENCE OF 139-147, PROCESSING, AND N-GLYCOSYLATION  
 RX MEDLINE=99240759; PubMed=10224132; DOI=10.1074/jbc.274.19.13613;  
 RA Lum L., Wong B.R., Josien P., Becherer J.D., Erdjument-Bromage H.,  
 RA Schloendorff J., Tempst P., Choi Y., Blobel C.P.;  
 RT Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-  
 RT converting enzyme-like protease in shedding of TRANCE, a TNF family  
 RT member involved in osteoclastogenesis and dendritic cell survival.";  
 RL J. Biol. Chem. 274:13613-13618(1999).  
 RL [8]  
 RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 158-316.  
 RX MEDLINE=21464816; PubMed=11581298;  
 RA Lam J., Nelson C.A., Ross F.P., Teitelbaum S.L., Fremont D.H.;  
 RT "Crystal structure of the TRANCE/RANKL cytokine reveals determinants  
 RT of receptor-ligand specificity.";  
 RL J. Clin. Invest. 108:971-979(2001).  
 RL [9]  
 RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 137-316.  
 RX MEDLINE=21839021; PubMed=11733492; DOI=10.1074/jbc.M106525200;  
 RA Ito S., Wakabayashi K., Ushikata O., Hayashi S., Okada F., Hata T.;  
 RT "Crystal structure of the extracellular domain of mouse RANK ligand at  
 RT 2.2-A resolution.";  
 RL J. Biol. Chem. 277:6631-6636(2002).  
 RL [10]  
 RP FUNCTION: Cytokine that binds to TNFRSF11B/OPG and to  
 CC TNFRSF11A/RANK. Osteoclast differentiation and activation factor.  
 CC Augments the ability of dendritic cells to stimulate naive T-cell  
 CC proliferation. May be an important regulator of interactions  
 CC between T cells and dendritic cells and may play a role in the  
 CC regulation of the T cell-dependent immune response. May also play  
 CC an important role in enhanced bone-resorption in humoral  
 CC hypercalcaemia of malignancy.  
 CC [11]  
 RP SUBUNIT: Homotrimer.  
 CC [12]  
 RP SUBCELLULAR LOCATION: Type II membrane protein and secreted  
 CC (isoforms 1 and 2); Cytoplasmic (isoform 3).  
 CC [13]  
 RP ALTERNATIVE PRODUCTS:  
 CC Event=Alternative splicing; Named isoforms=3;  
 CC Name=1;  
 CC IsoId=O35235-1; Sequence=Displayed;  
 CC Name=2;  
 CC IsoId=O35235-2; Sequence=VSP\_006449;  
 CC Name=3;  
 CC IsoId=O35235-3; Sequence=VSP\_006448;  
 CC [14]  
 RP TISSUE SPECIFICITY: Highly expressed in thymus and lymph nodes,  
 CC but not in nonlymphoid tissues and is abundantly expressed in T  
 CC cells but not in B cells. A high level expression is also seen in  
 CC the trabecular bone and lung.  
 CC [15]  
 RP PTM: N-glycosylated.  
 CC [16]  
 RP PTM: The soluble form of isoform 1 derives from the membrane form

CC by proteolytic processing. The cleavage may be catalyzed by  
 CC ADAM17. A further shorter soluble form was observed.  
 CC [17]  
 RP DISEASE: Deficiency in Tnfrsf11 results in failure to form lobulo-  
 CC alveolar mammary structures during pregnancy, resulting in death  
 CC of newborns. Transgenic mice show severe osteopetrosis, with  
 CC no osteoclasts, marrow spaces, or tooth eruption, and exhibit  
 CC profound growth retardation at several skeletal sites, including  
 CC the limbs, skull, and vertebrae and have marked chondroplasia,  
 CC with thick, irregular growth plates and a relative increase in  
 CC hypertrophic chondrocytes.  
 CC [18]  
 RP SIMILARITY: Belongs to the tumor necrosis factor family.  
 CC [19]  
 RP This Swiss-Prot entry is copyrighted. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use as long as its content is in no way modified and this statement is not  
 CC removed.  
 CC -----  
 DR EMBL; AF013170; AAC71061.1; -; mRNA.  
 DR EMBL; AF019048; AAB86812.1; -; mRNA.  
 DR EMBL; AF053713; AAC40113.1; -; mRNA.  
 DR EMBL; AB008426; BAA25425.1; -; mRNA.  
 DR EMBL; AB022039; BAA36970.1; -; Genomic\_DNA.  
 DR EMBL; AB032771; BAA97257.1; -; mRNA.  
 DR EMBL; AB032772; BAA97258.1; -; mRNA.  
 DR EMBL; AB036798; BAA97259.1; -; mRNA.  
 DR PDB; 1IOA; X-ray; A/B/C=157-316.  
 DR PDB; 1UTZ; X-ray; X/Y/Z=156-316.  
 DR Ensemble; ENSMUSG0000022015; Mus musculus.  
 DR MG1; MG1.1100089; Tnfrsf11.  
 DR GO; GO:0016021; C:integral to membrane; TAS.  
 DR GO; GO:0005515; P:protein binding; IPI.  
 DR GO; GO:0045453; P:bone resorption; IDA.  
 DR GO; GO:0007515; P:lymph gland development; TAS.  
 DR GO; GO:0009887; P:organogenesis; IMP.  
 DR GO; GO:0001503; P:ossification; IMP.  
 DR GO; GO:0045672; P:positive regulation of osteoclast different. . .; IDA.  
 DR GO; GO:0051260; P:protein homooligomerization; IDA.  
 DR InterPro; IPR006052; TNF family.  
 DR InterPro; IPR003636; TNF\_subf.  
 DR Pfam; PF00229; TNF\_1.  
 DR ProDom; PD002012; TNF\_subf; 1.  
 DR SMART; SM00207; TNF\_1.  
 DR PROSITE; PS00251; TNF\_1; FALSE\_NEG.  
 DR PROSITE; PSS0049; TNF\_2; 1.  
 KW 3D-structure; Alternative splicing; Cytokine; Developmental protein;  
 KW Differential; Direct protein sequencing; Glycoprotein; Receptor;  
 KW Signal-anchor; Transmembrane.  
 FT CHAIN 1 316  
 FT CHAIN 139 316  
 FT TOPO\_DOM 1 48  
 FT TRANSMEM 49 69  
 FT TOPO\_DOM 70 316  
 FT SITE 138 139  
 FT CARBOHYD 197 197  
 FT CARBOHYD 262 262  
 FT VARSPPLIC 1 117  
 FT VARSPPLIC 14 44  
 FT CONFLICT 99 99  
 FT CONFLICT 141 143  
 FT STRAND 164 169  
 FT TURN 171 172  
 FT STRAND 181 182  
 FT STRAND 186 187  
 FT TURN 191 192  
 FT STRAND 194 196  
 FT STRAND 198 201  
 /FTId=VSP\_006449.  
 G -> D (in Ref. 2).  
 Missing (in Ref. 5).

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using bw model

Run on: December 21, 2005, 12:35:06 (Search time 18.5902 Seconds  
(without alignments)  
1024.696 Million cell updates/sec

Title: US-09-211-297-32

Perfect score: 148  
Sequence: 1 NAA5IPGSHKVTLSWYHGRMAKIS 27

Scoring table: BLOSUM62  
Gapop 10.0, Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%  
Listing first 45 summaries

Database: UniProt\_05.80.\*

1: uniprot\_sprot.\*  
2: uniprot\_trembl.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result LNo.	Score	Query Match Length	ID	Description
1	148	100.0	316 1 TNF11_MOUSE	035235 m tumor nec
2	140	94.6	318 1 TNF11_RAT	09882 r tumor nec
3	136	91.9	244 2 054A98_HUMAN	054A98 homo sapien
4	136	91.9	317 1 TNF11_HUMAN	014788 h tumor nec
5	136	91.9	317 2 0579Y4_HUMAN	0579Y4 homo sapien
6	88	59.5	117 2 05X1H0_RABIT	05X1H0 oryctolagus
7	76	51.4	95 2 06UWL7_HUMAN	06UWL7 homo sapien
8	76	51.4	95 2 06UWL7_HUMAN	06UWL7 homo sapien
9	61.5	41.6	157 2 09C4K2_9EURY	09C4K2 uncultured
10	59	39.9	456 1 MNTN_BRUSU	09C4K2 uncultured
11	59	39.9	456 1 MNTN_BRUSU	09C4K2 uncultured
12	59	39.9	456 1 MNTN_BRUSU	09C4K2 uncultured
13	58.5	39.5	157 2 09C4G1_9EURY	09C4G1 uncultured
14	58.5	39.5	157 2 09C4H5_9EURY	09C4H5 uncultured
15	58.5	39.5	157 2 09C4H7_9EURY	09C4H7 uncultured
16	58.5	39.5	157 2 09C4I3_9EURY	09C4I3 uncultured
17	58.5	39.5	157 2 09C4J1_9EURY	09C4J1 uncultured
18	58.5	39.5	163 2 07ZAB6_9EURY	07ZAB6 uncultured
19	58	39.2	371 2 08QOC2_METMA	08QOC2 methanobact
20	57	38.5	255 2 041VP8_AZOVI	041VP8 azotobacter
21	56.5	38.2	157 2 09C4G8_9EURY	09C4G8 uncultured
22	56.5	38.2	162 2 06SEI7_9EURY	06SEI7 uncultured
23	56.5	38.2	224 2 06VVF0_9ARCH	06VVF0 uncultured
24	56.5	38.2	224 2 06VVF0_9ARCH	06VVF0 uncultured
25	56.5	38.2	235 2 06VVF2_9ARCH	06VVF2 uncultured
26	56.5	38.2	235 2 06VVF3_9ARCH	06VVF3 uncultured
27	56.5	38.2	235 2 06VVF5_9ARCH	06VVF5 uncultured
28	56.5	38.2	235 2 06VVF8_9ARCH	06VVF8 uncultured
29	56.5	38.2	235 2 05EGK0_9EURY	05EGK0 uncultured
30	56.5	38.2	254 2 05EGK6_9EURY	05EGK6 uncultured
31	56.5	38.2	254 2 05EGK6_9EURY	05EGK6 uncultured

## ALIGNMENTS

RESULT 1	UNIPROT_05.80.*	STANDARD	PRT	AA
AC	035235; 035306; 09JYK8; 09JYK9; 09R1Y0;			
DT	16-OCT-2001 (Rel. 40, Created)			
DT	16-OCT-2001 (Rel. 40, Last sequence update)			
DT	13-SEP-2005 (Rel. 48, Last annotation update)			
DE	Tumor necrosis factor ligand superfamily member 11 (Receptor activator of nuclear factor kappa B ligand) (RANKL) (TNF-related activation-induced cytokine) (TRANCE) (Osteoprotegerin ligand) (OPG) (Osteoclast differentiation factor) (ODF) [Contains: Tumor necrosis factor ligand superfamily member 11, membrane form; Tumor necrosis factor ligand superfamily member 11, soluble form]			
GN	Name=TNF11; Synonyms=opgl, Rankl, Trance;			
OS	Mus musculus (Mouse).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;			
OC	Muridae; Muridae; Murinae; Mus.			
OK	NCBI_TaxID=10090;			
RN	[1]			
RP	NUCLEOTIDE SEQUENCE (ISOFORM 1).			
RC	TISSUE=Hybridoma;			
RX	MEDLINE=97460112; PubMed=9312132; DOI=10.1074/jbc.272.40.25190;			
RA	Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M.,			
RA	Kalachikov S., Cayani E., Bartlett F.S. III, Frankel W.N., Lee S.Y.,			
RA	Choi Y.;			
RT	"TRANCE is a novel ligand of the tumor necrosis factor receptor family			
RL	that activates c-Jun N-terminal kinase in T cells.";			
RN	J. Biol. Chem. 272:25190-25194(1997).			
RP	NUCLEOTIDE SEQUENCE (ISOFORM 1).			
RC	TISSUE=Thymic lymphoma;			
RX	MEDLINE=98032977; PubMed=9367155; DOI=10.1038/36593;			
RA	Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall M.C.,			
RA	Tometsko M.E., Roux E.R., Teepe M.C., Dubose R.F., Cosman D.,			
RA	Galibert L.;			
RT	"A homologue of the TNF receptor and its ligand enhance T-cell growth			
RL	and dendritic-cell function.";			
RN	Nature 390:175-179(1997).			
RP	NUCLEOTIDE SEQUENCE (ISOFORM 1).			
RC	TISSUE=Bone marrow;			
RX	MEDLINE=98272661; PubMed=9568710; DOI=10.1016/S0092-8674(00)81569-X;			
RA	Lacey D.L., Timms E., Tan H.-L., Kelley M.J., Dunstan C.R.,			
RA	Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H.,			
RA	Sullivan J., Hawkins N., Davy E., Capparello C., Eli A., Qian Y.-X.,			
RA	Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J.,			
RA	Boyle W.J.;			
RT	"Osteoprotegerin ligand is a cytokine that regulates osteoclast			
RL	differentiation and activation.";			
RN	Cell 93:165-176(1998).			
RP	NUCLEOTIDE SEQUENCE (ISOFORM 1).			
RC	TISSUE=Bone marrow stroma;			

32	56.5	38.2	254 2 05EGK5_9EURY	05EGK5 uncultured
33	56.5	38.2	254 2 05EGJ9_9EURY	05EGJ9 uncultured
34	56.5	38.2	561 2 064CT0_9ARCH	064CT0 uncultured
35	56	37.8	334 2 07NRU9_CHRYO	07NRU9 chromobacte
36	56	37.8	756 2 041ZG3_AZOVI	041ZG3 azotobacter
37	55.5	37.5	162 2 06J1Z3_9EURY	06J1Z3 uncultured
38	55.5	37.5	224 2 06VVE9_9ARCH	06VVE9 uncultured
39	55.5	37.5	254 2 05EGJ8_9EURY	05EGJ8 uncultured
40	55.5	37.5	254 2 05EGJ6_9EURY	05EGJ6 uncultured
41	55.5	37.5	561 2 064B73_9ARCH	064B73 uncultured
42	55.5	37.5	561 2 06VUA1_9ARCH	06VUA1 uncultured
43	55	37.2	606 2 04TR89_9SPHN	04TR89 erythroba
44	54.5	36.8	156 2 06ZX88_9EURY	06ZX88 uncultured
45	54.5	36.8	157 2 09C4H0_9EURY	09C4H0 uncultured

RX MEDLINE=98188248; PubMed=9520411; DOI=10.1073/pnas.95.7.3597;  
 RA Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M.,  
 RA Mochizuki S.-I., Tomoyasu A., Yano K., Soto M., Murakami A., Tsuda E.,  
 RA Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T.;  
 RT Osteoclast differentiation factor is a ligand for  
 RT osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical  
 RT to TRANCE/RANKL.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 95:3597-3602(1998).  
 [5]  
 RN NUCLEOTIDE SEQUENCE (ISOFORM 1).  
 RP STRAIN=129;  
 RX MEDLINE=99214075; PubMed=10196481; DOI=10.1016/S0378-1119(99)00025-6;  
 RA Kodaira K., Kodaira K., Mizuno A., Yasuda H., Shima N., Murakami A.,  
 RA Ueda M., Higashio K.;  
 RT Cloning and characterization of the gene encoding mouse osteoclast  
 RT differentiation factor.";  
 RL Gene 230:121-127(1999).  
 [6]  
 RN NUCLEOTIDE SEQUENCE (ISOFORMS 1; 2 AND 3).  
 RP MEDLINE=21150053; PubMed=11250923; DOI=10.1210/en.142.4.1419;  
 RA Ikeda T., Kaebel M., Utsuyama M., Hirokawa K.;  
 RT Determination of three isoforms of the receptor activator of nuclear  
 RT factor-kappaB ligand and their differential expression in bone and  
 RT thymus.";  
 RL Endocrinology 142:1419-1426(2001).  
 [7]  
 RN PROTEIN SEQUENCE OF 139-147, PROCESSING, AND N-GLYCOSYLATION.  
 RP MEDLINE=99240759; PubMed=1024132; DOI=10.1074/jbc.274.19.1613;  
 RA Lum L., Wong B.R., Josien R., Becherer J.D., Erdjument-Bromage H.,  
 RA Schenck J., Tempst P., Choi Y., Blobel C.P.;  
 RT Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-  
 RT converting enzyme-like protease in shedding of TRANCE, a TNF family  
 RT member involved in osteoclastogenesis and dendritic cell survival.";  
 RL J. Biol. Chem. 274:13613-13618(1999).  
 [8]  
 RN X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 158-316.  
 RP MEDLINE=21464816; PubMed=11581298;  
 RA Lam J., Nelson C.A., Ross F.P., Teitelbaum S.L., Fremont D.H.;  
 RT Crystal structure of the TRANCE/RANKL cytokine reveals determinants  
 RT of receptor-ligand specificity.";  
 RL J. Clin. Invest. 108:971-979(2001).  
 [9]  
 RN X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 137-316.  
 RP MEDLINE=21839021; PubMed=11733492; DOI=10.1074/jbc.M106525200;  
 RA Ito S., Wakabayashi K., Ushikata O., Hayashi S., Okada F., Hata T.;  
 RT Crystal structure of the extracellular domain of mouse RANK ligand at  
 RT 2.2-A resolution.";  
 RL J. Biol. Chem. 277:6631-6636(2002).  
 CC -1- FUNCTION: Cytokine that binds to TNFRSF11B/OPG and to  
 CC TNFRSF11A/RANK. Osteoclast differentiation and activation factor.  
 CC Augments the ability of dendritic cells to stimulate naive T-cell  
 CC proliferation. May be an important regulator of interactions  
 CC between T cells and dendritic cells and may play a role in the  
 CC regulation of the T cell-dependent immune response. May also play  
 CC an important role in enhanced bone-resorption in humoral  
 CC hypercalcaemia of malignancy.  
 CC -1- SUBUNIT: Homotrimer.  
 CC -1- SUBCELLULAR LOCATION: Type II membrane protein and secreted  
 CC (isoforms 1 and 2); Cytoplasmic (isoform 3).  
 CC -1- ALTERNATIVE PRODUCTS:  
 CC Event=Alternative splicing; Named isoforms=3;  
 CC Name=1;  
 CC IsoId=O35235-1; Sequence=Displayed;  
 CC Name=2;  
 CC IsoId=O35235-2; Sequence=VSP\_006449;  
 CC Name=3;  
 CC IsoId=O35235-3; Sequence=VSP\_006448;  
 CC -1- TISSUE SPECIFICITY: Highly expressed in thymus and lymph nodes,  
 CC but not in nonlymphoid tissues and is abundantly expressed in T  
 CC cells but not in B cells. A high level expression is also seen in  
 CC the trabecular bone and lung.  
 CC -1- PTM: N-glycosylated.  
 CC -1- PTM: The soluble form of isoform 1 derives from the membrane form

CC by proteolytic processing. The cleavage may be catalyzed by  
 CC ADAM17. A further shorter soluble form was observed.  
 CC -1- DISEASE: Deficiency in TNFRSF11 results in failure to form lobulo-  
 CC alveolar mammary structures during pregnancy, resulting in death  
 CC of newborns. Transc-deficient mice show severe osteopetrosis, with  
 CC no osteoclasts, marrow spaces, or tooth eruption, and exhibit  
 CC profound growth retardation at several skeletal sites, including  
 CC the limbs, skull, and vertebrae and have marked chondrodysplasia,  
 CC with thick, irregular growth plates and a relative increase in  
 CC hypertrophic chondrocytes.  
 CC -1- SIMILARITY: Belongs to the tumor necrosis factor family.  
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use as long as its content is in no way modified and this statement is not  
 CC removed.  
 CC -----  
 DR EMBL; AF013170; AAC71061.1; -; mRNA.  
 DR EMBL; AF019048; AAB86812.1; -; mRNA.  
 DR EMBL; AF053713; AAC40113.1; -; mRNA.  
 DR EMBL; AB008426; BAA25425.1; -; mRNA.  
 DR EMBL; AB022039; BAA36970.1; -; Genomic\_DNA.  
 DR EMBL; AB032771; BAA97257.1; -; mRNA.  
 DR EMBL; AB032772; BAA97258.1; -; mRNA.  
 DR EMBL; AB036798; BAA97259.1; -; mRNA.  
 DR PDB; 1IC4; X-ray; A/B/C=157-316.  
 DR PDB; 1UT2; X-ray; X/Y/Z=156-316.  
 DR Ensembl; ENSMUSG0000002015; Mus musculus.  
 DR MGI; MGI:1100089; Thfafl1.  
 DR GO; GO:0016021; C:integral to membrane; TAS.  
 DR GO; GO:0005515; F:protein binding; IPI.  
 DR GO; GO:0045453; P:bone resorption; IDA.  
 DR GO; GO:0007515; P:lymph gland development; TAS.  
 DR GO; GO:0009687; P:organogenesis; IMP.  
 DR GO; GO:0001503; P:osteification; IMP.  
 DR GO; GO:0045672; P:positive regulation of osteoclast different. . .; IDA.  
 DR GO; GO:0051260; P:protein homooligomerization; IDA.  
 DR InterPro; IPR006052; TNF\_family.  
 DR InterPro; IPR003636; TNF\_subf.  
 DR Pfam; PF00229; TNF; 1.  
 DR ProDom; PD002012; TNF\_subf; 1.  
 DR SMART; SM00207; TNF; 1.  
 DR PROSITE; PS00251; TNF\_1; FALSE\_NEG.  
 DR PROSITE; PSS0049; TNF\_2; 1.  
 DR 3D-structure; Alternative splicing; Cytokine; Developmental protein;  
 DR Differentiation; Direct protein sequencing; Glycoprotein; Receptor;  
 DR Signal-anchor; Transmembrane.  
 DR CHAIN 1 316  
 FT CHAIN 139 316  
 FT TOPO\_DOM 1 48  
 FT TRANSMEM 49 69  
 FT TOPO\_DOM 70 316  
 FT SITE 138 139  
 FT CARBOHYD 197 197  
 FT CARBOHYD 262 262  
 FT VARSPPLIC 1 117  
 FT VARSPPLIC 14 44  
 FT VARSPPLIC 14 44  
 FT CONFLICT 99 99  
 FT CONFLICT 141 143  
 FT STRAND 164 169  
 FT TURN 171 172  
 FT STRAND 181 182  
 FT STRAND 186 187  
 FT TURN 191 192  
 FT STRAND 194 196  
 FT STRAND 198 201  
 FT STRAND 201



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:34:10 ; Search time 18.3689 Seconds  
(without alignments)  
645.834 Million cell updates/sec

Title:	US-09-211-297-32
Perfect score:	148
Sequence:	1 NAASIPGSHKVTLLSSWYHDRGAKIS 27

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

```
Minimum DB seq length: 0
Maximum DB seq length: 20000000000
```

Post-processing:	Minimum Match	0%
	Maximum Match	100%
	Listing first	45 summaries

```
Database : A_geneSeqp.21.180:
1: geneSeqp1590s:*
2: geneSeqp1590s:*
3: geneSeqp2008s:*
4: geneSeqp2001s:*
5: geneSeqp2002s:*
6: geneSeqp2003as:*
7: geneSeqp2003bs:*
8: geneSeqp2004s:*
9: geneSeqp2005s:*
```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	148	100.0	27	2	AAW83196	AAW83196 Murine OS
2	148	100.0	28	2	AAW83197	AAW83197 Murine OS
3	148	100.0	155	6	ABR3854	ABr3854 RANK ligA
4	148	100.0	155	7	ADC0334	Adc0334 Murine re
5	148	100.0	155	7	AD153055	AD153055 Human RAN
6	148	100.0	160	3	AA808227	AA808227 Amino aci
7	148	100.0	170	4	AAU08386	AAU08386 Mouse PLA
8	148	100.0	170	4	ADJ82132	Adj82132 Protein f
9	148	100.0	173	3	AAV84422	AAV84422 An osteop
10	148	100.0	173	3	AAV84422	AAV84422 A murine
11	148	100.0	173	3	AAV84422	AAV84425 DNA encod
12	148	100.0	173	3	AAV84421	AAV84421 Amino aci
13	148	100.0	182	3	AAV84424	AAV84424 Amino aci
14	148	100.0	187	3	AAV84420	AAV84420 Amino aci
15	148	100.0	188	3	AAV84423	AAV84423 An osteop
16	148	100.0	193	7	ADJ82129	Adj82129 Protein f
17	148	100.0	199	5	ABG84285	ABG84285 Mouse RAN
18	148	100.0	199	5	ABG80597	ABG80597 Mouse, rec
19	148	100.0	199	7	ADJ82119	Adj82119 Protein f
20	148	100.0	216	7	ADB16999	Adb16999 Murine RN
21	148	100.0	244	2	AAW83019	AAW83019 A murine
22	148	100.0	247	5	ABG94284	ABG94284 Mouse RAN
23	148	100.0	247	5	ABG80596	ABG80596 Mouse rec
24	148	100.0	247	7	ADJ82118	Adj82118 Protein f

25	148	100.0	249	6	ADA50081	Ada50081	Mouse	w11
26	148	100.0	294	6	AAW69956	AAW69956	NE-KB	rec
27	148	100.0	294	2	AAW68292	AAW68292	NE-KB	rec
28	148	100.0	294	4	AAE08737	AAE08737	Murine	rec
29	148	100.0	294	4	AAE04425	AAE04425	Murine	rec
30	148	100.0	294	4	AAE01992	AAE01992	Murine	rec
31	148	100.0	294	5	AAE26102	AAE26102	Murine	rec
32	148	100.0	294	7	ADB16986	ADB16986	Murine	rec
33	148	100.0	294	7	ADC73000	ADC73000	Murine	rec
34	148	100.0	294	7	ADG78266	ADG78266	Murine	rec
35	148	100.0	294	7	ADG46721	ADG46721	Murine	rec
36	148	100.0	294	9	ADMO9027	ADMO9027	Murine	rec
37	148	100.0	316	2	AAH83017	AAH83017	Human	ost
38	148	100.0	316	2	AAH83194	AAH83194	Human	ost
39	148	100.0	316	2	AAW59654	AAW59654	Murine	TR
40	148	100.0	316	2	AAV17874	AAV17874	Mouse	OB
41	148	100.0	316	3	AAV91024	AAV91024	Mouse	OB
42	148	100.0	316	3	AAH84418	AAH84418	Amno	act1
43	148	100.0	316	3	AAH84419	AAH84419	Amno	act1
44	148	100.0	316	5	AAU78289	AAU78289	Mouse	TR
45	148	100.0	316	5	ADZ29338	ADZ29338	Mouse	RAM

## ALIGNMENTS

RESULT 1	
AAW83196	
ID	AAW83196 standard; peptide; 27 AA

AC AAW83196 ;

DT 11-FEB-1999 (first entry)

DE Murine osteoprotegerin binding protein BB' loop peptide

Osteoprotegerin binding protein; arthritis; KM

hypercalcaemia; osteoclast differentiation and activation receptor; KW

XX pager & urbbacc

US  
XX  
mus. pp.

PN MO9846751-A1  
XX

PD 22-OCT-1998.  
YY

PF 15-APR-1998; 98WO-US007584.  
VY

PR	16-APR-1997;	97US-00842842.
PR	03 JUN 1997	97US-00842842.
PR	03 JUN 1997	97US-00842842.

PR 30-MAR-1998; 98US-00052521.

PA (AMGE-) AMGEN INC.

PI Boyle WJ;

WPI: 1998-594578/50.

PT Nucleic acid encoding

PT creating bone abscess diagnosis.

AA Example 11; Page 55; 47pp; English  
PS

xx The present sequence represents pe

acid molecules encoding OPG binding

CC recombinant OPG binding protein. OPG

CC for specific binding agents (particularly agonists and antagonists,  
CC including intracellular proteins): to raise Ab (useful in immunoassays

CC for detection of OPG binding protein) and to identify compounds that

modulate binding of OPG binding protein to osteoclast differentiation and activation receptor (ODAR). The nucleic acid molecule encoding OPG binding protein can be used to detect OPG binding protein-encoding sequences, e.g. screening for related sequences, also to produce transgenic animal models, while complementary sequences are used for antisense regulation of OPG binding protein expression. Modulators of OPG binding protein, particularly soluble forms of OPG binding protein or Ab, are used to treat or prevent bone diseases, e.g. osteoporosis, bone loss caused by arthritis or metastases, hypercalcaemia, Paget's disease, periodontal disease, osteoporosis, loosening of prostheses, optionally in combination with agents that promote bone growth.

Sequence 27 AA:

Query Match	100.0%	Score 148	DB 2	Length 27
Best Local Similarity	100.0%	Pred. No. 7.8e-16		
Matches 27	Conservative 0	Mismatches 0	Indels 0	Gaps 0

Qy	Db
1 NAASIPGSHKVTLLSSWYHGRGAKIS 27	1 NAASIPGSHKVTLLSSWYHGRGAKIS 27

RESULT 2  
AAW83197

ID AAW83197 standard; peptide; 28 AA.

AC AAW83197;

DT 11-FEB-1999 (first entry)

DE Murine osteoprotegerin binding protein BB' loop-Cys peptide.

KM Osteoprotegerin binding protein; OPB binding protein; arthritis;  
KM osteoporosis; osteoclast maturation; bone disease; metastasis; CDAR;  
KM hypercalcaemia; osteoclast differentiation and activation receptor;  
KM Paget's disease.

OS Mus sp.

PN W09846751-A1.

PD 22-OCT-1998.

PF 15-APR-1998;

PR 16-APR-1997; 97US-00842842.

PR 30-MAR-1998; 98US-00052521.

PA (AMGE-) AMGEN INC.

PI Boyle WJ;

DR WPI; 1998-594578/50.

PT Nucleic acid encoding osteoprotegerin binding protein - useful for, e.g.  
PT treating bone diseases by modulating osteoclast differentiation and for  
PT diagnosis.

PS Example 11; Page 55; 47pp; English.

CC The present sequence represents peptide from murine osteoprotegerin (OPG)  
CC binding protein. Host cells transfected with vectors containing nucleic  
CC acid molecules encoding OPG binding protein are used to produce  
CC recombinant OPG binding protein. OPG binding protein is used in binding  
CC assays to determine osteoprotegerin (OPG) in biological samples; to screen  
CC for specific binding agents (particularly agonists and antagonists,  
CC including intracellular proteins); to raise Ab (useful in immunoassays  
CC for detection of OPG binding protein) and to identify compounds that  
CC modulate binding of OPG binding protein to osteoclast differentiation and  
CC activation receptor (ODAR). The nucleic acid molecule encoding OPG  
CC binding protein can be used to detect OPG binding protein-encoding

CC transgenes, e.g., screening for related sequences, also are used to produce  
CC transgenic animal models, while complementary sequences are used for  
CC antisense regulation of OPG binding protein expression. Modulators of OPG  
CC binding protein, particularly soluble forms of OPG binding protein or Ab,  
are used to treat or prevent bone diseases, e.g., osteoporosis, bone loss  
CC caused by arthritis or metastases, hypercalcaemia, Paget's disease,  
CC periodontal disease, osteoporosis, loosening of prostheses, optionally in  
CC combination with agents that promote bone growth

**SQ Sequence 28 AA;**

Query Match	100.0%	Score 148;	DB 2;	Length 28;
Best Local Similarity	100.0%	Pred. No. 8.1e-16;		
Matches 27;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

Qy 1 NAASIPSGSHKVTLLSSWYHDRGWAKIS 27  
|||  
Db 1 NAASIPSGSHKVTLLSSWYHDRGWAKIS 27

RESULT 3  
ABR39854

ID ABR39854 standard; protein; 155 AA.

AC ABR39854;

DT 11-AUG-2003 (first entry)

DE RANK ligand (RANKL) protein fragment.

KW RANK; receptor activator of necrosis factor KB; RANK ligand; RANKL;

XX

XX

XX

XX

XXXXXX

PR 22-MAR-2002;

PA (BARN-) BARNES-JEWISH HOSPITAL.

PI Lam J, Ross FP, Teitelbaum SL, Nelson CA, Fremont DH;

DR WPI; 2003-256526/25.

PT Composition for identifying a compound with Receptor Activator of  
PT Necrosis Factor  $\kappa$ B, RANK modulating activity and for identifying RANK or  
PT osteoprotegerin modulating compound, has a protein complex in crystalline  
PT form.  
XX  
PS Disclosure; Fig 3; 66pp; English.

PS Disclosure; Fig 3; 66pp; English.

CC The invention relates to a composition (I) comprising a protein complex  
CC in crystalline form, where the complex comprises an amino acid sequence  
CC of a Receptor Activator of Necrosis Factor  $\kappa$ B (RANK) Ligand (RANKL),  
CC ectodomain. (I) is useful for identifying a compound with RANK modulating  
CC activity, and for identifying a RANK or OPG modulating compound. (I) is  
CC useful to intelligently design mutants that have altered biological  
CC properties and for identifying and/or designing compounds that bind RANK  
CC as an approach towards developing new therapeutic agents. (I) is also  
CC useful to computationally screen small molecule databases for chemical  
CC entities or compounds that can bind in whole, or in part, to RANK or  
CC RANKL. The present sequence represents a murine RANKL protein fragment  
XX  
XX Sequence 155 AA;  
XQ

**SQ Sequence 155 AA;**

Query Match	100.0%;	Score 148;	DB 6;	Length 155;
Best Local Similarity	100.0%;	Pred. NO. 6.6e-15;		

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:47:51; Search time 3.0541 Seconds  
(without alignments)  
850.612 Million cell updates/sec

Title: US-09-211-297-32

Perfect score: 148  
Sequence: 1 NAASIPSGSHKVTLSWYHGRMAKIS 27

Scoring table: BLOSUM62  
Gapop 10.0, Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database: 1: p1r1:\*  
2: p1r2:\*  
3: p1r3:\*  
4: p1r4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	59	39.9	456	2 AC3323	manganese transpor
2	49	33.1	369	2 C97484	outer membrane pro
3	49	33.1	369	2 AC2702	outer membrane pro
4	49	33.1	417	2 A96610	probable pectinase
5	49	33.1	747	2 F87263	TPR domain protein
6	49	33.1	780	2 G72724	probable penicillin
7	49	33.1	827	1 A36895	endopeptidase Ia (
8	48.5	32.6	199	2 AD2486	hypothetical prote
9	48.5	32.6	570	2 E29525	methyl coenzyme M
10	48	32.4	452	2 B86889	zinc ABC transport
11	48	32.4	452	2 E84186	hypothetical prote
12	48	32.4	831	2 T00323	chitinase (EC 3.2.
13	48	32.4	1888	2 T39009	hypothetical prote
14	47.5	32.1	197	2 B96568	hypothetical prote
15	47.5	32.1	230	2 A96565	hypothetical prote
16	47	31.8	398	2 I49443	gene 284 protein -
17	47	31.8	406	2 AG0548	probable ABC-trans
18	47	31.8	442	2 T50687	proline transport
19	47	31.8	479	2 S42864	protein kinase (EC
20	47	31.8	532	2 D96835	probable glycerol
21	47	31.8	576	2 A53982	capsid protein - E
22	47	31.8	693	2 A41617	dopamine transport
23	47	31.8	1520	2 T30820	carbamoyl-phosphat
24	46.5	31.4	172	2 E96518	protein T286.12 [1
25	46.5	31.4	197	2 A96568	hypothetical prote
26	46.5	31.4	637	2 S01509	NADH dehydrogenas
27	46	31.1	336	2 F84056	hypothetical prote
28	46	31.1	336	2 F95925	probable cell-wall
29	46	31.1	350	2 T32215	hypothetical prote

30	46	31.1	394	1 S77216	hypothetical prote
31	46	31.1	512	2 A54400	protein kinase (EC
32	46	31.1	605	1 O0B83R	BVRF2 (EC-RF3) pro
33	46	31.1	686	2 T15795	hypothetical prote
34	45.5	30.7	263	2 AD0851	secretory protein
35	45.5	30.7	756	2 A13275	phosphoenolpyruvat
36	45	30.4	105	2 T38761	hypothetical prote
37	45	30.4	112	2 E83817	hypothetical prote
38	45	30.4	205	2 A75165	thymidylate kinase
39	45	30.4	278	2 C43670	integral membrane
40	45	30.4	288	2 A05062	probable mbpy prot
41	45	30.4	325	2 S58146	hypothetical prote
42	45	30.4	334	2 T40042	conserved hypothet
43	45	30.4	345	2 F90194	treonine synthase
44	45	30.4	365	2 A82782	transcription regu
45	45	30.4	365	2 F97561	hypothetical prote

## ALIGNMENTS

RESULT 1  
AC3323  
manganese transport protein mntH [imported] - Brucella melitensis (strain 16M)  
C:Species: Brucella melitensis  
C:Date: 01-Feb-2002 #sequence\_revision 01-Feb-2002 #text\_change 09-Jul-2004  
C:Accession: AC3323  
R:DeVechio, V.G.; Kaput, V.; Redkar, R.J.; Patra, G.; Mujer, C.; Los, T.; Ivanova, .; Mazur, M.; Goldstein, E.; Selkov, E.; Elzer, P.H.; Hagius, S.; O'Callaghan, D.; Letess .; Mazur, M.; Goldstein, E.; Selkov, E.; Elzer, P.H.; Hagius, S.; O'Callaghan, D.; Letess .  
Proc. Natl. Acad. Sci. U.S.A. 99, 443-448, 2002  
A:Title: The genome sequence of the facultative intracellular pathogen Brucella melitensis  
A:Reference number: AD3252; PMID:11756688  
A:Accession: AC3323  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-456 <KUR>  
A:Cross-references: UNIPROT:O8YI76; UNIPARC:UPI0000057D23; GB:AE008917; PIDN:AAL51750.1;  
A:Experimental source: strain 16M  
C:Genetics: BMEI0569  
A:Map position: I  
C:Superfamily: natural resistance-associated macrophage protein 1

Query Match 39.9%; Score 59; DB 2; Length 456;  
Best Local Similarity 45.8%; Pred. No. 0.94;  
Matches 11; Conservative 4; Mismatches 9; Indels 0; Gaps 0;

QY 4 SIPSGSHKVTLSWYHGRMAKIS 27  
DB 6 SCPSGARVETFEGRERERASWS 29

RESULT 2  
C97484  
outer membrane protein a2 precursor [imported] - Agrobacterium tumefaciens (strain C58,  
C:Species: Agrobacterium tumefaciens  
C:Date: 30-Sep-2001 #sequence\_revision 30-Sep-2001 #text\_change 09-Jul-2004  
C:Accession: C97484  
R:Goodner, B.; Hinkle, G.; Gattung, S.; Miller, N.; Blanchard, M.; Qurollo, B.; Goldman, A.; Liu, F.; Mcliam, C.; Allinger, M.; Doughy, D.; Scott, C.; Lappas, C.; Markelz, B.; Science 294, 2333-2328, 2001  
A:Title: Genome Sequence of the Plant Pathogen and Biotechnology Agent Agrobacterium tur  
A:Reference number: A97359; MUID:21608551; PMID:11743194  
A:Accession: C97484  
A:Status: preliminary  
A:Molecule type: DNA  
A:Residues: 1-369 <KUR>  
A:Cross-references: UNIPROT:Q8UGL7; UNIPARC:UPI000000D19FA; GB:AE007869; PIDN:AAK86828.1;  
C:Genetics: AGR C 1878  
A:Map position: circular chromosome  
Query Match 33.1%; Score 49; DB 2; Length 369;

```

DB          374 NSPAIKNGIAVAGDWMYFERGAKL 399

RESULT 5
F87263
TPR domain protein [imported] - Caulobacter crescentus
C:Species: Caulobacter crescentus
C:Date: 20-Apr-2001 #sequence_revision 20-Apr-2001 #text_change 09-Jul-2004
C:Accession: F87263
R:Nieman, W.C.; Fealdlyum, T.V.; Paulsen, I.T.; Nelson, K.E.; Eisen, J.; Heidelberg, J.L.;
  B.; Laud, M.T.; DeBoy, R.T.; Dodson, R.J.; Durkin, A.S.; Gwinn, M.L.; Haft, D.H.; Kolon,
  n, J.; Ermolaeva, M.; White, O.; Salzberg, S.L.; Shapiro, L.; Venter, J.C.; Fraser, C.M.
Proc. Natl. Acad. Sci. U.S.A. 98, 4136-4141, 2001
A:Title: Complete genome sequence of Caulobacter crescentus.
A:Accession: number: A67249; MUID:21173698; PMID:11259647
A:Accession: F87263
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-747 <STO>
A:Cross-references: UNIPROT:Q9ABV1; UNIPARC:UP100000C6F34; GB:AE005673; NID:g13421226; P1
C:Genetics:
A:Gene: CC0119

QY          1 NNAATPSGSHKVTLSWYHDRGM 23
| | | | | | | | | | | | | | | |
DB          138 NTAAPESQAHALTSPNNHELGM 160

Query Match          33.1%; Score 49; DB 2; Length 747;
Best Local Similarity 43.5%; Pred. No. 46;
Matches 10; Conservative 4; Mismatches 9; Indels 0; Gaps 0;

```

RESULT 6  
 G72724  
 probable penicillin acylase APE0336 - Aeropyrum pernix (strain KI)  
 C|Species: Aeropyrum pernix  
 C|Date: 20-Aug-1999 #sequence \_revision 20-Aug-1999 #ext\_change 09-Jul-2004  
 C|Accession: G72724  
 R|Kawarabayashi, Y.; Hino, Y.; Horikawa, H.; Yamazaki, S.; Hattawa, Y.; Jin-no, K.; Takahara, H.; Takamiya, M.; Masuda, S.; Funahashi, T.; Tanaka, T.; Kudoh, Y.; Yamazaki, J.; Kawarabayashi, Y.  
 DNA Res. 6, 83-101, 1999  
 A|Title: Complete genome sequence of an aerobic hyper-thermophilic Crenarchaeon, Aeropyrum pernix strain KI  
 A|Accession: G72724  
 A|Reference number: A72450; MUID:99310339; PMID:10382966  
 A|Status: preliminary  
 A|Molecule type: DNA  
 A|Residues: 1-780 <KAM>  
 A|Cross-references: UNIPROT:Q9YFAS; UNIPARC:UPI000005DAD8; DDBJ:AP000059; NID:95103911; EMBL:AF0336; GenBank:AF0336  
 A|Experimental source: strain KI  
 C|Genetics:  
 A|Gene: APE0336  
  
 Query Match 33.1%; Score 49; DB 2; Length 780;  
 Best Local Similarity 50.0%; Pred. No. 48;  
 Matches 10; Conservative 3; Mismatches 7; Indels 0; Gaps 0;  
  
 QY 4 SIPSGSHKVTLLSSWYHIDRCM 23  
 ||||| |||||  
 Db 734 SLPGSSGVPILSSFYDNLTYW 753

C.Date: 09-Apr-1999 #sequence\_revision 09-Apr-1999 #text\_change 09-Jul-2004  
C.Accession: A36895; A36894  
R.Tojo, N.; Inouye, S.; Komano, T.  
J. Bacteriol. 175, 4545-4549, 1993  
A.Title: The lon gene is homologous to the lon gene encoding an ATP-dependent protease  
A.Reference number: A36895; M01D:93322335; PMID:831083

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 12:44:31 ; Search time 4.60328 Seconds  
(without alignments)  
484.925 Million cell updates/sec

Title: US-09-211-297-32

Perfect score: 148  
Sequence: 1 NAASIPSGSHKVTLSWYHGRMAKIS 27

Scoring table: BLOSUM62  
Gapop 10.0, Gapexc 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database: Issued Patents, AA:  
1: /cgn2\_6/ptodata/1/1aa/5-COMB.pep:\*  
2: /cgn2\_6/ptodata/1/1aa/6-COMB.pep:\*  
3: /cgn2\_6/ptodata/1/1aa/H-COMB.pep:\*  
4: /cgn2\_6/ptodata/1/1aa/BCTUS-COMB.pep:\*  
5: /cgn2\_6/ptodata/1/1aa/BE-COMB.pep:\*  
6: /cgn2\_6/ptodata/1/1aa/Backfile1.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	148	100.0	28	2	US-09-052-521C-34
2	148	100.0	77	2	US-09-632-287A-10
3	148	100.0	77	2	US-10-286-696-11
4	148	100.0	173	2	US-09-396-937-10
5	148	100.0	173	2	US-09-396-937-12
6	148	100.0	173	2	US-09-396-937-18
7	148	100.0	173	2	US-09-396-937-20
8	148	100.0	182	2	US-09-396-937-16
9	148	100.0	187	2	US-09-396-937-8
10	148	100.0	188	2	US-09-396-937-14
11	148	100.0	284	2	US-08-996-139-11
12	148	100.0	284	2	US-08-995-659-11
13	148	100.0	294	2	US-09-215-649A-11
14	148	100.0	294	2	US-09-577-780-11
15	148	100.0	294	2	US-09-577-800-11
16	148	100.0	294	2	US-09-466-496-11
17	148	100.0	294	2	US-09-871-856-11
18	148	100.0	294	2	US-09-871-291-11
19	148	100.0	294	2	US-09-877-650-11
20	148	100.0	294	2	US-09-865-363-11
21	148	100.0	294	2	US-09-688-459-11
22	148	100.0	316	1	US-08-942-842-7
23	148	100.0	316	1	US-08-989-362-2
24	148	100.0	316	2	US-09-052-521C-2
25	148	100.0	316	2	US-09-671-658A-2
26	148	100.0	316	2	US-09-396-937-4
27	148	100.0	316	2	US-09-396-937-6

28	148	100.0	316	2	US-09-957-944-8	Sequence 8, Appl
29	136	91.9	77	2	US-09-632-287A-11	Sequence 11, Appl
30	136	91.9	77	2	US-10-286-696-11	Sequence 11, Appl
31	136	91.9	317	2	US-08-996-139-13	Sequence 13, Appl
32	136	91.9	317	2	US-08-995-659-13	Sequence 13, Appl
33	136	91.9	317	2	US-09-215-649A-13	Sequence 13, Appl
34	136	91.9	317	2	US-09-052-521C-4	Sequence 4, Appl
35	136	91.9	317	2	US-09-577-780-13	Sequence 13, Appl
36	136	91.9	317	2	US-09-577-800-13	Sequence 13, Appl
37	136	91.9	317	2	US-09-466-496-13	Sequence 13, Appl
38	136	91.9	317	2	US-09-871-856-13	Sequence 13, Appl
39	136	91.9	317	2	US-09-871-291-13	Sequence 13, Appl
40	136	91.9	317	2	US-09-396-937-2	Sequence 2, Appl
41	136	91.9	317	2	US-09-877-650-13	Sequence 13, Appl
42	136	91.9	317	2	US-09-865-363-13	Sequence 13, Appl
43	136	91.9	317	2	US-09-688-459-13	Sequence 13, Appl
44	136	91.9	317	2	US-09-957-944-6	Sequence 6, Appl
45	135	91.2	27	2	US-09-052-521C-33	Sequence 33, Appl

## ALIGNMENTS

```

RESULT 1
US-09-052-521C-34
; Sequence 34, Application US/09052521C
; Patent No. 6316408
; GENERAL INFORMATION:
; APPLICANT: Boyle, William J.
; TITLE OF INVENTION: Osteoprotegerin Binding Proteins and Receptors
; FILE REFERENCE: A-451Bv
; CURRENT APPLICATION NUMBER: US/09/052,521C
; PRIOR FILING DATE: 1996-03-30
; PRIOR APPLICATION NUMBER: 08/880,855
; PRIOR FILING DATE: 1997-06-23
; PRIOR APPLICATION NUMBER: 08/842,842
; PRIOR FILING DATE: 1997-04-16
; NUMBER OF SEQ ID NOS: 40
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 34
; LENGTH: 28
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-052-521C-34
Query Match      100.0%  Score 148;  DB 2;  Length 28;
Best Local Similarity 100.0%;  Pred. No. 5.5e-15;
Matches 27;  Conservative 0;  Mismatches 0;  Indels 0;  Gaps 0;
QY 1 NAASIPSGSHKVTLSWYHGRMAKIS 27
Db 1 NAASIPSGSHKVTLSWYHGRMAKIS 27
RESULT 2
US-09-632-287A-10
; Sequence 10, Application US/09632287A
; Patent No. 6521422
; GENERAL INFORMATION:
; APPLICANT: Hsu, Hailing
; APPLICANT: Wooden, Scott K
; APPLICANT: Boyle, William J
; TITLE OF INVENTION: Ppm, A No. 6521422e1 Member of the TNF Ligand Supergene Family
; FILE REFERENCE: 01017/35560A
; CURRENT APPLICATION NUMBER: US/09/632,287A
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: US 60/147,294
; PRIOR FILING DATE: 1999-08-04
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn Ver. 2.0

```

SEQ ID NO 10  
LENGTH: 77  
TYPE: PRT  
ORGANISM: Mouse  
US-09-632-287A-10

Query Match 100.0%; Score 148; DB 2; Length 77;  
Best Local Similarity 100.0%; Pred. No. 1.9e-14;  
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 NAASIPSGSHKVTLSWYHDSGMAKIS 27  
|||||  
Db 14 NAASIPSGSHKVTLSWYHDSGMAKIS 40

RESULT 3  
US-10-286-696-10  
Sequence 10, Application US/10286696  
Patent No. 6852839  
GENERAL INFORMATION:  
APPLICANT: Heu, Hailing  
APPLICANT: Wooden, Scott K  
APPLICANT: Boyle, William J  
TITLE OF INVENTION: Fm, A No. 6852839e1 Member of the TNF Ligand Supergene Family  
FILE REFERENCE: 01017/35550A  
CURRENT APPLICATION NUMBER: US/10/286,696  
CURRENT FILING DATE: 2002-11-01  
PRIOR APPLICATION NUMBER: US 60/147,294  
PRIOR FILING DATE: 1999-08-04  
NUMBER OF SEQ ID NOS: 22  
SOFTWARE: PatentIn Ver. 2.0  
SEQ ID NO 10  
LENGTH: 77  
TYPE: PRT  
ORGANISM: Mouse  
US-10-286-696-10

Query Match 100.0%; Score 148; DB 2; Length 77;  
Best Local Similarity 100.0%; Pred. No. 1.9e-14;  
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 NAASIPSGSHKVTLSWYHDSGMAKIS 27  
|||||  
Db 14 NAASIPSGSHKVTLSWYHDSGMAKIS 40

RESULT 4  
US-09-396-937-10  
Sequence 10, Application US/09396937  
Patent No. 6645500  
GENERAL INFORMATION:  
APPLICANT: M&E Biotech A/S  
APPLICANT: HAKTER, Torben  
APPLICANT: HAANING, Jesper  
TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand  
TITLE OF INVENTION: Activity  
FILE REFERENCE: 22021 PC 1  
CURRENT APPLICATION NUMBER: US/09/396,937  
CURRENT FILING DATE: 1999-09-15  
NUMBER OF SEQ ID NOS: 35  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 10  
LENGTH: 173  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: DNA encoding  
OTHER INFORMATION: murine OPGL, residues 158-316, fused to His tag  
US-09-396-937-10

Query Match 100.0%; Score 148; DB 2; Length 173;  
Best Local Similarity 100.0%; Pred. No. 5e-14;  
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 NAASIPSGSHKVTLSWYHDSGMAKIS 27  
|||||  
Db 27 NAASIPSGSHKVTLSWYHDSGMAKIS 53

RESULT 5  
US-09-396-937-12  
Sequence 12, Application US/09396937  
Patent No. 6645500  
GENERAL INFORMATION:  
APPLICANT: M&E Biotech A/S  
APPLICANT: HAKTER, Torben  
APPLICANT: HAANING, Jesper  
TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand  
TITLE OF INVENTION: Activity  
FILE REFERENCE: 22021 PC 1  
CURRENT APPLICATION NUMBER: US/09/396,937  
CURRENT FILING DATE: 1999-09-15  
NUMBER OF SEQ ID NOS: 35  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 12  
LENGTH: 173  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Fusion of  
OTHER INFORMATION: murine OPGL, residues 158-316 with C to S  
US-09-396-937-12

Query Match 100.0%; Score 148; DB 2; Length 173;  
Best Local Similarity 100.0%; Pred. No. 5e-14;  
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 NAASIPSGSHKVTLSWYHDSGMAKIS 27  
|||||  
Db 27 NAASIPSGSHKVTLSWYHDSGMAKIS 53

RESULT 6  
US-09-396-937-18  
Sequence 18, Application US/09396937  
Patent No. 6645500  
GENERAL INFORMATION:  
APPLICANT: M&E Biotech A/S  
APPLICANT: HAKTER, Torben  
APPLICANT: HAANING, Jesper  
TITLE OF INVENTION: Method for Down-Regulating Osteoprotegerin Ligand  
TITLE OF INVENTION: Activity  
FILE REFERENCE: 22021 PC 1  
CURRENT APPLICATION NUMBER: US/09/396,937  
CURRENT FILING DATE: 1999-09-15  
NUMBER OF SEQ ID NOS: 35  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 18  
LENGTH: 173  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Fusion between  
OTHER INFORMATION: murine OPGL, residues 158-316 with tetanus toxoid  
OTHER INFORMATION: P2 epitope introduced, and His tag  
US-09-396-937-18

Query Match 100.0%; Score 148; DB 2; Length 173;  
Best Local Similarity 100.0%; Pred. No. 5e-14;  
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 NAASIPSGSHKVTLSWYHDSGMAKIS 27  
|||||  
Db 27 NAASIPSGSHKVTLSWYHDSGMAKIS 53

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model

Run on: December 21, 2005, 13:02:07 ; Search time 14.8721 Seconds  
(without alignments)  
758.559 Million cell updates/sec

Title: US-09-211-297-32

Perfect score: 148  
Sequence: 1 NAASIPSGSHKVTLSWYHDSGMAKIS 27

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :  
1: /cgn2\_6/prodata/1/pubpaa/US07\_PUBCOMB.pep.\*  
2: /cgn2\_6/prodata/1/pubpaa/US08\_PUBCOMB.pep.\*  
3: /cgn2\_6/prodata/1/pubpaa/US09\_PUBCOMB.pep.\*  
4: /cgn2\_6/prodata/1/pubpaa/US10\_PUBCOMB.pep.\*  
5: /cgn2\_6/prodata/1/pubpaa/US10\_PUBCOMB.pep.\*  
6: /cgn2\_6/prodata/1/pubpaa/US11\_PUBCOMB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	148	100.0	27	US-10-825-898-33	Sequence 33, Appl
2	148	100.0	28	US-10-825-898-34	Sequence 34, Appl
3	148	100.0	77	US-10-286-696-10	Sequence 10, Appl
4	148	100.0	77	US-10-890-368-10	Sequence 10, Appl
5	148	100.0	77	US-10-889-948-10	Sequence 10, Appl
6	148	100.0	160	US-09-779-050A-14	Sequence 14, Appl
7	148	100.0	170	US-09-791-153A-76	Sequence 76, Appl
8	148	100.0	170	US-10-289-456-99	Sequence 99, Appl
9	148	100.0	173	US-10-664-801-10	Sequence 10, Appl
10	148	100.0	173	US-10-664-801-12	Sequence 12, Appl
11	148	100.0	173	US-10-664-801-18	Sequence 18, Appl
12	148	100.0	173	US-10-664-801-20	Sequence 20, Appl
13	148	100.0	182	US-10-664-801-16	Sequence 16, Appl
14	148	100.0	187	US-10-664-801-8	Sequence 8, Appl
15	148	100.0	188	US-10-664-801-14	Sequence 14, Appl
16	148	100.0	193	US-10-289-456-96	Sequence 96, Appl
17	148	100.0	199	US-10-050-902-224	Sequence 224, App
18	148	100.0	199	US-10-050-902-224	Sequence 224, App
19	148	100.0	199	US-10-289-456-86	Sequence 86, Appl
20	148	100.0	244	US-10-167-182-16	Sequence 16, Appl
21	148	100.0	244	US-10-460-623-16	Sequence 16, Appl
22	148	100.0	244	US-10-854-300-16	Sequence 16, Appl
23	148	100.0	244	US-11-135-521-16	Sequence 16, Appl
24	148	100.0	247	US-10-050-902-223	Sequence 223, App
25	148	100.0	247	US-10-050-898-223	Sequence 223, App
26	148	100.0	247	US-10-289-456-85	Sequence 85, Appl
27	148	100.0	249	US-10-338-785A-3	Sequence 3, Appl

28	148	100.0	249	4	US-10-611-363-3	Sequence 3, Appl
29	148	100.0	294	3	US-09-871-856-11	Sequence 11, Appl
30	148	100.0	294	3	US-09-865-163-11	Sequence 11, Appl
31	148	100.0	294	3	US-09-871-291-11	Sequence 11, Appl
32	148	100.0	294	3	US-09-877-650-11	Sequence 11, Appl
33	148	100.0	294	3	US-10-405-878-11	Sequence 11, Appl
34	148	100.0	294	5	US-10-802-133-11	Sequence 11, Appl
35	148	100.0	316	3	US-09-957-944-8	Sequence 8, Appl
36	148	100.0	316	3	US-09-079-569-7	Sequence 7, Appl
37	148	100.0	316	3	US-09-873-829-4	Sequence 4, Appl
38	148	100.0	316	3	US-09-933-915A-16	Sequence 16, Appl
39	148	100.0	316	4	US-10-017-910-4	Sequence 4, Appl
40	148	100.0	316	4	US-10-105-057-2	Sequence 2, Appl
41	148	100.0	316	4	US-10-272-411-19	Sequence 19, Appl
42	148	100.0	316	4	US-10-272-328A-19	Sequence 19, Appl
43	148	100.0	316	4	US-10-326-052-2	Sequence 2, Appl
44	148	100.0	316	4	US-10-167-182-1	Sequence 1, Appl
45	148	100.0	316	4	US-10-460-623-1	Sequence 1, Appl

## ALIGNMENTS

```

RESULT 1
US-10-825-898-33
; Sequence 33, Application US/10825898
; Publication No. US20050003400A1
; GENERAL INFORMATION:
; APPLICANT: BOYLE, WILLIAM
; TITLE OF INVENTION: OSTROPROTEGERIN BINDING PROTEINS AND RECEPTORS
; FILE REFERENCE: A-451K REV 09-10-03 54SEQ
; CURRENT FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US/10/825,898
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 09/052,521
; PRIOR FILING DATE: 1998-03-30
; PRIOR FILING DATE: 1998-03-30
; PRIOR APPLICATION NUMBER: US 08/880,855
; PRIOR FILING DATE: 1997-06-23
; PRIOR APPLICATION NUMBER: US 08/842,842
; PRIOR FILING DATE: 1997-04-16
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 33
; LENGTH: 27
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-10-825-898-33

Query Match          100.0%; Score 148; DB 5; Length 27;
Best local similarity 100.0%; Pred. No. 6.8e-13;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 NAASIPSGSHKVTLSWYHDSGMAKIS 27
Db 1 NAASIPSGSHKVTLSWYHDSGMAKIS 27

RESULT 2
US-10-825-898-34
; Sequence 34, Application US/10825898
; Publication No. US20050003400A1
; GENERAL INFORMATION:
; APPLICANT: BOYLE, WILLIAM
; TITLE OF INVENTION: OSTROPROTEGERIN BINDING PROTEINS AND RECEPTORS
; FILE REFERENCE: A-451K REV 09-10-03 54SEQ
; CURRENT FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US/10/825,898
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 09/052,521
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 09/052,521

```

;; PRIOR FILING DATE: 1998-03-30  
;; PRIOR APPLICATION NUMBER: US 08/880,855  
;; PRIOR FILING DATE: 1997-06-23  
;; PRIOR APPLICATION NUMBER: US 08/842,842  
;; PRIOR FILING DATE: 1997-04-16  
;; NUMBER OF SEQ ID NOS: 54  
;; SOFTWARE: PatentIn version 3.1  
;; SEQ ID NO 34  
;; LENGTH: 28  
;; TYPE: PRT  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Synthetic Oligonucleotide  
US-10-825-898-34

Query Match 100.0%; Score 148; DB 5; Length 28;  
Best Local Similarity 100.0%; Pred. No. 7,1e-13;  
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 NAASIPSGSHKVTLSWYHDSGMWAKIS 27  
Db 1 NAASIPSGSHKVTLSWYHDSGMWAKIS 27

RESULT 3  
US-10-286-696-10  
;; Sequence 10, Application US/10286696  
;; Publication No. US20030129706A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Hsu, Hailing  
;; APPLICANT: Wooden, Scott K  
;; APPLICANT: Boyle, William J  
;; TITLE OF INVENTION: Fhm, A No. US20030129706A1 Member of the TNF Ligand Supergene F  
;; FILE REFERENCE: 01017/35550A  
;; CURRENT APPLICATION NUMBER: US/10/286,696  
;; CURRENT FILING DATE: 2002-11-01  
;; PRIOR APPLICATION NUMBER: US 60/147,294  
;; PRIOR FILING DATE: 1999-08-04  
;; NUMBER OF SEQ ID NOS: 22  
;; SOFTWARE: PatentIn Ver. 2.0  
;; SEQ ID NO 10  
;; LENGTH: 77  
;; TYPE: PRT  
;; ORGANISM: Mouse  
US-10-286-696-10

Query Match 100.0%; Score 148; DB 4; Length 77;  
Best Local Similarity 100.0%; Pred. No. 2e-12;  
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 NAASIPSGSHKVTLSWYHDSGMWAKIS 27  
Db 14 NAASIPSGSHKVTLSWYHDSGMWAKIS 40

RESULT 4  
US-10-890-368-10  
;; Sequence 10, Application US/10890368  
;; Publication No. US20040248324A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Hsu et al.  
;; TITLE OF INVENTION: FHM, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY: MATERIALS  
;; FILE REFERENCE: 01017/35550D  
;; CURRENT APPLICATION NUMBER: US/10/890,368  
;; CURRENT FILING DATE: 2004-07-13  
;; PRIOR APPLICATION NUMBER: US 10/286,696  
;; PRIOR FILING DATE: 2002-11-01  
;; PRIOR APPLICATION NUMBER: US 09/632,287  
;; PRIOR FILING DATE: 2000-08-03  
;; PRIOR APPLICATION NUMBER: US 60/147,294  
;; PRIOR FILING DATE: 1999-08-04  
;; NUMBER OF SEQ ID NOS: 22  
US-10-890-368-10

;; SOFTWARE: PatentIn Ver. 2.0  
;; SEQ ID NO 10  
;; LENGTH: 77  
;; TYPE: PRT  
;; ORGANISM: Mouse  
US-10-890-368-10

Query Match 100.0%; Score 148; DB 5; Length 77;  
Best Local Similarity 100.0%; Pred. No. 2e-12;  
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 NAASIPSGSHKVTLSWYHDSGMWAKIS 27  
Db 14 NAASIPSGSHKVTLSWYHDSGMWAKIS 40

RESULT 5  
US-10-889-948-10  
;; Sequence 10, Application US/10889948  
;; Publication No. US20040265913A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Hsu et al.  
;; TITLE OF INVENTION: FHM, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY: ANTIBODY  
;; FILE REFERENCE: 01017/35550C  
;; CURRENT APPLICATION NUMBER: US/10/889,948  
;; CURRENT FILING DATE: 2004-07-13  
;; PRIOR APPLICATION NUMBER: US 10/286,696  
;; PRIOR FILING DATE: 2002-11-01  
;; PRIOR APPLICATION NUMBER: US 09/632,287  
;; PRIOR FILING DATE: 2000-08-03  
;; PRIOR APPLICATION NUMBER: US 60/147,294  
;; PRIOR FILING DATE: 1999-08-04  
;; NUMBER OF SEQ ID NOS: 22  
;; SOFTWARE: PatentIn Ver. 2.0  
;; SEQ ID NO 10  
;; LENGTH: 77  
;; TYPE: PRT  
;; ORGANISM: Mouse  
US-10-889-948-10

Query Match 100.0%; Score 148; DB 5; Length 77;  
Best Local Similarity 100.0%; Pred. No. 2e-12;  
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 NAASIPSGSHKVTLSWYHDSGMWAKIS 27  
Db 14 NAASIPSGSHKVTLSWYHDSGMWAKIS 40

RESULT 6  
US-09-779-050A-14  
;; Sequence 14, Application US/09779050A  
;; Patent No. US20020160416A1  
;; GENERAL INFORMATION:  
;; APPLICANT: BOYLE, WILLIAM  
;; APPLICANT: HSU, HAILING  
;; TITLE OF INVENTION: RECEPTOR FROM TNF FAMILY  
;; FILE REFERENCE: A-570B  
;; CURRENT APPLICATION NUMBER: US/09/779,050A  
;; CURRENT FILING DATE: 2001-02-12  
;; PRIOR APPLICATION NUMBER: 60/181,800  
;; PRIOR FILING DATE: 2000-02-11  
;; NUMBER OF SEQ ID NOS: 52  
;; SOFTWARE: PatentIn version 3.0  
;; SEQ ID NO 14  
;; LENGTH: 160  
;; TYPE: PRT  
;; ORGANISM: Mus musculus  
US-09-779-050A-14

Query Match 100.0%; Score 148; DB 3; Length 160;  
Best Local Similarity 100.0%; Pred. No. 4,2e-12;



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: December 21, 2005, 13:03:52; Search time 0.840984 Seconds  
(without alignments)  
228.978 Million cell updates/sec

Title: US-09-211-297-32

Perfect score: 148

Sequence: 1 NAASIPGSHKVTLSWYHGRGMAKIS 27

Scoring table: BLOSUM62

Searched: Gapop 10.0, Gapext 0.5

Total number of hits satisfying chosen parameters: 53982

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database:

Published Applications\_AA\_New:\*

- 1: /cgn2\_6/ptodata/2/pubpa/US08\_NEW\_PUB.pdb.\*
- 2: /cgn2\_6/ptodata/2/pubpa/US06\_NEW\_PUB.pdb.\*
- 3: /cgn2\_6/ptodata/2/pubpa/US07\_NEW\_PUB.pdb.\*
- 4: /cgn2\_6/ptodata/2/pubpa/PCT\_NEW\_PUB.pdb.\*
- 5: /cgn2\_6/ptodata/2/pubpa/US05\_NEW\_PUB.pdb.\*
- 6: /cgn2\_6/ptodata/2/pubpa/US10\_NEW\_PUB.pdb.\*
- 7: /cgn2\_6/ptodata/2/pubpa/US11\_NEW\_PUB.pdb.\*
- 8: /cgn2\_6/ptodata/2/pubpa/US60\_NEW\_PUB.pdb.\*

Prod. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	132	89.2	109	US-11-065-669-8	Sequence 8, Appl
2	53.5	36.1	1649	US-10-995-561-974	Sequence 974, Appl
3	53.5	36.1	1694	US-11-135-855-36	Sequence 36, Appl
4	53.5	36.1	1709	US-10-995-561-973	Sequence 973, Appl
5	53.5	36.1	1709	US-11-135-855-35	Sequence 35, Appl
6	46	30.4	532	US-11-152-747-2	Sequence 4, Appl
7	45	30.4	53	US-10-467-657-4496	Sequence 4496, Ap
8	44	29.7	401	US-10-510-386-68	Sequence 68, Appl
9	43.5	29.4	367	US-10-821-234-1569	Sequence 1569, Ap
10	43.5	29.4	401	US-11-097-749-3	Sequence 3, Appl
11	43.5	29.4	863	US-11-097-749-2	Sequence 2, Appl
12	43	29.1	245	US-10-793-626-2910	Sequence 2910, Ap
13	43	29.1	588	US-10-793-626-3328	Sequence 3328, Ap
14	42.5	28.7	447	US-11-112-882-4	Sequence 4, Appl
15	41	27.7	272	US-10-467-657-2730	Sequence 2730, Ap
16	41	27.7	288	US-10-131-826A-316	Sequence 316, Appl
17	41	27.7	987	US-10-770-726-61	Sequence 61, Appl
18	40.5	27.4	250	US-10-454-437-388	Sequence 388, Appl
19	40.5	27.4	378	US-11-080-091-3	Sequence 3, Appl
20	40.5	27.4	378	US-11-080-091-11	Sequence 11, Appl
21	40.5	27.4	378	US-11-087-177-39	Sequence 39, Appl
22	40.5	27.4	378	US-11-087-177-41	Sequence 41, Appl
23	40.5	27.4	498	US-10-821-234-1060	Sequence 1060, Ap
24	40	27.0	296	US-11-074-176-166	Sequence 166, Appl
25	40	27.0	362	US-10-821-234-1148	Sequence 1148, Ap

26	40	27.0	651	6	US-10-821-234-1480	Sequence 1480, Ap
27	40	27.0	2261	6	US-10-995-561-600	Sequence 600, Appl
28	40	27.0	2516	6	US-10-647-966A-2	Sequence 2, Appl
29	39.5	26.7	343	7	US-11-080-991-86	Sequence 86, Appl
30	39.5	26.7	393	6	US-10-821-234-1043	Sequence 1043, Ap
31	39	26.4	199	6	US-10-467-657-8058	Sequence 8058, Ap
32	39	26.4	261	6	US-10-617-034A-12	Sequence 12, Appl
33	39	26.4	282	6	US-10-467-657-810	Sequence 810, Appl
34	39	26.4	309	7	US-11-109-156-24	Sequence 24, Appl
35	39	26.4	309	7	US-11-109-156-39	Sequence 39, Appl
36	39	26.4	311	6	US-10-467-657-1638	Sequence 1638, Ap
37	39	26.4	322	6	US-10-821-234-1354	Sequence 1354, Ap
38	39	26.4	322	6	US-10-878-556A-59	Sequence 59, Appl
39	39	26.4	998	6	US-10-510-524-1	Sequence 1, Appl
40	39	26.4	1467	6	US-10-507-956-1	Sequence 9, Appl
41	38.5	26.0	366	7	US-11-091-334-9	Sequence 38, Appl
42	38.5	26.0	484	6	US-10-873-528-38	Sequence 67, Appl
43	38.5	26.0	617	6	US-10-878-556A-67	Sequence 6006, Ap
44	38.5	26.0	659	6	US-10-467-657-6006	Sequence 122, Appl
45	38	25.7	179	6	US-10-467-657-122	

#### ALIGNMENTS

```

RESULT 1
US-11-065-669-8
; Sequence 8, Application US/11065669
; Publication No. US2005024411A1
; GENERAL INFORMATION:
; APPLICANT: Mackay, Fabienne
; APPLICANT: Kalled, Susan
; TITLE OF INVENTION: BAPF, INHIBITORS THEREOF AND THEIR USE IN THE
; FILE OF INVENTION: MODULATION OF B-CELL RESPONSE
; FILE REFERENCE: 08201.0024-04000
; CURRENT APPLICATION NUMBER: US/11/065,669
; CURRENT FILING DATE: 2005-02-24
; PRIOR APPLICATION NUMBER: 10/045,574
; PRIOR FILING DATE: 2001-11-07
; PRIOR APPLICATION NUMBER: 09/911,777
; PRIOR FILING DATE: 2001-07-24
; PRIOR APPLICATION NUMBER: 60/143,228
; PRIOR FILING DATE: 2001-07-09
; PRIOR APPLICATION NUMBER: PCT/US00/01788
; PRIOR FILING DATE: 2000-01-25
; PRIOR APPLICATION NUMBER: 60/117,169
; PRIOR FILING DATE: 1999-01-25
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 8
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-065-669-8

Query Match      89.2%; Score 132; DB 7; Length 109;
Best Local Similarity 85.2%; Pred. No. 3.2e-12;
Matches 23; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

CY      1 NAASIPGSHKVTLSWYHGRGMAKIS 27
DB      11 NATDIPGSHKVTLSWYHGRGMAKIS 37

RESULT 2
US-10-995-561-974
; Sequence 974, Application US/10995561
; Publication No. US20050272054A1
; GENERAL INFORMATION:
; APPLICANT: CARGILL, Michele et al.
; TITLE OF INVENTION: GENETIC POLYMORPHISMS ASSOCIATED WITH
; TITLE OF INVENTION: CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF
; TITLE OF INVENTION: DETECTION AND USES THEREOF

```

```
FILE REFERENCE: CL001559
CURRENT APPLICATION NUMBER: US/10/995,561
CURRENT FILING DATE: 2004-11-24
NUMBER OF SEQ ID NOS: 85702
SOFTWARE: FASTSEQ for Windows Version 4.0
SEQ ID NO 974
LENGTH: 1649
TYPE: PRT
ORGANISM: Homo sapiens
US-10-995-561-974

Query Match          36.1% Score 53.5; DB 6; Length 1649;
Best Local Similarity 31.2% Pred. No. 4.2;
Matches 10; Conservative 5; Mismatches 6; Indels 11; Gaps 1;

QY 3 ASIPSG-----SHKVTLSWYHNRGW 23
DB 1269 AAVPEGAPITVTCADPAHAHPTLYTWYHNGRW 1300

RESULT 3
US-11-135-855-36
Sequence 36, Application US/11135855
Publication No. US2005025557A1
GENERAL INFORMATION:
APPLICANT: SMITHKLINE BEECHAM CORPORATION
TITLE OF INVENTION: NOVEL COMPOUNDS
FILE REFERENCE: GP50013
CURRENT APPLICATION NUMBER: US/11/135,855
CURRENT FILING DATE: 2005-05-24
PRIOR APPLICATION NUMBER: US/10/203,708
PRIOR FILING DATE: 2002-08-13
PRIOR APPLICATION NUMBER: PCT/US01/04703
PRIOR FILING DATE: 2001-02-14
PRIOR APPLICATION NUMBER: 60/182,172
PRIOR FILING DATE: 2000-02-14
PRIOR APPLICATION NUMBER: 60/186,084
PRIOR FILING DATE: 2000-02-29
NUMBER OF SEQ ID NOS: 46
SOFTWARE: FASTSEQ for Windows Version 3.0
SEQ ID NO 36
LENGTH: 1694
TYPE: PRT
ORGANISM: Homo sapiens
US-11-135-855-36

Query Match          36.1% Score 53.5; DB 7; Length 1694;
Best Local Similarity 31.2% Pred. No. 4.3;
Matches 10; Conservative 5; Mismatches 6; Indels 11; Gaps 1;

QY 3 ASIPSG-----SHKVTLSWYHNRGW 23
DB 1263 AAVPEGAPITVTCADPAHAHPTLYTWYHNGRW 1294

RESULT 4
US-10-995-561-973
Sequence 973, Application US/10995561
Publication No. US20050272054A1
GENERAL INFORMATION:
APPLICANT: CARGILL, Michele et al.
TITLE OF INVENTION: GENETIC POLYMORPHISMS ASSOCIATED WITH
CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF
TITLE OF INVENTION: DETECTION AND USES THEREOF
FILE REFERENCE: CL001559
CURRENT APPLICATION NUMBER: US/10/995,561
CURRENT FILING DATE: 2004-11-24
NUMBER OF SEQ ID NOS: 85702
SOFTWARE: FASTSEQ for Windows Version 4.0
SEQ ID NO 973
LENGTH: 1709
TYPE: PRT
```

```
ORGANISM: Homo sapiens
US-10-995-561-973

Query Match          36.1% Score 53.5; DB 6; Length 1709;
Best Local Similarity 31.2% Pred. No. 4.3;
Matches 10; Conservative 5; Mismatches 6; Indels 11; Gaps 1;

QY 3 ASIPSG-----SHKVTLSWYHNRGW 23
DB 1269 AAVPEGAPITVTCADPAHAHPTLYTWYHNGRW 1300

RESULT 5
US-11-135-855-35
Sequence 35, Application US/11135855
Publication No. US2005025557A1
GENERAL INFORMATION:
APPLICANT: SMITHKLINE BEECHAM CORPORATION
TITLE OF INVENTION: NOVEL COMPOUNDS
FILE REFERENCE: GP50013
CURRENT APPLICATION NUMBER: US/11/135,855
CURRENT FILING DATE: 2005-05-24
PRIOR APPLICATION NUMBER: US/10/203,708
PRIOR FILING DATE: 2002-08-13
PRIOR APPLICATION NUMBER: PCT/US01/04703
PRIOR FILING DATE: 2001-02-14
PRIOR APPLICATION NUMBER: 60/182,172
PRIOR FILING DATE: 2000-02-14
PRIOR APPLICATION NUMBER: 60/186,084
PRIOR FILING DATE: 2000-02-29
NUMBER OF SEQ ID NOS: 46
SOFTWARE: FASTSEQ for Windows Version 3.0
SEQ ID NO 35
LENGTH: 1709
TYPE: PRT
ORGANISM: Homo sapiens
US-11-135-855-35

Query Match          36.1% Score 53.5; DB 7; Length 1709;
Best Local Similarity 31.2% Pred. No. 4.3;
Matches 10; Conservative 5; Mismatches 6; Indels 11; Gaps 1;

QY 3 ASIPSG-----SHKVTLSWYHNRGW 23
DB 1263 AAVPEGAPITVTCADPAHAHPTLYTWYHNGRW 1294

RESULT 6
US-11-152-747-2
Sequence 2, Application US/11152747
Publication No. US20050251881A1
GENERAL INFORMATION:
APPLICANT: E. I. du Pont de Nemours, Inc.
APPLICANT: Cheng, Qiong
APPLICANT: Tao, Luan
TITLE OF INVENTION: CAROTENOID KETOLASE GENE
FILE REFERENCE: CL-1849 US NA
CURRENT APPLICATION NUMBER: US/11/152,747
CURRENT FILING DATE: 2005-06-14
PRIOR APPLICATION NUMBER:
PRIOR FILING DATE:
NUMBER OF SEQ ID NOS: 47
SOFTWARE: Microsoft Office 97
SEQ ID NO 2
LENGTH: 532
TYPE: PRT
ORGANISM: Rhodococcus erythropolis AN12
US-11-152-747-2

Query Match          31.1% Score 46; DB 7; Length 532;
Best Local Similarity 39.3% Pred. No. 16;
Matches 11; Conservative 4; Mismatches 7; Indels 6; Gaps 2;
```